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Abstract 
Enzyme discovery today is proceeding at an enormous pace due to ever-growing 
technology development. As a result of this, more than 21000 cytochrome P450s have 
been identified in all kingdoms of life to date, making a wide range of enzyme resources 
with outstanding potential for biocatalytical implementation available. P450s from 
filamentous fungi, such as Beauveria bassiana, represent particularly compelling targets 
for the discovery of novel enzymes as these organisms have a long history of application in 
industrial hydroxylation reactions, many of which are believed to be P450-dependent. In 
addition, the genome sequence of B. bassiana has recently been completed revealing 83 
putative P450s. 
In order to uncover new cytochrome P450-based biocatalysts from the fungus Beauveria 
bassiana extensive bioinformatics analysis of the Beauveria CYPome were performed. As 
a result 7 genes encoding for heme domains with possible alkane hydroxylase function and 
one encoding a naturally fused P450 with homology to P450foxy from Fusarium oxysporum 
could be identified for subsequent cloning, heterologous expression and characterization. 
Different expression hosts as well as various expression conditions have been investigated. 
Despite our efforts, delivery of active biocatalysts could not be realized. However, 
empirical data acquired in this project will be of value for future studies of fungal P450s. 
In addition, 23 cytochrome P450 heme domains from Rhodococcus jostii fused to the P450 
reductase domain (RhfRED) of cytochrome P450Rhf from Rhodococcus sp. NCIMB 9784 
have been investigated in a further strand of this work and provided a screening platform 
that could be applied for industrial purposes.  
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1. Introduction 
1.1 Cytochrome P450 
Cytochrome P450 enzymes (P450s) can generally be described as heme-thiolate proteins 
widely distributed in all forms of life from prokaryotes (archaea, bacteria) and lower 
eukaryotes (fungi and insects) to higher eukaryotes (plants and animals including 
humans).[1] They are involved in numerous processes, which include the metabolism of 
aliphatic, alicyclic and aromatic molecules in reactions resulting in hydroxylation, 
epoxidation, dealkylation, sulfoxidation, deamination, desulfuration, dehalogenation, and 
N-oxide reduction.[2] The fact that these systems catalyse such a vast and interesting set of 
reactions combined with the availability of new genetic engineering techniques makes 
them especially promising candidates for preparative biocatalysis. 
1.1.1 Discovery and Nomenclature  
The foundation that preceded the discovery of cytochrome P450 (P450) was set by an 
important finding in cell biology in the early 1940s. In 1943 Albert Claude and his 
collaborators discovered a novel subcellular fraction, called microsomes, after establishing 
a method for cell fractionation of animal tissue.[3] As a result, many scientists, especially in 
the field of biochemistry, showed particular interest in these newly found subcellular 
fractions and started to investigate morphological and biochemical properties of these 
microsomes. Thereby, and with the advancement in available analysis tools like mass 
spectrometry and spectrophotometry, the first microsomal NAD(P)H-linked electron-
transfer components: NADPH-cytochrome c reductase[4], cytochrome b5[5] and NADH-
cytochrome b5 reductase[6] were discovered. Although their physiological functions were 
speculated upon, no evidence for their natural role was elucidated in the 1950s. However, 
the knowledge and techniques acquired in cytochrome b5 studies[7] paved the way for the 
identification of P450 proteins. 
Other observations in the mid-1950s also contributed to the classification of cytochrome 
P450. Axelrod demonstrated in his studies of drug metabolism in liver microsomes that 
NADPH and oxygen were required[8-9] and Ryan and Engels suggested in 1957 that steroid 
hydroxylases of adrenal cortex microsomes hold a heavy metal, possibly iron, due to the 
inhibition by carbon monoxide which was reversible by white light irradiation.[10] Yet, one 
of the most important observations was made in 1958 by Klingenberg, while studying the 
2 
spectral properties of rat liver microsomes, and would later be accountable for the naming 
of P450s. The microsomes showed, in the presence of a reducing agent and carbon 
monoxide, a prominent optical absorption peak at 450 nm which was unusual among the 
known coloured proteins at that time.[11] However, the nature of these enzymes remained 
unknown until the discovery of P450s by Omura in 1962. Omura repeated Klingenbergs 
experiments and noticed a new spectral peak at 420 nm upon treatment of the enzyme with 
detergents while the 450 nm peak disappeared. This new spectrum had a lot in common 
with that of hemoglobin, but contamination of the original microsomes with hemoglobin 
was precluded. To distinguish the original microsome-bound pigment from its detergent-
solubilized form, the former was named P450.[12]  
After these first simple spectral studies, the identification and characterization of P450s 
leapt forward and started to become a major topic in drug metabolism. Selected milestones 
of the key scientific discoveries in cytochrome P450 research during the past 50 years are 
highlighted in Figure 1.2. 
Today, cytochrome P450 hemoprotein enzymes constitute one of the largest protein 
superfamilies found in nature with more than 21000 officially by the P450 Nomenclature 
Committee accepted P450s (http://drnelson.uthsc.edu/cytochromeP450.html) (Figure 1.1). 
 
Figure 1.1: Schematic distribution of cytochromes P450 among the different kingdoms (August 2013) 
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Figure 1.2: Selected milestones in cytochrome P450 research (1962-2000) 
Discovery of P450[12] 
First P450 function 
determined[13] 
P450 discovered in mitochondria[29]  
P450 discovered in yeast[30] 
Purification of adrenedoxin and adrenodoxin reductase. First elucidation of a P450 
enzyme system[31-32] 
P450 discovered in bacteria[15]  
Eucaryotic P450 purification[16] 
P450cam (CYP101) discovered and purified 
(first purified P450)[33] 
P450 redox potential determined[17] 
First P450 structure: 
Prokaryotic P450cam[36]  
First heterologous expression of P450: Rat CYP11 is expressed in 
yeast[34]  First expression of P450 
(P450cam) in E.coli[35] 
Discovery of P450BM3: The 
first P450 fusion protein[26] 
Establishment of P450 nomenclature 
system[27] 
First eucaryotic P450 
structure (CYP2C5)[28]  
Development of E.coli expression systems to produce high levels of P450 for structural/function 
analysis[37-38] 
P450 mtetabolism of drugs[14] 
Confirmation of thiolate 
ligand to P450 heme[18] 
Multiplicity of P450s 
confirmed[19-20] 
First P450 amino acid sequence 
(P450cam)[21]  
First P450 cDNA (CYP2B4)[22] 
Resolution of human P450 
enzymes[23-25] 
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Ever since the discovery of cytochrome P450 in 1962[12], more than 37000 papers (NCBI, 
http://www.ncbi.nlm.nih.gov/) related to P450 research have been published and the 
number of academic research paper increases steadily with about 2000 per year 
(Figure 1.3) still being added (http://webtools.mf.uni-lj.si/public/medsum.html).    
 Figure 1.3: Scientific articles published on National Center for Biotechnology Information. 
With the emergence of multiple forms and isoforms of P450s[19-20, 39] in this rapidly 
growing research field, a classification system for the naming of P450 soon became a 
requirement. But in order to classify P450s based on the similarity of their primary 
sequences the accessibility of complete amino acid sequences was necessary. 
Pseudomonas putida P450cam was the first primary sequence determined[21] followed by a 
phenobarbital-induced P450 of rat liver derived from cloned cDNA[22] and many more 
were to come due to the rapid expansion of sequence data in the 1980s. It so happened that 
in 1987 Nebert and collaborators proposed a commonly accepted nomenclature system for 
cytochrome P450 (CYP)[27] with follow-ups in 1989[40] and 1991[41]. P450s that share 
>40% amino acid identity are grouped into the same family which will then be divided into 
subfamilies when members have >55% identity. Designated Arabic numbers indicate the 
gene family (CYP1, CYP2, etc.) and a subsequent capital letter the subfamily (CYP1A, 
CYP1B, CYP2A, CYP2B, etc.). Individual genes, on the other hand, are specified by 
another number (CYP1A1, CYP1A2, CYP2A1, CYP2A2, etc.). Moreover, additional 
nomenclature describing allelic variants are applied when P450 sequences share more than 
97% amino acid identity (v1, v2, etc.). Eventually, David Nelson established, out of a need 
for unlimited space to present nomenclature and annotation information, a publicly 
accessible homepage (http://drnelson.utmem.edu/CytochromeP450.html) in 1995.[42] 
Despite facilitating the naming of enzymes, it should be noted that the naming system does 
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not reflect on the function of the enzymes. Therefore, members within the same family 
may have completely different functions and enzymes with similar roles may belong to 
different families.  
1.1.2 Structure and Classes  
The first crystal structure of a P450, namely CYP101A1 (P450cam) from Pseudomonas 
putida, was determined by Poulus and coworkers 23 years after the first discovery of 
P450s.[36] Since then, the number of crystal structures identified for P450s increased 
rapidly with more than 600 entries in the Protein Data Bank for P450s to date 
(http://www.rcsb.org). With the availability of these structures, it has become apparent that 
the general structural fold across the P450 superfamily, including eukaryotic and 
mitochondrial P450s, is strongly conserved (as shown in Figure 1.4) despite often low 
sequence identity between the different families (10-30%)[43], and with only three 
absolutely conserved amino acids across this gene superfamily.[44-45] Furthermore, no other 
proteins apart from cytochromes P450 showed this structural arrangement. Not even 
prokaryotic and eukaryotic enzymes like nitric oxide synthases, which execute similar 
reaction chemistry to P450s and have cysteinate-coordinated heme iron, displayed any 
similarity in their structural topology.[46-47] 
 
Figure 1.4: Structure of cytochrome P450 using the Pseudomonas putida camphor hydroxylase P450cam (CYP101A1) as an example. A: overall structure[48]; selected helices labelled according to standard nomenclature[49]; α helices = blue cylinders; β sheet components = brown arrows; Interconnecting loop regions = cyan string; heme cofactor = red; B: space-filling model showing the access channel with camphor above the heme (PDB code: 2CPP) 
A B 
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The general shape of P450s resembles a trigonal prism with the heme cofactor concealed at 
the center. The overall structure of P450 enzymes contain four β-sheets (β5 is variable) and 
approximately 13 α-helices that can be distributed into the α (helix-rich) domain and the β 
(sheet-rich) domain (the top left of the P450cam structure in Figure 1.4 A) as shown in 
Figure 1.5.[48, 44] 
 
Figure 1.5: Topographic map showing the secondary elements commonly found among P450 enzymes[44] α helices = blue cylinders; β sheet components = brown arrows; Interconnecting loop regions = cyan string; heme cofactor = red 
β1 and β2 of the smaller β domain are involved in the formation of the hydrophobic 
substrate access channel.[44] The highest structural conservation is found in the structural 
core which is composed of helices D, E, I, and L and helices J and K, two sets of β sheets, 
and a coil called the  ”meander” .[50] The “meander” is a structurally conserved region 
that is spanned by 10-15 amino acid residues between K and the Cys-pocket [loop region 
(the β-bulge) preceding the L helix which contains the thiolate heme ligand] and is 
supposed to take part in heme binding and stabilization of the tertiary structure. Major 
structural elements include the long I helix, which is located diagonally across the heme 
cofactor and the L helix that runs behind the cofactor.[48] Those positions of structural 
elements close to the heme are generally well conserved and have regions of highly 
conserved amino acid motifs that center on the heme thiolate ligand and oxygen activation 
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chemistry. Figure 1.6 shows the most common amino acids motifs among the P450 
superfamily using the primary structure of a class II enzyme as example (additional 
transmembrane domain).   
 
Figure 1.6: Map of the signature motifs in the P450 proteins of an ER-bound P450 protein (class II enzyme) 
The cysteine ligand to the heme iron is absolutely conserved and critical to P450 
oxygenase function. It is located just prior the L helix in the heme-binding loop, which 
contains the most characteristic P450 consensus sequence (Phe-X-X-Gly-X-Arg-X-Cys-X-
Gly). The structural organization of this segment protects the Cys ligand and enables it to 
accept hydrogen bonds from peptide NH-groups. The only other motif considered 
absolutely conserved in the P450 superfamily is an EXXR motif in the K helix.[50] These 
residues appear to be important for hydrogen bonding and maintaining the “meander” 
region. The EXXR motif forms the so-called ERR triad using the R of the meander region 
(consensus sequence: PERF) as second “R“ in the motif. The ERR triad is believed to play 
an important role in heme binding due to single point mutation experiments of the K-helix 
glutamate[51] and arginine[52-54] or the meander arginine[55] in four separate enzymes that 
resulted in inactive protein. Helix I contains another consensus sequence considered as 
P450 signature (Ala/Gly-Gly-X-Asp/Glu-Thr-Thr/Ser) and includes the highly conserved 
Thr with important roles in coupling of electron transfer to substrate oxygenation and in 
substrate specificity.[48, 50]  
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Although the topology of almost all crystallised P450s are highly similar (Figure 1.4) they 
differ in substrate specificity and their electron transfer partners. These differences are 
facilitated by the diverse regions, which vary in both sequence and structure.[56] For 
instance, Gotoh described in 1992 six regions based on the comparison between the CYP2 
family and P450cam, the so called SRS (substrate recognition sites), that are participating in 
substrate recognition and binding. These variable regions include helices A, B, B’, F, and 
G and their flanking loops.[57] The loop region B–B’ and B’–C line the active site and 
harbour SRS1 while helices F and G and corresponding loop, that form part of the access 
channel and ceiling of the active site, hold SRS2 in the C-terminal end of F and SRS3. The 
N-terminus of β-strand 1–4 houses SRS-5 and the β-turn at the end of β sheet 4 (β 4-1) 
SRS6. SRS4 lies in the center portion of the I helix but is in comparison to the other SRSs 
conserved throughout the P450 family.[44] 
SRSs are generally associated to be involved in substrate orientation in the pocket since 
most of them are actually in the active-site/heme pocket of the P450 enzymes. Substrate 
recognition on the other hand is achieved through helix A, the F–G loop and β-strands 1–1 
and 1–2 given that mutation in this region influence the substrate binding.[58] Furthermore, 
these regions, except for helix A, are believed to be associated with the membrane in the 
membrane-associated P450s because of their increased hydrophobicity.[59]  
In addition, P450 enzymes require electrons for catalysis which are usually supplied by 
cofactors NADPH or NADH. In order to shuttle required electrons from cofactor to the 
heme domain, most P450s are associate with a NAD(P)H-linked reductase or reducing 
system in the cell. Interactions between P450 and its redox partner have to be well 
regulated to overcome the issue of heterogeneity among the P450 population in general 
and also their outnumbering of reductase molecules.[44, 60] It is believed that a 
complementary charge interaction is involved in redox-partner docking which allow P450s 
to interact with their electron donor at the proximal face of the molecule.[43] While the 
P450 itself has positively charged residues at the surface as indicated by mutation 
studies[54, 61-64], the reductase has conserved negative charges[65-67] that positively affect the 
alignment between the redox-partner and the P450. However, alignment studies of 
structurally known P450s shown different, but nonetheless unique charge distributions on 
the proximal face indicating that the binding between the P450 and the reductase will differ 
between P450 families.[56] Regarding P450 – redox partner arrangement, there are 10 
different classes of P450 systems described to date (summarized in Table 1.1).   
9 
Table 1.1: Classes of P450 redox partners [50, adapted] red: P450; light brown: ferredoxin (Fdx), flavodoxin (FMN); dark brown: ferredoxin reductase (FdR), [2Fe–2S] ferredoxin domain (Fe/S), flavin adenine dinucleotide (FAD); yellow: P450 reductase, CPR; blue: 2-oxoacid:ferredoxin oxidoreductase (OFOR) domain; 
 
Class/ Source Domain Organization Localization/ Remarks Example Reference Class I  
Bacterial 
 
Cytosolic Soluble CYP101 CYP105D1 [33], [68] [69] 
Mitochondrial 
P450: inner mitochondrial membrane  FdR: membrane associated Fdx: mitochondrial matrix, soluble 
CYP11A1 [32] 
Class II  
Bacterial 
 
Cytosolic Soluble CYP105A3 [70] 
Microsomal A ER  Membrane anchored CYP3A4 [71] Class III  
Bacterial 
 
Cytosolic Soluble CYP176A [72], [73] 
Class IV  
Bacterial 
 
Cytosolic Soluble CYP119 [74], [75] 
Class V  
Bacterial 
 
Cytosolic Soluble CYP51FX [76] 
Class VI  
Bacterial 
 
Cytosolic Soluble CYP177A1 [77], [78] 
Class VII  
Bacterial 
 
Cytosolic Soluble CYP116B2 CYP116B3 [79] [80] 
Pyruvate 
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Class I P450s (I) are three-component systems consisting of a flavin adenine dinucleotide 
(FAD)-containing reductase (FDR) that transfers electrons supplied by a cofactor to an 
iron-sulfur protein (ferredoxin, Fdx) which then reduces the P450. This system occurs 
solubly in prokaryotes and usually utilizes NADH as electron source but can also be found 
in mitochondria of eukaryotes in which the P450s and reductase are membrane bound and 
prefer NADPH.[87-88] It was first elucidated in Pseudomonas putida (CYP101) in 1968 by 
Katagiri and co-workers who were able to separately purify all elements of the electron 
transport chain and restore its activity.[33] 
Eukaryotic organisms usually possess the class II P450 system (II), a microsomal system 
typically located in the endoplasmatic reticulum (ER), consisting of 2 integral membrane 
proteins. One is a single NADPH specific P450 reductase (CPR) that contains both FAD 
and FMN domains for mediating electron transfer from NADPH[89-90] and the other is the 
P450 itself. Microsomal P450s in mammalian liver also utilize cytochrome b5 as a second 
source of electrons, where the reductant is NADH and electron transfer is mediated by 
cytochrome b5 reductase which is an FAD-containing oxidoreductase.[91] One prokaryotic 
soluble class II monooxygenase system has been described in Streptomyces carbophilus. It 
consists of a NADH-dependent P450 reductase containing both FAD and FMN and the 
CYP105A3 (P450sca).[70]  
In 2002, Hawkes and collaborators observed a unique arrangement of P450 and putative 
redox partner (III) that deviate from the originally proposed class I and class II systems. 
Class/ Source Domain Organization Localization/ Remarks Example Reference Class VIII  
Bacteria Fungi 
 
Prokaryotic: Cytosolic, Soluble Eukaryotic: membrane anchored   
CYP102A1 CYP505A1  [81] [82] 
Class IX  
Fungi 
 
Cytosolic Soluble Only NADH dependent CYP55 [83] 
Class X  
Plants Mammals 
 
ER  Membrane bound CYP74A [84], [85], [86] 
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CYP176A1 from the bacterium Citrobacter braakii contains in contrast to bacterial class I 
systems not an iron-sulfur domain as second mediator protein but a flavodoxin, so that 
electrons are transferred via the redox centres FAD and FMN.[72] 
Class IV systems (IV) which receive electrons from a non-NAD(P)H-dependent reductase 
were discovered in extremophile bacteria like Sulfolobus solfataricus[92], and Sulfolobus 
tokodaii[93]. The P450 CYP119 obtains its reducing equivalents from 2-oxoacid:ferredoxin 
oxidoreductase (OFOR)[94-95] that uses pyruvic acid instead of NAD(P)H as the source of 
electrons.[96] 
A fifth class of P450-redox partner association (V) was found in the bacterium 
Methylococcus capsulatus, one of the few bacteria that can synthesise sterols de novo.[76] 
The CYP51 P450 heme domain is fused at the C-terminus to a ferredoxin domain utilizing 
an oxogenous ferredoxin reductase as the third electron-transfer protein component.[97] 
Another novel P450 fusion arrangement was identified in Rhodococcus rhodochrous 
(strain 11Y) (VI) consisting of a fusion between a soluble C-terminal P450 domain (XplA) 
and an FMN-containing N-terminal flavodoxin domain.[77] XplA is encoded in a gene 
cluster that includes the putative redox-partner upstream of xplA, the FAD-containing 
reductase protein (XplB). XplA catalyses the degradation of nitramine explosive and 
pollutant hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) by reductive denitration and allows 
R. rhodochrous 11Y to use it as its only nitrogen source.[98] 
Another natural P450 fusion enzyme (VII) was found in the bacterium Rhodococcus sp. 
NCIMB 9784.[99] The protein was named CYP11B2 (P450Rhf) and comprises a soluble 
P450 heme domain fused to a FMN-and a 2Fe2S-containing reductase at the C-terminus. 
Homologues of this fusion system, which endogenous function is not known, were also 
discovered in Ralstonia metallidurans (CYP116B1) and Rhodococcus ruber 
(CYP116B3).[80] 
In 1986, a naturally occurring P450 fusion enzyme (CYP102A1; P450BM3) was discovered 
in Bacillus megaterium that for the first time deviated from the standard class I and class II 
systems.[26] Enzymes belonging in the class VIII system (VIII) are catalytically self-
sufficient monooxygenases in which the N-terminal heme domain is linked to an 
eukaryotic-like diflavin reductase domain (CPR) at the C-terminus. P450BM3 has amongst 
all P450 monooxygenases the highest reported turnover rate which is probably due the 
rapid intratransfer of electrons between the fused protein domains.[100] Homologues of 
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CYP102A1 could be found in Bacillus subtilis (CYP102A2 and CYP102A3) as well as in 
Ralstonia metallidurans, Bradyrhizobium japonicum, and various bacilli and 
streptomycetes.[101] Apart from class VIII systems in prokaryotes, eukaryotic counterparts 
exist like the ER membrane bound CYP505A1 (P450foxy) from Fusarium oxysporum.[102] 
Unlike most P450s that need a redox partner for catalysis, P450s of class IX (IX) function 
without participation of any NAD(P)H-linked reductase or reducing system. CYP55A1 
(P450nor) of the fungus Fusarium oxysporum is the first example ever been described for 
this class.[103] In case of P450nor the heme prostetic group receives electrons directly from 
NADH to catalyse the reduction of nitric oxide to nitrous oxide. Homologues could be 
found in Trichosporon cutaneum[104], Cylindrocarpon tonkinense, Histoplasma capsulatum 
and Aspergillus oryzae[105].  
The final class of P450s (X) can catalyse the rearrangement of the oxygen atoms in the 
substrate molecule itself and therefore don’t require NAD(P)H or any redox partners. 
CYP8A1 for example, can synthesize prostaglandin H2 from prostacycline[106] whereas the 
microsomal P450 CYP5A1 utilizes prostaglandin H2 to build tromboxane A2[107] without 
the supply of reducing equivalents. Other examples can be found in plants in the CYP74 
family which encode allene oxide synthases[108].  
1.1.3 Catalytic Reaction Mechanism 
The classical reaction catalysed by cytochromes P450 is a monooxygenase reaction 
(alternative reaction see chapter 1.1.4) in which one oxygen atom, originating from 
molecular O2, is incorporated into the substrate while the second oxygen atom is reduced 
to water. This reaction utilizes two electrons usually derived from reduced pyridine 
nucleotides (NADH or NADPH)[109].  
RH + O2 + NAD(P)H + H+ → ROH + H2O + NAD(P)+ 
Oxygen is a highly abundant element in aerobic organisms and although it is generally 
regarded as being a chemically reactive element, the dioxygen molecule is relatively inert 
because of the high stability of the dioxygen bond (497 kJ mol/l) and its unusual electronic 
structure[110-111]. In order to utilize its inherent oxidative properties for metabolism, it is 
crucial to activate oxygen. This activation can be achieved by metal-dependent 
oxygenases, like cytochromes P450 which contain a prosthetic group constituted of an iron 
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(III) protoporphyrin-IX with thiolate as fifth (axial) ligand, leaving the sixth coordination 
site open to bind and activate molecular oxygen (Figure 1.7)[112].  
 
Figure 1.7: Prosthetic of cysteinato-heme enzymes An iron-(III) protoporphyrin-IX linked with proximal cysteine ligand of the cytochrome P450 
In order to understand the reason for, and mechanism of, oxygen activation by 
cytochromes P450, it is important to consider the different spin- and redox states of the 
dioxygen molecule as well as the iron atom present in the heme group. In dioxygen, each 
oxygen atom contributes eight electrons to the molecule. Half of these electrons occupy 
sigma bonding and antibonding orbitals, formed by overlap of the 1s and the 2s orbitals. Of 
the remaining eight electrons, six occupy, in accordance to the aufbau principle, the 2σ and 
the 2π bonding orbitals, leaving two electrons which must be placed in the two 2π* 
antibonding orbitals. These electrons will each - according to Hund's Rule - occupy one of 
the degenerate (same energy) orbitals, and they are therefore unpaired and have parallel 
spins.[113] Figure 1.8 A illustrates this ground-state of dioxygen which is commonly 
referred to as the triplet ground state. The triplet electronic state can be traced back to the 
formula for the spin quantum number [(2S + 1); S = ½ for each unpaired electron] which 
yields a value of 3 for the overall spin state as the total S = 1 (½ + ½). Thus, the triplet 
state is regarded as 1 plus the number of unpaired electrons. This feature, makes oxygen 
paramagnetic and according to Pauli’s exclusion principle very unlikely to participate in 
reactions with organic molecules which are usually in a singlet state because they generally 
don’t contain unpaired electrons (S = 0; 2S + 1 = 1). In order to overcome the spin 
restriction, the triplet oxygen has to form the singlet state by absorption of sufficient 
energy to reverse the spin on one of the unpaired electrons (Figure 1.8 B and C). Another 
mechanism for oxygen activation involves monovalent reduction. [110, 113-114] However, the 
iron in P450s is able to interact with O2 when both are in their high-spin states. 
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Figure 1.8: The three electronic configurations of molecular oxygen, O2.  A: the triplet ground state 1Σg− ; B: the singlet oxygen ¹Σg+ excited state; C: the singlet oxygen ¹Δg excited state. 
When the P450 enzyme is in its resting state (prior substrate binding), the ferric iron [Fe3+ 
or Fe(III); valence shell electrons: 3d5], that lies within the plane of the heme group, is 
predominantly low spin (two electron pairs and only one unpaired electron in the d orbital). 
Substrate binding at the enzymes’ active site, however, leads to a change in the ferric iron 
spin-state from low spin to high spin due to the displacement of the distal water molecule 
(Figure1.9 A-B) which consequently causes the iron to move out of plane of the porphyrin 
ring as the central cavity is too small to accommodate the increased cationic size. The 
transition to a high spin state (degenerate orbitals occupied with five unpaired electrons; 
spin-free) and the changes in heme geometry, trigger the reduction of the P450 enzyme by 
its redox partner as substrate binding lowers the Fe(III) redox potential of the P450 such 
that the reduction from ferric to ferrous state [Fe2+ or Fe(II)] is favoured (Figure 1.9 C). It 
is believed that Fe(II) in its high spin form (four unpaired electrons in the d orbital) ensures 
a spin-favoured interaction with the triplet ground-state dioxygen as both are in their high 
spin states which leads to the activation of O2 to superoxide (Figure 1.9 D, ferric 
superoxide complex) by substrate induced spin and redox changes.[110-111, 115-116]   
Once the ferric superoxide complex is formed, the P450 undergoes a second reduction in 
order to complete its cycle. This second electron transfer, that is usually the rate limiting 
step of the catalytic cycle, generates the ferric peroxy anion which is protonated to form 
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the ferric hydroperoxo species known as compound 0 (Figure 1.9 E). The ferric 
hydroperoxo intermediate, however, readily undergoes a second protonation as it is 
unstable and that gives rise to a porphyrin radical cation Fe(IV) species (alternative 
species: protein radical cation Fe(IV) F’ or Fe(V) species F’’) also known as compound I 
(Figure 1.9 F). This ferryl intermediate is able to attack the substrate which produces the 
hydroxylated metabolite (Figure 1.9 G). The enzyme will then return to its resting ferric 
state due to product release and reequilibration with water to complete the cycle.[117] 
 
Figure 1.9: The cytochrome P450 catalytic cycle.  heme group: solid bars; iron: Fe; cysteine thiolate: Cys-S; substrate hydrocarbon: RH; hydroxylated product: ROH; The +. over one of the heme bars indicates the radical cation is located on the porphyrins, whereas its placement besides the brackets indicates that the radical is located somewhere on the protein. See main text for detailed description. 
During the P450 reaction cycle, forms of active oxygen species (Oଶି , Oଶଶି, OH) are 
produced ,which are usually only formed in situ. However, in the event of a so called 
uncoupling there are three reaction mechanisms that lead to the break down of the oxo 
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intermediates. The first is the autoxidation of the ferric superoxide complex D which 
reforms the ferric P450 and produces superoxide radicals. In the second uncoupling 
scenario, known as the peroxide shunt, compound 0 E collapses and hydrogen peroxide is 
released. This reaction is reversible and can be exploited by some P450s to bypass the need 
of a redox partner by introducing the oxygen from hydrogen peroxide into the substrate. In 
the third reaction (oxidase shunt) the compound I F is protonated and reduced again by the 
dissociation of water instead of an insertion of the oxygen into the substrate.[48, 118] 
1.1.4 Evolution and Catalysed Reactions 
P450s are well known for their broad substrate range and the variety of reactions they 
catalyse. The functional diversity among this gene family can be caused through a variety 
of genetic mechanisms (e.g., exon shuffling, alternative splicing and RNA editing).[119] The 
most commonly acknowledged mechanism driving the expansion and diversification, 
however, is gene duplication.[120] 
It is proposed that the first cytochrome P450 originated from an ancestral gene that existed 
three and a half billion years ago[121], thus before the accumulation of an oxygen-rich 
atmosphere and the advent of eukaryotes. It is therefore believed that cytochrome P450s 
originally performed nitroreductase or endoperoxide isomerase reactions.[122] With the 
buildup of significant levels of molecular oxygen in the earth’s atmosphere (approximately 
2.8 billion years ago) the function of cytochrome P450s may have then shifted to protect 
early life forms from oxygen toxicity.[123] Additionally, repeated rounds of expansion by 
gene and genome duplication lead most likely to the modern form of P450s. One of the 
first expansions occurred probably one and a half billion years ago and evoked the 
development of cytochrome P450 families that may played a role in maintaining the 
membrane integrity of early eukaryotic cells and were therefore involved in the 
metabolism of endogenous fatty acids, cholesterol and its derivatives (e.g., CYP11 and 
CYP4 families).[124] The most recent and possibly most dramatic expansion started about 
four hundred million years ago and was driven by two major events: (1) emergence of 
aquatic organisms onto land and (2) exposure of terrestrial organisms to hydrocarbon-
based combustion products in the atmosphere).[125] It appears that the process of co-
evolution between plants, animals, fungi and prokaryotes sustained the expansion and 
diversification of the cytochrome P450 superfamily and led to a multiplicity of reactions 
catalysed by P450s.  
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Figure 1.10: Schematic summary of the diverse P450-catalysed reactions[2]  
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 Figure 1.11: P450-catalysed C–C bond coupling in isoquinoline alkaloid biosynthesis of plants 
Modern P450s play important roles in catalysing key steps of many different pathways and 
their reaction repertoire extends from hydroxylation and oxidation, which are the most 
common P450 reactions, to alkylation, dealkylation, epoxidation, demethylation, aryl 
migration and many more. A summary of the most common P450 reactions is given in the 
review by Sono et al. (Figure 1.10) describing more than 20 different reaction types.[2] In 
addition, P450-catalysed C–C bond couplings are common in the metabolism of many 
plants. These reactions are often critical in the biosynthesis of plant secondary metabolites 
(e.g., alkaloidbiosynthesis, Figure 1.11).[126] Guengerich and Munro provided a recent 
description of unusual P450 reactions including nitration of tryptophan, cyclopropanation 
via carbene transfer, and intramolecular C-H amination.[126] 
1.1.5 Applications 
1.1.5.1 Potential and Limitations of P450s in biocatalysis 
For a long time, enzyme catalysis was not acknowledged as a first choice option in organic 
synthesis because of observed or often assumed disadvantages (e.g., narrow substrate 
range, limited stability of enzymes, low efficiency) and was only applied in the production 
of chemicals that were too difficult to synthesize in conventional ways. However, over the 
last 20-30 years enzymes have been recognized as viable tools for biotechnological 
application due to the tremendous progress in enzyme discovery, enzyme engineering, 
process development and, nonetheless, the rising pressure to design greener processes.[127] 
In order to meet green chemistry criteria, enzymes offer a major advantage because they 
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are usually able to operate at ambient temperature and pressure conditions which support 
lower energy processes. Furthermore, enzymes present the probability to reduce or even 
end the need for dangerous, toxic reagents as well as organic solvents in synthetic 
chemistry. However, several criteria have to be considered in order to apply 
biotransformations in an industrial context to maximise cost efficiencies. High conversion 
rates enabling for consumption of the maximal substrate amount and thus contributing to a 
decrease in substrate costs are of particular interest. Moreover, a high enantio- and 
regioselectivity is very desirable for the resulting product. Furthermore, substrate and 
product concentrations have to be considered for biotransformations as well as volumetric 
productivities.[128]  
One of the main reason P450s attracted so much attention in the first place is their ability 
to oxyfunctionalize non-activated C-H bonds which still remains a major challenge in 
chemistry.[129] In addition, P450s are able to catalyse numerous different reaction types 
beside oxygenation (see 1.1.4)[2, 126] under ambient conditions and offer the advantage of a 
broad substrate range (e.g., xenobiotics, antibiotics, steroids, terpenes, alkanes, fatty acids, 
alkaloids, etc.) often exhibiting high regio-, chemo-, and/ or stereoselectivity,[130] which 
makes them excellent starting materials to engineer new powerful biocatalysts. The most 
powerful source in P450 engineering is, however, the wide-ranging knowledge that has 
been acquired about P450s in last 50 years. 
Although CYPs are generally regarded as biocatalyst with extraordinary potential, 
commercial applications of P450 catalysed reactions are rather scarce due to intrinsic 
drawbacks that continue to create major challenges when working with this class of 
enzymes (Table 1.2). One of the main issues is their natural occurring low turnover rate 
when compared to other enzyme classes. Also, the dependence on expensive cofactors like 
NAD(P)H as a source of electrons that have to be transferred to the heme domain using 
complex electron-transfer systems causes problems for the implementation of P450s to 
perform in an cost efficient industrial scale. Furthermore, the P450 origin has to be 
considered. While most bacterial P450s are easily expressed as soluble, stable enzymes in 
recombinant hosts and are therefore easier to handle than eukaryotic P450s, which are 
generally membrane bound and often unstable or inactive in the purified form, the 
substrate spectra and reactions catalysed by eukaryotic P450s are often more amenable to 
industrial applications.[130-133] 
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Table 1.2: Challenges and limitations for biotechnological application of CYPs 
Limitation Explanation/Cause Possible solution(s) General for CYPs   Low CYP activity Natural role of P450s Protein engineering Need for electron transfer partners Channeling of electrons to active site Use of heterologous redox partners Peroxide shunt Electrochemical and photo-chemical reduction of heme iron Limitations of electron transfer rate Complexity of catalysis Fusions between CYP and electron transfer proteins Mismatch between redox partners Redox chain optimization Uncoupling Poor fit of substrate to active site Protein engineering Overoxidation Product is also substrate In situ product removal NAD(P)H requirement Source of electrons Enzymatic cofactor regeneration Coupling with plant photosynthesis Electrochemical heme reduction Low substrate solubility Substrates are often hydrophobic and/or poorly soluble in water 
Two-liquid phase systems (dissolving substrate in an inert organic solvent) Addition of co-solvents or cyclodextrins Specific for whole-cell biocatalysts   Limited substrate uptake Hydrophobic compounds disrupt cell membranes Alternative hosts with altered uptake profiles Limited product efflux Lack of specific efflux pumps in host Cell membrane permeabilization Modulation of efflux system Limited oxygen transfer rate Competition with endogenous respiration Addition of oxygen Substrate or product toxicity General toxicity of polar compounds Alternative hosts with enhanced resistance Product degradation  Two-liquid phase systems 
Efforts to overcome limitation concerning enzyme activity and substrate specificity include 
predominantly enzyme engineering via site directed mutagenesis[134-135] or direct 
evolution.[136-137] With regard to cofactor-dependency for biotransformation, whole cell 
systems are often employed to take advantage of cell internal cofactor recycling and thus 
bypass the constant addition of expensive material. Although this seem to be an elegant 
solution, significant bottlenecks related to whole cell systems, like limited substrate uptake, 
toxicity of the substrate or product, and product degradation need to be taken into account 
as well.[131] Nonetheless, it was possible to employ several well engineered P450s as 
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catalysts for various applications due to the extended research in the field of cytochromes 
P450. 
1.1.5.2 Commercial applications 
As already mentioned above, the implementation of cytochrome P450s in fine chemical 
synthesis has to meet certain requirements for industrial (minimum space–time yield of 
0.1 g l-1 h-1; minimum final product concentration of 1 g l-1) as well as in pharmaceutical 
(minimum space-time yield of 0.001 g l-1 h-1; minimum final product concentration of 
0.1 g l-1) production.[138] An analysis of 12 CYP-based processes by Julsing and coworkers 
(shown in Figure 1.12) commenced in 2008 demonstrates the difficulties related to P450 
linked industrial application.[139] At that time, only one of the analysed cytochrome P450s 
fulfilled the minimal requirements defined for fine chemical synthesis (A Figure 1.12), 
while 4 CYP450s couldn’t even meet the minimum requirements set for the 
pharmaceutical industry (I, J, K and L Figure 1.12). Furthermore, the operational time 
window of CYP450-based processes appears very high when compared to nonheme 
oxygenases. Nonetheless, it becomes apparent how subsequent optimization unlocks 
completely new perspectives for CYP application when looking at the example of the 
engineered S. cerevisiae strain (H Figure 1.12) that was part of Julsing’s analysis.  
In that particular case, a S. cerevisiae strain has been facilitated to produce artemisinic acid 
(precursor of the antimalarial drug artemisinin) from simple sugars.[146] Figure 1.13 shows 
the schematic representation of the engineered artemisinic acid biosynthetic pathway in the 
S. cerevisiae strain EPY224 expressing amorphadiene synthase (ADS), CYP71AV1 and its 
cognate CPR from the plant Artemisia annua. First consideration in the engineering 
process was to increase the production of farnesyl pyrophosphate (FPP) and decrease its 
use for sterols. To increase FPP production in S. cerevisiae, Ro and coworker upregulated 
the expression level of several genes responsible for FPP synthesis and downregulated one 
gene responsible for FPP conversion to sterols (not shown in Figure 1.13) using 
chromosomal integration to implement these modifications. The second step, after the 
generation of a high FPP producing yeast strain, was the introduction of the amorphadiene 
synthase gene (ADS) from A. annua, which has been characterized and used for de novo 
production of amorphadiene in E. coli.[147-148] The third and final obstacle to overcome was 
the production of artemisinic acid from amorphadiene.  
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 Figure 1.12: Industrial potential of CYP450-catalysed bioprocesses ( [139], altered) dark grey area: requirements for fine-chemical industry; light and dark grey area together: requirements for pharmaceutical industry; : production of pharmaceutical products;    : production of fine chemicals; black filling: oxygenases containing nonheme-iron or flavin centers; red filling: bacterial P450s; orange filling: mammalian P450s;   : engineered Saccharomyces cerevisiae strain exploiting a plant P450 for production of pharmaceutical products ([140], see text below); tmin: minimum process running time; tP450; longest reported CYP450 enzyme activity time; STYP450: theoretical maximum space–time yield for CYP450-based processes; STYminC: minimum required space–time yield for bioprocesses in the chemical industry; STYminPh: minimum required space–time yield for bioprocesses in the pharmaceutical industry; CminC: minimum required product concentration for bioprocesses in the fine-chemical industry; CminPH: minimum required product concentration for bioprocesses in the pharmaceutical industry; A: Candida tropicalis strain engineered for the P450 catalysed production of long-chain dicarboxylic acids; B: (CYP153A14) from Mycobacterium sp. expressed in Pseudomonas putida converts limonene to the anticancer drug perillyl alcohol; C: CYP102A1 mutant used in a biphasic system to hydroxylate cyclohexane, octane and myristic acid; D: P450 catalysed bioconversion of compactine into pravastatin by Streptomyces sp.; E: optimization of fed-batch condition resulting in 25-fold increase of CYP102A1 expression level in E. coli; F: P450BM3 expression in E. coli whole cells lead to controlled regioselective oxidation of fatty acids; G: Human CYP2D6 overexpressed in Schizosaccharomyces pombe catalyses the oxidation 4‘-hydroxymethyl-α-pyrrolidinobutyrophenone; H: engineered Saccharomyces cerevisiae strain produces antimalarial drug precursor artemisinic acid; H’: further engineered Saccharomyces cerevisiae strain produces antimalarial drug precursor artemisinic acid ([140]; see text below) I: engineered yeast catalyses self-sufficient biosynthesis of pregnenolone and progesterone; J: addition of cyclodextrin enhances P450 catalysed hydroxylation of vitamin D3 to 25-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 by Amycolata autotrophica; K: Transformation of vitamin D3 to 1α,25-dihydroxyvitamin D3 via 25-hydroxyvitamin D3 using Amycolata sp. strains; L: Bioconversion using immobilized recombinant flocculent yeast cells carrying a fused enzyme gene in an ‘intelligent’ bioreactor; M-Q: comparison of biosynthesis processes catalysed by oxygenases other than P450s, see references [141] [142] [143] [144] [145] 
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For that, the CYP71AV1 gene, also from A. annua, was employed to oxyfunctionalize 
amorpha-4,11-diene and produce artemisinic acid in a three-step oxidation. As a result, this 
system yielded up to 0.1 g l-1 artemisinic acid, and thus barley fulfilled the minimal 
requirements for pharmaceutical compounds as defined by Julsing.[139] Advances within 
the next 4 years after Julsings publication to further improve this strain, made it, however, 
possible to yield a final concentration of 1.6 g l-1 of artemisinic acid.[149] Moreover, this 
artificial multi-enzyme cascade system originally developed by Ro and coworkers also 
paved the way for further improved yeast systems. In 2009 Teoh and coworkers reported a 
yeast system that employed, in addition to the synthase and the CYP71AV1, an alcohol 
and aldehyde dehydrogenases from A. annua.[150] All these findings and subsequent 
improvements finally led to an engineered yeast system that could produce up to 25 g l-1 in 
fermentation experiments as very recently reported by Paddon et al..[140] The bioprocess 
catalysed by this strain is shown in Figure 1.12 (H’) in comparison to the original strain 
(H) and strinkingly demonstrates the potential of bioprocess engeneering. Based on this 
engineered yeast strain, Sanofi (a Paris-based pharmaceutical company) officially launched 
a new production facility in 2013 to produce artemisinin in large scale 
(http://www.rsc.org/chemistryworld/2013/04/sanofi-launches-malaria-drug-production).  
24 
 Figure 1.13: Schematic representation of the engineered artemisinic acid biosynthetic pathway[146] the green background indicates the engineered mevalonate pathway in S. cerevisiae strain EPY224; the blue background shows the introduced artemisinic acid pathway; blue arrows: directly upregulated genes; purple arrows: upc2-1 expression (global transcription factor regulating the biosynthesis of sterols) indirectly upregulated genes; red arrows: introduced biochemical pathway leading from farnesyl pyrophosphate (FPP) to artemisinic acid; IPP: isopentenyl pyrophosphate; DMAPP; dimethyl allyl pyrophosphate; GPP: geranyl pyrophosphate; ADS: amorphadiene synthase; see main text for description. 
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Another example of CYP implementation in artificial multi-enzyme cascades is the 
synthesis of the steroids pregnenolone and progesterone, mediated by bovine P450scc 
(CYP11A1) in recombinant S. cerevisiae, co-expressing adrenodoxin and adrenodoxin 
reductase to support activity of CYP11A1 (Figure 1.14).[151] The strain was able to produce 
a total pregnenolone concentration of 60 mg l-1. Further improvement of this strain by 
Szczerbara and co-worker led to a full biosynthetic pathway for the production of 
hydrocortisone via progesterone, 17-hydroxy-progesterone and 11-deoxycortisol. The 
improved pathway involved 13 genes of which four were P450s.[152] Sanofi-Aventis, 
finally, adapted this system for industrial production. Further well-established commercial 
applications in the P450 based biotransformation of steroids is the 11-β-hydroxylation of 
Reichstein S to hydrocortisone and other antiinflammatory corticosteroids by Curvularia 
sp. (Schering, now Bayer)[153] as well as the conversion of progesterone to cortisone by 
Rhizopus sp. (Upjohn, now Pfizer). [154] 
 Figure 1.14: Schematic representation of the final step in progesterone biosynthesis by engineered yeast. ADR: Adrenodoxin reductase; ADX: adrenodoxin; P450scc: bovine CYP11A1; 3β-HSD: human 3β-hydroxysteroid dehydrogenase/isomerase  
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In addition to drug and drug metabolite production, CYPs are utilized for several other 
commercial products. Amazing examples for this are transgenic plants that are able to 
produce flowers with unusual colours due to transferred CYP colouration genes from other 
plants.[130] Three classes of pigments (flavonoids, carotenoids, and betalains) primarily 
attribute to the colour of flowers, whereas the anthocyanins (class of flavonoids) cover 
colour ranges from orange over red to blue and violet as shown in Figure 1.15.[155] In order 
to obtain flowers with a blue or violet colour the biosynthesis of the pigment delphinidin 
by flavonoid 3’,5‘-hydroxylase (CYP75A/F3‘5’H) is essential. The gene encoding F3‘5’H 
was first isolated from petunia[156] and many other plants subsequently, and although it 
diverged before the specification of higher plants, numerous plants aren’t able to 
synthesize delphinidin due to deficiency of F3‘5’H.[157] Among them are Rosa hybrida 
(rose), Chrysanthemum moriflolium (chrysanthemum), Dianthus caryophyllus (carnation) 
and Lilium spp. (lily), which occupy more than 50 % of the cut-flower market. In order to 
gain access to an untapped market like this researchers develop genetically engineered 
transgenic “blue roses” by introducing CYPs from blue pansy and dihydroflavonol 
reductase from petunia into the rose with simultaneous suppression of dihydroflavonol 
reductase (Suntory Ltd, Japan; Calgene Pacific, now Florigene Pty Ltd, Australia).[158] 
Others plants like mauve carnations (“Moon dust”) and violet carnation (“Moon shadow”) 
have been developed and are available on the market in Japan and Australia.  
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Figure 1.15: Anthocyanidins and flavonoid biosynthetic pathway relevant to flower colour. red letters: P450 enzymes; PAL: phenylalanine ammonia lyase; C4H: cinnamic acid 4-hydroxylase, 4CL: 4-coumarate CoA ligase; CHS: chalcone synthase; CHI: chalcone isomerase; F3H: flavanone 3-hydroxylase; F3’H: flavonoid 3‘-hydroxylase; F3‘5’H: flavonoid 3‘5‘-hydroxylase; DFR: dihydroflavonol 4-reductase; ANS: anthocyanidin synthase; colour-modified transgenic flowers by expression of  F3’H and/or F3‘5’H in carnation (A), rose (B) and chrysanthemum (C). 
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1.1.5.3 Medicine 
In recent years increased attention regarding the use of P450s in the medical sector has 
been concentrated on gene-directed enzyme prodrug therapy (GDEPT). It’s a strategy that 
comprises a three-component system (Figure 1.16) and aims to convert prodrugs into 
active therapeutic metabolites in the cancer cell itself and thus improve the efficacy and 
reduce toxicity of cancer chemotherapeutic agents.[159] Although, no GDEPT product is 
currently available on the market it has shown great promise in cancer therapy. 
One of the most intensively studied prodrug/enzyme system involving P450 gene transfer 
is the cytochrome P450/oxazaphosphorines system. Oxazaphosphorines include 
cyclophosphamide (CPA) which holds substantial antitumour activity but requires 
activation by hepatic cytochrome P450 (CYP2B6) catalysed 4-hydroxylation to yield 4-
hydoxyl derivatives which are further metabolized to cytotoxic phosphoramide 
mustard.[160] Phosphoramide mustard, however, is in contrast to the 4-hydroxy metabolites 
unable to cross cell membranes. Consequently, activation of the prodrug in the liver can’t 
produce effective local tumour concentrations as well as bystander cytotoxic effect.[161] 
The P450 GDEPT approach conquers this issue by introducing P450-expressing genes into 
tumour cells and therefore generating high levels of 4-OH-CPA directly in the tumour cells 
which in turn leads to strong bystander effects. Trials applying this system using human 
CYP2B6, CYP2C18 and CYP3A4 in 9L-gliosarcoma cells showed a strong cytotoxicity 
with CPA.[162] Even more encouraging are the results of phase II clinical trials using 
CYP2B6 conducted by Hunt and coworkers which led to the selective death of the tumour 
cells inflicting only minimal harm to normal cells.[163] Other CYPs apart from human 
P450s have been tested and shown great promise as well. The canine CYP2B11 for 
example showed in comparison to CYP2B6 an increased intratumoural concentration of 4-
OH-CPA when tested in vivo.[164] 
As P450s are responsible for drug metabolism in the body they also attracted attention for 
medical applications as biosensors to monitor drug levels in blood plasma.[165] In order to 
bypass the need for an electron donor (NADPH) and electron transfer partner (CPR), CYP 
enzymes that are employed as biosensors are usually immobilized on an electrode which 
directly transfers required electrons to the enzyme that either binds to or converts the drug. 
By unravelling the P450 substrate profile of a drug, biosensors allowing for example for 
the prediction of damaging drug-drug or food-drug interactions caused by the CYP 
metabolism.[166]  
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Figure 1.16: Schematic representation of gene directed enzyme pro-drug therapy (GDEPT) The 3 component system usually comprises: an inactive drug (prodrug), a gene coding for an enzyme that converts inactive prodrug to an active drug, and a carrier (vector) that delivers the gene to a tumour cell with or without carriers.  
1.1.5.4 Bioremediation 
Soil and water pollution due to industrial chemicals like polycyclic aromatic hydrocarbons 
(PAHs); polychlorinated dibenzo-p-dioxins (PCDDs); and polychlorinated biphenyls 
(PCBs) as well as herbicides and explosives are a leading cause for environmental 
contamination. Detoxification of affected areas still remains a major challenge but is of 
crucial importance in order to exploit unused contaminated land, increase crop production 
and improve underground water quality, which is often used as drinking water. An 
alternative treatment technique to already existing physicochemical methods, applies 
enzymes that are able to transform or degrade these chemicals.[167-168] Recombinant 
bacteria expressing P450s that are involved in deactivation or degradation of toxic 
xenobiotics can for example be used for waste water treatment while transgenic plants can 
be used for detoxifacation of contaminated soil. 
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Figure 1.17: Oxidation of PCDDs by rat CYP1A1 and CYP1A2 expressed in S. cerevisiae 
Numerous wild-type P450s of plant, bacterial and mammalian origin have been 
investigated with regard to potential detoxification capacities. Human CYP1A1 and 
CYP2B6, for example, could metabolize several herbicides as well as PAHs (CYP1A1) 
and PCBs (CYP2B6).[168] CYP76B1 from Helianthus tuberos[169] and CYP71A10 from 
soybeans[170] showed activity against herbicides such as phenylureas. Furthermore, 
enzymes engineered by either rational or directed evolution can be employed for possible 
bioremediation as shown for engineered P450BM3 and P450cam. Mutants of P450BM3 showed 
enhanced activity towards terpenes and gaseous alkanes, while some P450cam mutants were 
able to metabolize PAHs and PHBs.[168] Construction of recombinant cells and transgenic 
plants expressing CYPs already showed high potential. Sakaki and coworker were able to 
express rat CYP1A1 and CYP1A2 in yeast which as a result were able to biodegrade 
PCDDs (Figure 1.17).[171] Moreover, some transgenic plants showed herbicide resistance 
as well as phytoremediation of environmental contaminants. Transgenic potato and rice 
plants generated by Inui and Ohkawa, for example, metabolized several herbicides, 
insecticides and industrial chemicals.[172] Another exceptional example for utilization of 
transgenic plants is an Arabidopsis thaliana strain that has been engineered to express a 
P450 fusion (XplA fused to flavodoxin redox partner) from Rhodococcus rhodochorus 
which enabled the plant to degrade RDX (hexahydro-1,3,5-trinitro-1,3,5-triazine) from 
contaminated soil.[77] 
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1.1.6 The fungal Kingdom 
1.1.6.1 Fungi – the double-edged sword 
Fungi are members of a large group of lower eukaryotic microorganisms, morphologically 
clustered into yeast, filamentous or dimorphic fungi.[1] They are classified as a kingdom, 
Fungi[173], which is separate from plants and animals, even though they share key 
components in cellular physiology and genetics with other kingdoms. Like plant cells, 
fungal cells possess a cell wall, which, however, lacks cellulose and contains chitin (a 
component of arthropod exoskeletons) instead. They live, similarly to animals, in a 
predominantly heterotrophic mode and inhabit a broad range of environments. Many play 
fundamental roles in nutrient cycling by decomposing organic matter, while others derive 
their nutrients from animal or plant hosts as either obligate or opportunistic pathogens, as 
well as through symbiotic relationships.[1, 174] The estimated origin of fungi is very 
inconsistent (660 Ma to 2.5 Ga)[175], but recent studies support an estimated time span 
between 760 Ma and 1.06 Ga.[176-177]  
Within these approximately 900 million years of evolutionary history, the fungal kingdom 
developed a enormous diversity of taxa (Figure 1.18) with an estimated number of 1.5[178] 
to 5.1 million[179] species which are organised in four major groups, i.e., ascomycetes, 
basidiomycetes, zygomycetes, and chytrids.[174]  
The members of this kingdom have adapted to diverse ecological niches and therefore 
affecting nearly all other forms of life in either beneficial or detrimental manner. 
Moreover, it is assumed that symbiotic relationships of fungi with photosynthesizing 
organism paved the way in the establishment of eukaryotic life on land and thus affected 
Earth's atmosphere, climate, and evolution of animals.[180-181] Close relationships between 
fungi and plants still play a decisive role today as shown by the fact that 95% of all plant 
families have associated mycorrhizal fungi.[182] Furthermore, fungi play an important role 
in the global carbon cycle and in degrading organic material. Although fungi take up many 
beneficial roles in nature, they can have equally devastating impacts in form of pathogens 
for animals, plants and humans, respectively. Fungal plant pathogens which infect all 
major crop plants, for example, not only cause tremendous loss of crop yields (e.g., M. 
grisea destroys enough rice annually to feed 60 million people)[183] but also lead to food 
contamination through the production of mycotoxins.  
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Figure 1.18: Phylogeny of the fungal kingdom[174] Diamonds indicate evolutionary branch points, and their approximate dating (time line is displayed at the bottom of the image). 
An astonishing example of how fungal plant pathogens even influence cultural 
development in human civilization is the fungus Hemileia vastatrix, which is responsible 
for the preference of tea over coffee in the British Empire due to infection of coffee plants 
in the 1870s and the consequential use of these fields for tea.[174] Furthermore, fungal 
pathogens like Candida and Aspergillus species pose a dramatic risk to 
immunocompromised or therapeutically immunosuppressed patients causing mortality 
rates between 20%[184] and 49%.[185] But also the healthy population get threatened by 
fungal infections as demonstrated by an outbreak of C. neoformans (2002, Vancouver 
Island, British Columbia)[186] and the annual increasing cases of Coccidioides infections in 
the USA.[187] Effective measures against fungal diseases are, however, hard to come by due 
to the eukaryotic biology they share with humans which usually leads to serious side 
effects of most existing antifungal drugs.[188] Nonetheless, fungi, particularly filamentous 
fungi, are of tremendous beneficial use for humans as they produce a vast array of 
secondary metabolites which are of significance for biomedicine, agriculture and 
industry.[189]  
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The growing interest in bioactive fungal metabolites, may they beneficial or detrimental, as 
well as the advancement of powerful available genomic tools in the last decade, have 
driven efforts in the development of genome-wide functional studies for an increasing 
number of fungal species. Several large-scale genomics initiatives like the 1000 Fungal 
Genomes Project contribute towards an ever growing number of complete fungal genomes 
(Figure 1.19) and thus providing an unique opportunity to study the biology and evolution 
of an entire eukaryotic kingdom.[190] 
1.1.6.2 Fungal P450 
Fungi, especially filamentous fungi, exhibit a long history of successfully occupying 
various ecological niches due to their ability to adapt to changing environments, which is 
owed to a large array of enzymatic mechanisms. Cytochrome P450 enzymes notably 
contribute to this fitness and fertility as they participate in a wide variety of physiological 
reactions. CYPome analysis of the white rot fungus Phanerochaete chrysosporium, which 
belongs to the only known group of microorganisms in nature that are capable of 
completely breaking down lignin to carbon dioxide and water, for example, suggest that 
several P450s are involved in the degradation of lignin and a broad range of environmental 
toxic chemicals.[191] CYPs also play important roles in the production of secondary 
metabolites like mycotoxins (e.g., aflatoxin[192], trichothecenes[193], and fumonisins[194]) 
which usually serve to disable host defence responses or defend the fungus against other 
microorganisms[195] but pose potential problems to both public health and economics. 
Furthermore, cytochromes P450 are believed to be associated with fungal 
pathogenicity.[196] In addition to these highly specialized P450 functions, there are also 
Figure 1.19: Growth of annotated genomes in MycoCosm (fungal genomics portal; update 2013).[190] The genomes sequenced by JGI (Joint Genome Institute) are shown in blue and those sequenced by others are shown in red. 
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CYPs that are essential to the primary metabolism and participate, for example, in 
membrane ergosterol biosynthesis.[1] Consequently, these housekeeping CYPs became 
popular antifungal targets.[197]  
20 years have passed by since the first complete fungal genome (S. cerevisiae)[198] was 
reported. With the sequencing of the first filamentous fungus (Neurospora crassa) [199], 
however, it became apparent that diversity within the fungal kingdom is much more 
substantial than previously assumed, as the newly acquired data revealed nearly twice as 
many genes in N. crassa and the lack of homologs to known proteins for over 40% of these 
genes. The same applies to fungal CYPomes which sizes can vary greatly from one P450 
found in Eremothecium cymbalariae to over 300 in Moniliophthora perniciosa and Postia 
placenta (Figure 1.20), albeit relative species usually show some similarities in CYPome 
distribution.[1, 177] In general, filamentous fungi possess high numbers of CYP genes, while 
yeast-form fungi contain only very few CYP genes. It is therefore believed that the 
CYPome size reflects both evolutionary history and adaptation to the environment.[1]  
 Figure 1.20: Relative P450ome sizes of fungal species belonging to different fungal (sub)phyla, grouped by their morphology.[1] 
Although the CYP number in fungi is generally lower than that in plants, filamentous fungi 
have the highest density of CYPs considering the relative genome size leading to a great 
diversity. The family diversity of P450 genes, which mainly arose through events of gene 
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duplication and horizontal gene transfer,[200] differs considerably between species even 
among relatives. For instance, the Aspergilli A. flavus, A fumigatus and A. nidulans possess 
93, 57 and 90 family types, respectively whereas they only share 45.[177] Although, fungal 
CYP families (399 families)[97] are currently allocated to the groups CYP51-CYP69, 
CYP501-CYP699 and CYP5001-CYP6999 the vast majority of their functions and 
biological roles still remain unclear. Furthermore, there are still many fungal CYPs that 
need to be newly assigned. However, most fungi share two global highly conserved 
families, CYP51 and CYP61, which play essentials roles in fungi housekeeping functions 
(sterol biosynthesis)[1, 201] and could provide important information on evolution on fungi 
and CYPome. 
1.2 Beauveria bassiana 
The impact of insects on the economic and health sector, either as a result of agricultural 
pests or through vector-induced diseases in humans and animals, is a serious problem for 
society. Attempts to control insect infestations usually employ methods such as the use of 
chemical insecticides. The increase of environmental awareness, public concern about food 
safety as well as development of insect resistance to chemicals, however, led to an 
advanced interest in alternative strategies. Biopesticides based on entomopathogenic fungi 
like Beauveria bassiana (Figure 1.21) offer therefore a perfect solution as they already 
play major roles in the natural regulation of insect populations.[202] Unlike other insect-
pathogenic microorganisms, entomopathogenic fungi infect target hosts by penetrating 
through their cuticle and thus act by contact and do not require ingestion, which makes 
them very promising in the development of biological control agents (BCAs).[203] The 
epicuticle itself is the outermost insect surface, composed of very long-chain hydrocarbons 
with variable amounts of fatty alcohols, fatty acids and wax esters and therefore represents 
the first barrier against chemical and biological attacks, as well as desiccation.[204-205] 
Infection of target insects usually begins with adhesion of fungal spores or conidia to the 
surface of the insect cuticle. The conidium will then germinate and form a germ tube that 
couples mechanical pressure to the secretion of degrading enzymes in order to penetrate 
the host cuticle. Once the fungus has passed through the cuticle, invasion of the insect 
body and circulatory system (hemolymph) follows, leading to the death of the host by 
physiological starvation in 3-7 days.[202, 206] Of the approximately 750 known species of 
entomopathogenic fungi only 12 are used for currently available commercial products, 
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whereas B. bassiana accounts for nearly 40% of these mycoinsecticides (e.g., Ostrinil, 
Boverin, Boveriol).[202, 207]  
 
 
 
 
 
 
 
 
 
Beauveria bassiana belongs to the Division of Ascomycota and is one of the best-known 
species of entomopathogenic fungi. It was first discovered by Agostino Bassi de Lodi in 
1835 during his investigation of the heavy decline in larval silkworms caused by 
muscardine disease.[208] Since then more 700 host species have been reported for 
B. bassiana including major economic insect pests (e.g., European corn borer, Ostrinia 
nubilalis; codling moth, Laspeyresia pomonella; Japanese beetle, Popillia japonica; 
Colorado potato beetle, Leptinotarsa decemlineata; chinch bug, Blissus leucopterus; and 
the European cabbageworm, Pieries brassicae)[209] as well as mosquito[210] and flea 
vectors.[211] Furthermore, B. bassiana can also adopt a saprophytic lifestyle and recent 
studies indicate interaction of B. bassiana with plants in form of endophytes 
(endosymbiont that lives within a plant) as an adaptive protection against herbivorous 
insects.[202] For instance, B. bassiana has been found in plant tissues of corn (Zea 
mays)[212], cacao (Theobroma cacao)[213] and poppy (Papaver somniferum)[214]. The 
underlying mechanisms that allow for such physiological plasticity of B. bassiana are still 
poorly understood. Enzymes taking part in the degradation of the insect cuticle like 
chitinases, lipases, proteases and, as of recently, putative cytochromes P450 are believed to 
contribute to B. bassiana pathogenesis.[215-217] Also secreted protein toxins (bassiacridin) 
and primary metabolites (oxalic acid) as well as several secondary metabolites 
(beauvericin, bassianolide) produced by B. bassiana appear to play significant roles as 
virulence factors, but may also serve beyond that, in form of antibiotics, antifungals, 
Figure 1.21: A spider colonized by B. bassiana 
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insecticides and nematicides, in order to defend against competing parasites and 
saprophytes in nature.[218]  
In addition to its use as biopesticide, Beauveria bassiana ATCC 7159 is also employed as 
whole cell biocatalysts in chemical and industrial applications and is second only to 
Aspergillus niger as the most frequently used fungal biocatalyst. In 2000 Grogan and 
Holland summarized the range and applications of Beauveria’s biocatalytic reactions, 
many of which are believed to involve cytochrome P450s (Figure 1.22), corroborating its 
potential as a powerful tool in synthetic chemistry, especially for hydroxylation 
processes.[219] Furthermore, the genome of B. bassiana strain ARSEF 2860 has recently 
been sequenced[208], and revealed 83 open reading frames (ORF) that putatively encode 
P450s, each of which have yet to be analysed in more detail. 
 
Figure 1.22: Variety of B. bassiana’s reaction attributable to cytochrome P450  
1.3 Rhodococcus jostii 
Rhodococci belong to the genus of aerobic, non-motile and non-sporulating bacteria with 
DNA containing high GC content (63-73 %). They are commonly found in soil, where they 
degrade a wide range of organic compounds but inhabit also environmental niches like salt 
water, foams in activated sludge, guts of blood-sucking arthropods and herbivore dung[220] 
as well as animals and plants.[221] Because of their robust nature and their outstanding 
ability to degrade aromatic compounds, steroids and a vast variety of other chemicals, they 
are used as biocatalysts in industry.[220, 222-223] Applications of Rhodococci include 
bioactive steroid production, fossil fuel biodesulfurization, and the production of 
acrylamide and acrylic acid.[223] This outstanding metabolic versatility is most likely 
attributed to the large number of genes encoding oxygenase-like proteins such as 
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cytochrome P450s. Genome analysis of Rhodococcus jostii by McLeod et al. in 2006[223] 
revealed at least 25 ORFs for putative P450s. However, to date not much is known about 
the in vivo role of CYPs identified in Rhodococcus jostii RHA1, except for CYP125 and 
CYP257A1, which are thought to be involved in bacterial sterol/steroid degradation.[224-225] 
Further investigation of Rhodococcus jostii RHA1 with regard to the diversity of P450s 
may thus result in the identification of interesting biocatalysts for applications in 
bioconversion and biotransformation processes, but also increase our fundamental 
knowledge about physiological and metabolic properties of members of the genus 
Rhodococcus. 
1.4 Project Aim 
Cytochrome P450 enzymes from filamentous fungi, such as Beauveria bassiana, present 
attractive targets for industrial applications due to their involvement in the catalysis of 
various hydroxylation reactions. Genome sequencing programs revealed very recently 83 
genes encoding putative P450s of mostly unknown function in B. bassiana that needed to 
be investigated in more detailed.  
But also bacteria such as Rhodococcus sp. have a long standing history in industrial 
biocatalysis and offer, just like filamentous fungi, an interesting set of cytochrome P450 
enzymes which have yet to be studied to a greater extend. 
The aim of this project is to identify P450s of B. bassiana for cloning, recombinant 
expression and as subjects for functional studies for further characterisation and industrial 
application. Extensive bioinformatics studies of the Beauveria CYPome will be conducted 
and diverse expression systems as well as expression conditions will be tested to obtain 
functional enzymes.  
A further aim of this project is focused on a library of 23 chimeric P450 fusion enzymes 
from Rhodococcus jostii. Optimal expression conditions for these fusion enzymes will be 
determined in order to provide a screening platform that can be applied in an industrial 
context.   
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2. General Material and Methods  
2.1 Chemicals 
Chemicals used in this study were purchased from AGTC Bioproducts Ltd (Hessle, UK), 
Alfa Aesar (Heysham, UK), Fisher Scientific UK Ltd. (Loughborough, UK), Merck 
Chemicals Ltd. (Nottingham, UK), Scientific Laboratory Supplies Ltd. (Nottingham, UK), 
Sigma-Aldrich Company Ltd. (Dorset, UK), Takara Bio Europe Clontech (St Germain-en-
Laye, France), and VWR International Ldt. (Lutterworth, UK).   
Limonene was donated by the Giulia Paggiola of the Green Chemistry Department 
(University of York, UK). 65 commercial available drugs used for screening assays of 
Rhodococcus jostii chimeric fusion were kindly provided by AstraZeneca.  
Restriction enzymes were bought from New England Biolabs (Ipswich, UK), Promega UK 
Ltd. (Southampton, UK), and Thermo Fisher Scientific Biosciences GmbH (St. Leon-Rot, 
Germany).  
PCR Primers were synthesised by Eurofins Scientific (Wolverhampton, UK) and genes by 
GeneArt (now Life Technologies Ltd, Paisley, UK). 
2.2 Strains and Plasmids 
2.2.1 Escherichia coli strains 
Bacterial strains are summarized in Table 2.1. 
Table 2.1: List of E. coli strains used for cloning and recombinant expression 
Strain name Genotype Manufacturer 
BL21(DE3) Singles™ F– ompT hsdSB (rB– mB–) gal dcm (DE3) Novagen-Merck 
NovaBlue Singles™ 
endA1 hsdR17 (rK12– mK12+) supE44 thi-1 recA1 gyrA96 relA1 lac F′[proA+B+ lacIqZΔM15::Tn10] (TetR) 
Novagen-Merck 
Rosetta™ 2(DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR) Novagen-Merck 
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2.2.2 Yeast strains 
The properties of the strain used for microsome preparation are summarized in Table 2.2.  
Table 2.2: Saccharomyces cerevisiae strain used in this work 
Strain name Genotype optained from 
Saccharomyces WAT11 MATa; ade2–1; his3–11,-15; leu2-3,-112; ura3–1; canR; cyr+ (a derivative of the W303-B strain) 
Prof. D. Werck Reichhart (CNRS-Institute de Biologie moléculaire des plantes, Strasbourg) 
2.2.3 Plasmids 
Plasmids for gene cloning and enzyme expression are shown in Table 2.3. 
Table 2.3: Plasmids for gene cloning and enzyme expression 
vector antibiotic resistance features source 
LIC Kanamycin pETYSBLIC3C vector, cleavable his tagged N-terminus 
Dr. Gideon Grogan[226] 
LICRED Kanamycin 
pETYSBLIC3C vector, cleavable his tagged N-terminus, contains Rhf reductases from Rhodococcus sp. 
Dr. Federico Sabbadin[227] 
pGro7 Chloramphenicol Chaperone groES-groEL, araB Promotor Takara 
pYeDP60 Ampicillin GAL10-CYC1 promoter Prof. Daniele Werck-Reichart[228] 
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The LICRED[227] (Figure 2.1) and the LIC-vector are based on pETYSBLIC3C vector[228], 
which contains an additional cleavable his tagged N-terminus. 
 
 
 
 
Figure 2.2 shows the LIC-RED region of the LICRED-vector[227] in more detail. 
 
Figure 2.2: LIC-RED cloning site pT7 = T7 promotor, oLAC = Lac operator, RBS = ribosome binding site, His = 6x histidines residues, which can be cleaved, 3C = HRV 2C protease site, tT7 = T7 terminator, Gene = exchangeable cytochrome P450, RhfRED = permanent P450 reductase domain of cytochrome P450Rhf from Rhodococcus sp. NCIMB 9784  
Figure 2.1: Vector map of LICRED LICRED = Ligation independent cloning site with additional P450 reductase domain (RhfRED) of cytochrome P450Rhf from Rhodococcus sp. NCIMB 9784, f1 ori = f1 phage origin of replication, pBR322 ori =  origin of replication of the plasmid pBR322, KanR = kanamycin resistence gene, LacI = repressor gene for IPTG induction 
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The vector pYeDP60 (Figure 2.3) is used as a shuttle vector for cloning in E. coli but 
expression in yeast.[228]  
 
 
 
2.3 Media 
2.3.1 Escherichia coli 
Escherichia coli were grown in Lysogeny broth (LB) and M9 minimal media. Super 
Optimal broth with Catabolite repression (SOC) was used for recovering E. coli cells after 
plasmid DNA transformation. 
LB-Medium[229]  
Tryptone  10 g Yeast extract 5 g NaCl  10 g H2O fill up to 1000 ml 
The pH of this medium ranges between 7 and 7.5. 1.5 % [w/v] agar was added to LB prior 
autoclaving for the preparation of the solid agar plates. Depending on requirements 
supplements listed in Table 2.4 were added. 
Figure 2.3: pYeDP60 shuttle vector map  tPGK = phosphoglycerate kinase terminator, pGAL = galactose promoter, ADE 2d and URA3 = selection marker for adenine and uracil auxotrophy, ampR = ampicillin resistence gene, BamHI and KpnI = restriction site, ori E. coli = origin of replication for E. coli, ori yeast = origin of replication for yeast 
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M9-Medium[229]  
Preparation of M9 Salt stock: 
Na2HPO4  33.9 g KH2PO4 15 g NaCl 2.5 g NH4Cl 5.0 g H2O fill up to 1000 ml 
 Autoclave 
Preparation of M9 minimal medium: 
M9 salts  200 ml  20 % glycerol/glucose 20 ml  1 M MgSO4 2 ml 1 M CaCl2 100 l  H2O fill up to 1000 ml 
 sterile filtrated prior usage 
Depending on requirements supplements listed in Table 2.4 were added. 
SOC-Medium[229] 
Tryptone 20 g Yeast Extract 5 g MgSO4 4.8 g Glucose 3.603 g NaCl 0.5g KCl 0.186 g H2O fill up to 1000 ml 
Sterile filtrated glucose was added after autoclaving 
2.3.2 Yeast 
Saccharomyces WAT11 was cultivated in YPAG medium while SGI medium was 
employed to select positive transformants. YPGE medium was used for expression of 
microsomes subsequently.  
YPGA-Medium[230]  
Bactopeptone  10 g Yeast extract 10 g Glucose 20 g Adenine 200 mg H2O fill up to 1000 ml 
2 % [w/v] pastagar was added to YPGA prior autoclaving for the preparation of the solid 
agar plates. 
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SGI-Medium[230]  
Bactocasamino acids  1 g Yeast nitrogen base 7 g Glucose 20 g Tryptophan 20 mg H2O fill up to 1000 ml 
2 % [w/v] pastagar was added to YPGA prior autoclaving for the preparation of the solid 
agar plates. 
YPGE-Medium[230]  
Bactopeptone  10 g Yeast extract 10 g Glucose 5 g Ethanol 30 ml H2O fill up to 1000 ml 
Ethanol was added after autoclaving 
2.3.3 Supplements 
Table 2.4: Supplements for bacteria and yeast media 
Supplement Stock solution Concentration in medium Chloramphenicol 20 mg/ml in ethanol 20 g/ml Kanamycin 34 mg/ml in H2O 34 g/ml δ-aminolevulinic acid 0.5 M in H2O 0.5 mM FeCl3 0.5 M in H2O 0.5 mM IPTG 1 M in H2O 1 mM (L)-arabinose 20 g/l in H2O 3 mg/ml Galactose 200 g/l in H2O 10 g/l 
2.4 Glycerol stocks 
E. coli laboratory stocks were prepared for long-term storage by adding 500 μl of sterile 
80% glycerol to 500 l of logarithmic growing cells in LB. The addition of glycerol 
stabilizes the frozen bacteria, prevents damage to the cell membranes and keeps the cells 
alive. The glycerol stocks were stored stably at -80°C. 
Yeast glycerol stocks were prepared by adding 40 % sterile glycerol in a ratio of 1:1 to 
overnight cultures of yeast grown in the appropriate medium. 
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2.5 Working with nucleic acids 
2.5.1 Enzymatic restriction of DNA 
Sequence specific hydrolysis of nucleic acids by restriction endonucleases is used to create 
fragments with defined ends. For preparative digests, DNA was purified prior to the 
reaction by gel purification (2.5.3). Restriction of DNA was performed using the buffer 
system supplied by the manufacturer (Table 2.5). Plasmid DNA and PCR-fragments were 
incubated for 2-4 h at 37 °C. The digest of 1 μg DNA required a volume of at least 10 μl 
with no more than 10 % enzyme in the total volume. The reaction stop was initiated by 
either adding 6x Loading Dye or by heat inactivation. Restriction endonucleases used in 
this project are listed in Table 2.5. 
Table 2.5: List of restriction endonucleases 
Restriction endonuclease Manufacturer Cut site Buffer NheI Thermo Scientific 5'-G^CTAGC-3' Tango™ XbaI Promega 5'-T^CTAGA-3' Buffer D BseRI NEB 5'-GAGGAG(N)10^-3' NEBuffer 2 BamHI Thermo Scientific 5'-G^GATCC-3' Buffer BamHI KpnI Thermo Scientific 5'-GGTAC^C-3' Buffer BamHI 
2.5.2 Plasmid DNA preparation 
5 ml LB medium (2.3.1) containing the appropriate antibiotics (2.3.3) were inoculated with 
E. coli cells comprising the anticipated plasmid and incubated overnight at 37 ºC and 
180 r.p.m.. The cultures were harvested by centrifugation at 13000 r.p.m. for 1 min (Sigma 
2k15 centrifuge). A GenElute (TM) HP Plasmid Miniprep Kit (Sigma) was used to purify 
the plasmids according to the manufacturer’s instructions. 
2.5.3 Purification of DNA fragments 
DNA fragments resulting from PCR amplification and restriction digest were separated 
using agarose gel electrophoresis (2.5.4) and excised from the gel before purification. A 
GenElute Gel Extraction Kit (SigmaAldrich) was used according to the manufacturer’s 
protocol to purify DNA fragments cut out of agarose gels. 
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2.5.4 Agarose gel electrophoresis 
Horizontal agarose gel electrophoresis was used for preparative and analytical separation 
of DNA. Separation took place in gel electrophoresis cells (Hybaid or Whatman Biometra). 
Depending on the size of the expected DNA fragments, agarose concentration varied 
between 0.8-1.5 % (w/v). Agarose was dissolved in 1x Tris-acetate-EDTA (TAE) buffer, 
prepared from a 50x TAE stock. To visualise DNA under UV light SYBR® Safe DNA Gel 
Stain (Fisher Scientific Ltd) was added directly to the gel. Samples have been mixed with 
0.2 Vol. 6x Loading Dye (Promega) for visual tracking of DNA migration during 
electrophoresis. Furthermore, the presence of glycerol ensures that the DNA in the ladder 
and sample forms a layer at the bottom of the well. To determine the product size 1 kb 
DNA ladder (NEB) was used according to the manufacturer’s instruction. Electrophoresis 
usually took place at a constant voltage of 100 V using 1x TAE running buffer. Running 
times were set between 0.75 to 1.5 h. 
50x TAE-Puffer[229] 
Tris  242 g  10 mM Glacial acetic acid 57 ml  1 mM EDTA (0.5 M, pH 8.0)  100 ml  50 mM H2O  fill up to 1000 ml Adjusting of pH 7.5 takes place using HCl. 
2.5.5 In vitro-Amplification of DNA by PCR 
Fragments for cloning reactions have been amplified by polymerase chain reaction (PCR) 
using KOD Hot Start DNA Polymerase (Merck Chemicals Ltd). KOD Hot Start DNA 
Polymerase generates blunt-ended PCR products suitable for cloning LIC Vector Kits. 
Primers for ligation independent cloning have been designed manually or with HiTel 
software (TF Protein Production Laboratory, University of York, 
http://bioltfws1.york.ac.uk/cgi-bin/primers.cgi?). Primers for In-Fusion cloning were 
designed using the TaKaRa Clontech online tool 
(http://www.clontech.com/US/Support/xxclt_onlineToolsLoad.jsp?citemId=https://www.ta
kara-bio.co.jp/infusion_primer/infusion_primer_form.php&section=16260&xxheight=180
0). Eurofins mwg/operon synthesised the in this work used Primers. PCR components and 
reaction conditions are shown in table Table 2.6 and Table 2.7. 
 
 
47 
Table 2.6: Components of the PCR reaction 
Component Volume (µl) 
Template DNA 1 
Forward primer 1 
Reverse primer 1 
MgSO4 (25 mM) 1 
dNTP’s (2 mM each) 5 
KOD hot start polymerase buffer (10x) 5 
KOD hot start polymerase 1 
water to a final volume of 50 μl 
 for colony PCR: cell material from selected colonies using sterile pipette tip 
Table 2.7: PCR reaction conditions 
 Temp (ºC) Time No Cycles 
Initial Denature 95 2 min 1 
Denature 95 30 s 
35 Anneal 55-58 30 s 
Extension 72 30 s per 500 bp 
Final Extension 72 10 min 1 
Hold 4 n 1 
2.5.6 Ligation independent cloning method 
The cloning method used was based on T4 polymerase treatment of insert and vector 
resulting in complementary long overhangs and therefore required no ligation step in 
between. 
Genes, amplified by PCR (2.5.5), were cloned into LIC-3-C or LICRED (Table 2.3) 
vector. Both vectors needed to be linearized prior to T4 polymerase treatment by digestion 
with restriction enzyme BseRI (Table 2.5). The linearized vectors as well as the PCR 
products were then separated on a 1% agarose gel (2.5.4) and purified by gel elution 
(2.5.3) with a GenElute Gel Extraction Kit (SigmaAldrich). 
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Figure 2.4: Scheme of T4 polymerase treatment A) Insert, B) LIC-vector. BseRI restriction site (blue letters), AscI restriction site (green letters), 3C protease site (red letters); see text below for further description. 
The purified insert and vector are treated with T4 polymerase (LIC qualified, Novagen-
Merck) which has a 3´→ 5´ exonuclease activity and therefore creates complementary long 
sticky ends when supplied with bases T (in vector; Figure 2.4 A) and A (in insert; 
Figure 2.4 B). The protocol for the T4 polymerase treatment is shown in Table 2.8. 
Table 2.8: Protocol for T4 polymerase treatment 
vector   insert  
40 μl 10x T4 pol buffer  2 μl 10x T4 pol buffer 
4 pmol linearised vector  0.2 pmol insert 
20 μl 100 mM DTT  1 μl 100 mM DTT 
10 μl 100 mM dTTP  0.5 μl 100 mM dATP 
8 μl T4 DNA polymerase*  0.4 μl T4 DNA polymerase* 
water to a final volume of 400 μl   water to a final volume of 20 μl 
* 2.5U/ l LIC qualified T4 DNA polymerase, Novagen/Merck 
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Adding 1 l LIC prepared vector (~50 ng/l) to 2 l insert, incubation at room temp 
(~20-22 ºC) for 10 min, followed by addition of 1 l EDTA (25 mM) to give a final 
volume of 4 l and further 10 min incubation at room temperature, leads to an annealing 
reaction. 2 l of LIC annealing reaction is then transformed (2.6.3) into NovaBlue Single 
competent cells (Table 2.1).  
2.5.7 In Fusion cloning 
The In-Fusion® HD Cloning System (Clontech) employs the In-Fusion HD enzyme which 
is able to fuse PCR-generated sequences to linearized vectors by recognizing a 15 bp 
overlap at their ends. Therefore, this system provides the advantage to clone any PCR 
fragment or multiple fragments into any linearized vector in a single reaction without the 
need for additional vector dephosphorylation, blunt-end polishing or PCR fragment 
digestion. 
Figure 2.5 shows the principle of the In-Fusion® HD Cloning System which is based on a 
ligase-independent mechanism. The ability of the In-Fusion enzyme to create single-
stranded regions at the ends of the PCR insert and linearized vector exposes the 15 bp 
complementary regions. The insert and vector DNA molecules will then spontaneously 
anneal through base pairing. Any single-stranded gaps will be repaired by transformation 
into E. coli, subsequently. Furthermore, this method allows for >95% cloning efficiency 
according to the manufacturer. 
Table 2.9 gives an overview of the set up for the In-Fusion reaction comprising reaction 
components and quantity. The mix was then incubated for 15 minutes at 50 ˚C and placed 
on ice, subsequently. Transformation into NovaBlue competent E. coli cells followed as 
described in 2.6.3.  
Table 2.9: In-Fusion cloning reaction set up 
Reaction Component Quantity 
Purified PCR fragment 10–200 ng* 
Linearized vector 50–200 ng** 
5x In-Fusion HD Enzyme Premix 2 μl 
Deionized Water to 10 μl 
*<0.5 kb: 10–50 ng, 0.5 to 10 kb: 50–100 ng, >10 kb: 50–200 ng **<10 kb: 50–100 ng, >10 kb: 50–200 ng 
50 
 
Figure 2.5: Assembly scheme of the In-Fusion® HD Cloning System  Primers for the PCR (top right) are colour-coded to emphasize their homology to the DNA template (blue) and cloning sites of the linearized vector (top left). The gene specific areas of forward (Primer FWD) and reverse primer (Primer REV) are indicated in blue and the 15 bp extension homologous to the corresponding sites in the vector are shown in either red or green. The In-Fusion enzyme (grey) fuses the PCR-generated sequence and linearized vector by recognizing a 15 bp overlap at their ends. 
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2.6 Preparation of recombinant microorganisms 
2.6.1 Preparation of CaCl2-competent E. coli-cells 
Since E. coli is not naturally transformable, the ability to take up DNA or competency 
must be induced by chemical methods using divalent and multivalent cations (calcium, 
magnesium, manganese, rubidium, or hexamine cobalt)[231-232]. Alteration in the 
permeability of the membranes allows DNA to cross the cell envelope of E. coli which is 
composed of an outer membrane, an inner membrane, and a cell wall. The negative 
charges of the incoming DNA, however, are repelled by the negatively charged portions of 
the macromolecules on the bacterium’s outer surface. The addition of CaCl2 serves to 
neutralize the unfavourable interactions between the DNA and the polyanions of the outer 
layer. The reaction mixture is then exposed to a brief period of heat-shock at 42 ˚C. The 
change in temperature alters the fluidity of the semi-crystalline membrane state achieved at 
0 ˚C thus allowing the DNA molecule to enter the cell through the zone of adhesion. 
Procedure[231]: 5 ml overnight culture was prepared using LB medium (2.3.1) containing 
required antibiotics (2.3.3). Fresh LB medium was inoculated the following morning with 
overnight culture in a 1:100 dilution and incubated at 37 °C (shaking: 180 r.p.m.) until 
OD600 reached 0.4 - 0.6. Cells were then harvested by centrifugation (Sorvall RC 5B plus 
centrifuge, SS34 rotor) at 4000 r.p.m. for 5 min. The cell pellet was resuspended in about 
half culture volume ice-cold sterile 50 mM CaCl2 and incubated on ice for 30 min 
subsequently. After incubation, cells were spun down (Sorvall RC 5B plus centrifuge, 
SS34 rotor) at 1500 r.p.m. for 10 min (4 ˚C) and the cell pellet resuspended in 1/50th of the 
original culture volume ice-cold sterile 50 mM CaCl2, followed by additional incubation 
on ice for at least 30 min (ideally 2 h). 200 l of the cell suspension were then dispensed 
into pre-cooled Eppendorf tubes and transformed (2.6.2) with appropriate vector. 
Cells will remain competent for up to 24 h at 4˚C. Transformation efficiency increases 
four- to six-fold during this time. Alternatively, it is possible to use 50 mM cold CaCl2 
solution (50 mM CaCl2, 15% glycerol, 10 mM piperazine-N,N’-bis-2-hydroxypropane-
sulfonic acid, pH 7) instead of only 50 mM CaCl2 for long-term storage at -70 ˚C. 
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2.6.2 Plasmid transformation into BL21 (DE3) and Rosetta2 (DE3) competent 
E. coli cells 
Rosetta2 (DE3) cells (2.2.1) were used in this project because they are designed to enhance 
the expression of eukaryotic proteins that contain codons rarely used in E. coli. 
25 l competent cells were defrosted on ice for 10 – 15 min before 1 l of the plasmid was 
added. Incubation of the mixture for another 30 min on ice was followed by a 45 s heat 
shock at 42 °C. 1 ml LB medium (2.3.1) was added afterwards and cells were incubated 
shaking for 60 min at 37 °C. Cells were then centrifuged (Sigma 2k15 centrifuge) at 
4000 r.p.m. for 5 min. The cell pellet was resuspended in 150 l LB medium and spread on 
LB agar (2.3.1) containing appropriate antibiotics (2.3.3). Incubation of the plates took 
place overnight at 37 ˚C. 
2.6.3 Plasmid transformation into NovaBlue competent E. coli cells 
Due to their high-efficiency transformation, NovaBlue competent cells (2.2.1) were only 
used for cloning. 
25 l competent cells were defrosted on ice for 10 – 15 min before 1 l of the plasmid was 
added. The mixture was incubated on ice for 5 min followed by a 30 s heat shock at 42 °C 
and an additional 2 min incubation on ice. 150 l SOC medium (2.3.1) was added to the 
reaction mixture and cells were incubated shaking for 60 min at 37 °C. Cells were then 
spread on LB agar (2.3.1) containing appropriate antibiotics (2.3.3). Incubation of the 
plates took place overnight at 37 ˚C. 
Several colonies were picked for an initial screen of positive transformants by control 
digest with XbaI and NheI or BamHI and KpnI (2.5.1) prior to the final confirmation by 
sequencing (GATC). 
2.6.4 Plasmid transformation into Saccharomyces cerevisiae WAT11 
The transformation was carried out using a modified protocol developed in 1989 by 
Schiestl & Gietz.[230] 
20 ml overnight cultures were prepared in YPGA medium (2.3.2) using a single yeast 
colony as inoculum and incubated shaking at 200 r.p.m. and 30 °C. The OD600 of the 
overnight culture was measured the following morning in a 1:100 dilution to calculate the 
appropriate volume of overnight culture necessary to inoculate 50 ml YPGA main culture 
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to an OD600 of 0.15. The main culture was then incubated for 5 h at 200 r.p.m. and 30°C. 
Carrier DNA and transformation mix were prepared as described in Table 2.10 30 min 
prior to the end of the incubation period. Cells were harvested by centrifugation (Sorvall 
RC 5B plus centrifuge, SS34 rotor) at 4500 r.p.m. for 5 min. The cell pellet was washed in 
25 ml of cold sterile water and spun down subsequently at 4500 r.p.m. (Sorvall RC 5B plus 
centrifuge, SS34 rotor) for 5 min at 4 ˚C. Cells were resuspended in 1ml cold sterile water 
and 100 l aliquots of the cell suspension were prepared in pre-cooled, sterile 1.5 ml 
Eppendorf tubes. Eppendorf tubes containing the cell suspension were centrifuged (Sigma 
2k15 centrifuge) at high speed for 30 s and the supernatant discarded. Prepared 
transformation mix (Table 2.10) was added to the cell pellet and cells were transformed by 
heat shock at 42°C for 30 min. The reaction mix was placed on ice for at least 2 min 
subsequently to the heat shock followed by centrifugation (Sigma 2k15 centrifuge) at high 
speed for 30 s to remove the transformation mix. The cell pellet was washed once in 1 ml 
sterile cold water and was subsequently resuspended in 1ml sterile cold water. 1/20th of 
the cell suspension was then spread on appropriate selective plate (SGI, 2.3.2) and 
incubated at 30 °C for 3 to 4 days. 
Table 2.10: Yeast transformation mix suitable for 1 transformation 
Reaction Component Quantity 
PEG 3500 50% w/v 240 l 
Li Acetate 1M 36 l 
Single stranded carrier DNA (2 mg/ml)* 50 μl 
Plasmid DNA 250 ng 
Deionized water to 360 l 
* Boil prior use for 20 minutes and chill on ice  
2.7 Working with Proteins 
2.7.1 Cell growth and protein expression 
E. coli BL21 (DE3) (2.2.1), which has been made competent using 50 mM CaCl2 (2.6.1) 
and transformed with pGro7 plasmid (Table 2.3) or E. coli Rosetta 2 (DE3) (2.2.1), were 
used for transformation with the plasmid containing the gene of interest. 
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2.7.1.1 Small scale expression test 
Starter cultures of positive transformants were grown overnight at 37 °C and 180 r.p.m. in 
5 ml LB (2.3.1) containing the required supplements (2.3.3). M9 minimal medium (2.3.1) 
was used as growth medium (unless stated otherwise) for 10 ml main cultures which have 
been inoculated with 0.5 ml starter culture and incubated shaking at 37 °C until an OD600 = 
0.6 - 0.9 was reached. Gene expression was then induced by adding 1 mM IPTG, 0.5 mM 
FeCl3 and 0.5 mM ALA (δ-aminolevulinic acid, a heme ring precursor) (2.3.3). The 
proteins were expressed with shaking (180 r.p.m.) at 16 °C overnight (unless stated 
otherwise). Cells were harvested by centrifugation (Sorvall RC 5B plus centrifuge, SS34 
rotor) at 5000 r.p.m. for 15 min. Supernatant was discarded and the cell pellet resuspended 
in 600 l of buffer A (50 mM Tris/HCl pH 7.5, 300 mM NaCl). The resuspension was then 
sonicated and centrifuged at 13000 r.p.m. (Sigma 2k15 centrifuge) for 30 min to separate 
insoluble (pellet after centrifugation; resuspended in buffer A) and soluble fraction 
(supernatant). 
2.7.1.2 Scaled up protein expression 
In order to perform protein expression in larger scale, one colony has been picked from 
plates with positive transformants to inoculate 5 ml of LB (2.3.1) containing the required 
antibiotics (2.3.3). This starter culture was grown for 6 h at 37 ˚C and 180 r.p.m.. 0.5 ml 
starter LB culture was used to inoculate 10 ml of M9 medium (2.3.1) preculture which was 
incubated overnight at 37 ˚C and 180 r.p.m.. 2 ml preculture was used as inoculum for a 
200 ml main M9 medium culture. Induction and the harvest of cells (Sorvall RC 5B plus 
centrifuge, F10-6x500 rotor) was performed as described for small scale expression test 
(2.7.1.1). Depending on further use of cells, the pellet was resuspended in 1/10th to 1/50th 
original culture volume buffer A (50 mM Tris/HCl pH 7.5, 300 mM NaCl) and used for 
whole cell assays (4.1.3.2 and 6.3.2) or purification (2.7.2 and 6.3.3). 
2.7.2 Protein purification 
Cells were grown to a total volume of 2 l (10 x 200 ml) and harvested as described in 
2.7.1.2. The resuspension was sonicated at 4 ˚C in 6 x 30 s intervals with 30 s delay 
between each interval. Soluble and insoluble fractions have then been separated by high 
speed centrifugation (~ 16000 r.p.m., Sorvall RC 5B plus centrifuge, F10-6x 500 rotor) for 
30 min. The obtained cell lysate was purified by nickel affinity chromatography. A 5 ml 
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HisTrap FF Crude nickel column (GE Healthcare Life Sciences) was loaded with the clear 
supernatant. However, the column needed to be prepared prior to protein loading as 
follows: first, the column was rinsed with 5 column volume distilled, filtered water, 
subsequently with 5 column volume 0.5 M NaCl solution containing 0.1 M EDTA and 5 
column volume 0.5 M NaCl solution and once more with 5 column volume distilled, 
filtered water to strip off the storage solution; the second step was to charge the column by 
rinsing it with 5 column volume 0.1 M Ni2SO4 solution; the equilibration of the column 
with 5 column volume Buffer A (50 mM Tris/HCl pH 7.5, 300 mM NaCl) marked the last 
preparation step. 
After column loading, the protein was eluted with a gradient of imidazole (0–500 mM) 
over 20 column volumes using a programmed ÄKTA purifier system operated by 
UNICORN 5 control software. Column fractions containing anticipated protein were 
pooled and concentrated by centrifugation (SIGMA 3-16PK centrifuge, Swing-out rotor 
for 4 buckets) using Amicon Ultra-15 Centrifugal Filter Units (Millipore).  
2.7.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE[233] is a method to separate proteins according to their molecular weight at 
denaturating conditions. Electrophoresis took place in Mini Vertical Electrophoresis Units 
(Hoefer, Inc.) using gel solutions listed in Table 2.11. Stacking gels constantly contained 
4 % acrylamide [w/v] while the amount of acrylamide in the resolving gels varied between 
12 % and 10 %. Samples were mixed with 2x SDS loading buffer in a 1:1 ratio and 
denaturated at around 100 ˚C for 5 min before applied to the gel. Electrophoresis usually 
took place at a constant voltage of 200 V and room temperature using 1x running buffer, 
until running front reached the end of the gel. Size estimation of samples was carried out 
by applying a broad or low range marker (BIO-RAD) which contains proteins of defined 
molecular weight (Table 2.12). 
After separation, the gel was carefully transferred to a plastic container filled with 
Coomassie stain solution and heated up in a microwave for 70 s. Subsequently, the 
Coomassie stain solution has been removed and filtered for reuse. The stained gel was 
briefly rinsed with water to remove residual staining solution and incubated with destain 
solution to visualize protein bands. 
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Table 2.11: SDS-PAGE gel solutions 
 Stacking gel 4% Resolving gel 10% Resolving gel 12% H2O 3.2 ml 4 ml 3.2 ml 4x resolving buffer - 2.5 ml 2.5 ml 
4x stacking buffer 1.3 ml - - 
Acrylamide 0.5 ml 3.3 ml 4.2 ml 
APS (10 % [w/v]) 25 l 50 l 50 l 
TEMED 8 l 8 l 8 l 
 
Table 2.12: BIO-RAD Protein Molecular Weights in dalton 
Protein Molecular weight Broad range Low range Myosin 200,000 X  
ß-galactosidase 116,250 X  
Phosphorylase b 97,400 X X 
Serum albumin 66,200 X X 
Ovalbumin 45,000 X X 
Carbonic anhydrase 31,000 X X 
Trypsin inhibitor 21,500 X X 
Lysozyme 14,400 X X 
Aprotinin 6,500 X  
 
4x Resolving buffer 
Tris-HCl (pH 8,8)  1,5 M 
SDS (w/v)  0,4 % 
 
4x stacking buffer 
Tris-HCl (pH 6,8)  0,5 M 
SDS (w/v)  0,4 % 
 
1X Running Buffer 
4X SDS-PAGE Running Buffer 250 ml  Tris Base 12 g  Glycine 58 g  H2O fill up to 1000 ml H2O   750 ml 10% SDS    10 ml 
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2x SDS loading buffer 
Glycerol 1 ml  β-mercaptoethanol 0.5 ml 10 % SDS 2 ml 0.1 % bromphenol blue 0.5 ml 0.5 M Tris-HCl (pH 6.8)  1.2 ml H2O fill up to 10 ml 
 Coomassie stain solution 
Propan-2-ol  250 ml Glacial acetic acid  100 ml Coomassie brilliant blue R  2 g H2O fill up to 1000 ml 
 
Destain solution 
Propan-2-ol  50 ml Glacial acetic acid  70 ml H2O fill up to 1000 ml 
2.7.4 Western blot 
Western blots[234] can be used to transfer proteins, prior separated by SDS-PAGE (2.7.1), 
onto a nitrocellulose membrane by electroelution (Figure 2.6). The probing of proteins 
takes place in 1 instead of 2 steps using antibodies, which recognize the protein of interest 
(specific to the His-tag) and contain a detectable label. A horseradish peroxidase linked to 
the antibody serves as label. It has the ability to cleave a chemiluminescent agent 
producing a luminescent reaction product that can be detected in proportion to the amount 
of protein. 
2.7.4.1 Western blot set up and protein transfer 
A Immobilon™ PVDF membrane (0.45 μm, Millipore) and Whatman® 3MM paper 
(Sigma) was used for the set up. The transfer took place in a Trans-Blot® SD semi-dry 
transfer cell (BIO-RAD) and constant voltage, power, and current was provided by a 
PowerPac 1000 Power Supply (BIO-RAD). 
Nitrocellulose membrane and Whatman paper needed to be equilibrated prior to the final 
Western blot set up. The membrane was incubated in 100 % methanol for 15 s, then 
transferred into Milli-Q water for 2 min and equilibrated in transfer buffer for additional 10 
min while the Whatman paper has only been soaked in transfer buffer. The Western blot 
was set up in the following order: 4 layers of Whatman paper followed by nitrocellulose 
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membrane, polyacrylamide gel and another 4 layers of Whatman paper subsequently 
(Figure 2.6). After residual fluid was removed to provide semidry transfer condition, the 
transfer cell was close and connected to PowerPac 1000. 
 
Figure 2.6: Western blot set up SDS gel containing separated protein samples is placed against a membrane, and current is passed across the gel to the membrane, transferring the proteins onto the membrane. 
Protein transfer took place by applying a constant voltage of 25 V and maximum current of 
500 mA for 55 min. The membrane was then removed from the transfer apparatus and 
rinsed in 1x TBST to remove loose acrylamide. Ponceau Red was added to stain the 
membrane for 5 min and visualize proteins. Marker bands have then been marked with a 
pencil.  
2.7.4.2 Immunoprecipitation 
Non-specific binding sites were blocked by immersing the membrane in 1x TBST buffer 
containing 5% non-fat dried milk for 1 h at room temperature on an orbital shaker. The 
membrane was then briefly rinsed with three changes of 1x TBST, followed by 60 min 
incubation with the antibody (Monoclonal Anti-polyHistidine Peroxidase Conjugate, 
1:2000 dilution; Sigma) diluted in TBST plus 5% milk at room temperature. Subsequently 
to the antibody treatment, 3 washing steps at room temperature for at least 10 min each 
were required using fresh changes of 1x TBST buffer. Chemifluorescent detection took 
place by using ECL Plus Western blotting Detection Reagents (GE Healthcare UK Ltd.) 
according to the manufactures instruction. Figure 2.7 gives an overview of the steps 
necessary to develop proteins after transfer to a membrane A G:Box Syngene system and 
GeneSnap software was used for the documentation of the Western blot results. 
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Figure 2.7: Immunoprecipitation after Western blot The transferred protein is detected using specific primary and secondary enzyme labeled antibody. Antibodies bind to specific sequences of amino acids. Substrate that reacts with the enzyme linked to the secondary anitbody is used to visualise the antibody/protein complex. 
Transfer Buffer (pH 8.3) 
Tris  25 mM  Glycine  192 mM  Methanol  20%  H2O  fill up to. 1000 ml 
10X TBST pH 7.5 
Tris  100 mM  NaCl  1 M  Tween 20  1 %  H2O  fill up to. 1000 ml 
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3. Selection of Beauveria bassiana P450 targets 
3.1 In situ analysis of CYPome 
The overall nucleotide and amino acid sequences for in situ analysis were downloaded 
from NCBI (http://www.ncbi.nlm.nih.gov/gene). Sequences were determined via shotgun 
sequencing from Beauveria bassiana ARSEF 2860.[208] 83 mRNA sequences annotated as 
cytochrome P450 could be identified for detailed review. 
The 83 annotated P450 sequences (Appendix A, Table A.1) have been analysed using 
bioinformatic tools in order to pick suitable targets for cloning and expression. Several 
sequences couldn’t be considered to encode for functional CYPs and were dismissed 
before looking at actual conserved domains. 5 genes which code for less than 400 amino 
acids (aa) as well as 9 genes encoding unusually long runs of amino acids in a row were 
therefore dismissed before the analysis started. Of the remaining 69 sequences, 5 encode 
for proteins that consist of more than 1000 aa and were consequently regarded separately.  
 
 
 
 
 
 
 
 
Although sequence similarity shared amongst fungal CYPs is rather low, some conserved 
domains exist relating to key characteristics of CYPs. Figure 3.1 summarizes the 
characteristic motifs of 47 investigated fungal CYPs by Wanping Chen et al. in 2014.[177] 
They are fairly similar to those of animal, plant, and even archaea and bacteria but display 
predominance for specific aa.[235] According to P450 crystal structure comparison of 
various organisms, the highest structural conversation is found in the core of the protein 
around the heme. The heme-binding domain FXXGXXXCXG, which is the most 
conserved region, contains the axial cysteine ligand to the heme (Figure 3.1 d). The second 
absolutely conserved motif is E-X-X-R (Figure 3.1 b) and PER (Figure 3.1 c) which form 
the E–R–R triad. The triad stabilizes the core structure and is important for locking the 
Figure 3.1: Sequence logos of the conserved CYP motifs from 47 tested fungi[177] The four regions a, b, c, and d correspond to the positions 273–279, 330–333, 383–388, and 405-414, respectively. Bits shown on the left side specify the abundance (high bits = high abundance) of the individual aa among the tested fungi. See text below for description of conserved motifs. 
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heme pocket into position. Another consensus sequence considered as P450 signature 
(AGXDTT, Figure 3.1 a) can be found in the central part of the I helix and contributes to 
oxygen binding and activation.[50, 200-201]  
In order to identify CYPs which have at least the potential of functionality, only P450s of 
Beauveria bassiana that possessed all 4 above described structural properties could be 
considered for further investigation. After alignment and sequence comparison of the 65 
putative heme domains only 33 P450s containing these consensus sequences remained for 
construction of a phylogenetic tree. Figure 3.2 shows the alignment results of these 33 
P450s with regard to the above mentioned consensus sequence using Clustal W version 
2.0.[236] The 5 sequences with more than 1000 aa have not been included into this 
alignment as they interfere with the alignment quality. After investigation of the 5 
sequences it, however, became evident that only one could be considered as potential P450 
(CYP505A1) as the other four lack the most conserved FXXGXXXCXG region. 
Furthermore, it needs to be mentioned that one of the 69 analysed P450s (i.e., CYP505A2) 
didn’t contain P450 consensus sequences, but flavodoxin and a FAD binding domain. 
Thus, this gene probably corresponds to a cytochrome P450 reductase.  
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CYP505A1 showed high identity to a catalytically self-sufficient fatty acid hydroxylase 
from Fusarium oxysporum (P450foxy) which is known as the eukaryotic counterpart of 
P450BM3 from Bacillus megaterium. In addition to all conserved motifs (shown in 
Figure 3.3) contains CYP505A1 flavodoxin as well as a FAD binding domain which are 
typical for CYP reductases. 
 
 
 
 
Figure 3.2: Alignment of 33 P450s with relevant CYP-numbers from B. bassiana in accordance with their conserved motifs The AGXDTT motif (A) contributes to oxygen binding and activation; EXXR motif (B) and PER motif (C) form the E–R–R triad which stabilizes the core structure; the heme binding motif FxxGxxxCxG (D) contains the conserved cysteine residue that ligates to the Fe of the heme cofactor; numbers on the right side indicate amino acid position; CYP-numbers are located left of the alignment 
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Figure 3.3: Alignment of self-sufficient P450s from B. megaterium, F. oxysporum and B. bassiana with regard to conserved motifs 102_Bm: P450BM3 from B. megaterium; foxy_Fo: P450foxy from F. oxysporum; 505A1: CYP505A1 from B. bassiana; conserved motifs are in accordance with motifs shown in Figure 3.2; numbers on the right side indicate amino acid position. 
3.2 Phylogenetic tree 
In order to generate the phylogenetic tree, sequences were used as input into the 
PhylOgenetic WEb Repeater (POWER) which performs MSA in ClustalW[236] and builds a 
dendrogram based on the PHYLIP package.[237] The tree was constructed by using the 
neighbour joining method with an associated bootstrap in which 1000 datasets were 
generated by SEQBOOT. The final tree was drawn in Drawtree 3.66[238] and is displayed in 
Figure 3.4. 
The 33 P450s are clustered in 5 groups. It was possible to classify these groups by 
potential catalysis function using Basic Local Alignment Search Tool (BLAST) and 
comparing them to P450s of known or assumed function. For example: the majority of 
heme domains shown with a yellow background have similarity to P450s with benzoate-4-
monooxygenase activity while clustered heme domains with a green background have 
more in common with phenylacetate hydroxylases. P450s with a purple background, 
however, couldn’t be classified as no known or described P450 showed any similarity to 
this group when using BLAST analysis. As expected, CYP505A1 is clustered with the 
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self-sufficient P450 from B. megaterium (102 BM) and F. oxysporum (foxy Fo), although 
it seems to be phylogenetically closer related to P450foxy. 
 
Figure 3.4: Phylogenetic tree of 33 P450 heme domains and 1 putative natural fusion gene from B. bassiana in relation to 2 well-known self-sufficient P450s. The gene encoding the presumed fusion protein CYP505A1 (displayed as ‘505A1’) from B. bassiana is clustered with genes coding for the self-sufficient P450BM3 from B. megaterium (displayed as ‘102 BM’) and the self-sufficient P450foxy from F. oxysporum (displayed as ‘foxy Fo’). B. bassiana P450 heme domains (presented by CYP numbers, compare Appendix, Table A.1) are clustered in 5 groups. Comparison of individual B. bassiana P450s with P450s of known or assumed function indicates a correlation between gene clusters and subsequent function of their respective proteins with regard to biocatalysis. The background colour of clustered P450s correlates to the potential catalysis function displayed in the image legend (upper left corner).  
3.3 Discussion 
Despite considerable variation in sequence, P450 enzymes maintain a conserved P450 fold 
perpetuated by very few invariant residues known as the P450 motifs (Figure 3.1). As the 
availability of sequences increases, exceptions of these motifs become, however, more 
apparent. The conserved Thr in the AGXDTT motif, for example, was long considered to 
be invariant owing to mutagenesis studies which resulted in loss of activity when it was 
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substituted.[239] P450s such as CYP107A1 (P450eryF)[240] and CYP176A (P450cin)[241] 
proved this belief to be wrong as they lack this conserved Thr and are still fully functional. 
The same applies to the EXXR motif, which is missing in the CYP157C1 of 
Streptomyces sp but still yields a correctly folded and spectrally normal P450.[242] 
Moreover, there are examples of orphan P450s in which the haem axial ligand Cys - 
allegedly the only common feature of P450s – is replaced.[200] These exceptions are often a 
clue to a peculiarity of P450 catalysis. Especially modifications in the heme-binding 
domain indicate that oxygen is not required for catalytic activity and thus indicate novel 
catalytic activities.[177] This project is, however, focused on the identification and 
exploitation of cytochrome P450-based biocatalysts, thus P450s from Beauveria bassiana 
with biocatalytic activity. Since there is only little knowledge about the functionality of 
individual P450s in B. bassiana, as well as the fact that no more than eight of these 83 
P450s were to be selected for investigation, it appeared to be more reasonable to consider 
P450s with typical CYP motifs, as they most likely correspond to catalytically active 
proteins. On this basis, 33 out of the original 83 P450s remained for further investigation. 
Dismissed genes with insufficient conformation in the CYP motif, however, may have still 
catalytic activity as affirmed by the above mentioned examples. A noteworthy exception is 
the protein annotated as CYP505A2, which completely lacks the CYP motifs. It contains, 
like the potential B. bassiana natural fusion P450, CYP505A1, a flavodoxin and a FAD 
binding domain instead and acts presumably as natural reductase partner for B. bassiana 
P450s.  
The nomenclature system for CYPs is based upon amino acid identity (40% identity and 
above place a CYP in the same family, more than 55% identity places them in the same 
subfamily[27]) grouping fungal CYP families currently into more than 337 CYP gene 
families.[201] The 33 remaining B. bassiana heme domains (plus CYP505A1) are 
distributed into 20 families. Table 3.1 gives an overview of the distribution of these 33 
P450s among the 20 different families with regard to the phylogenetic clustering 
(Figure 3.4) and corresponding similarity towards P450s of known or assumed function. In 
accordance to a distribution study of 47 fungal CPYomes from 4 different phyla, 
Ascomycota seem to have some frequently present CYP families (e.g., CYP52, CYP56, 
CYP65, CYP68, CYP505, CYP532, CYP537, CYP539, CYP540, CYP548, CYP578, 
CYP584, CYP617, CYP682, CYP53, and CYP504).[177] Nearly 60 % of the selected 
B. bassiana P450s belong to these families, leading to the assumption that these CYPs are 
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possibly biocatalytically active proteins as they are widely distributed among this specific 
phylum. The CYP52 family in particular appears to be very interesting as they are known 
to participate in the degradation of alkanes and insect epicuticle.[243]  
Table 3.1: CYP family distribution of 33 analysed B. bassiana P450s in accordance to similarity with P450s of known or assumed function 
CYP family Number of members Similarity to CYP504 2 Phenylacetate hydroxylase CYP505 1 Self-sufficient P450 CYP52 5 Alkane hydroxylase CYP539 1 CYP584 2 CYP617 4 P450 homolog CYP620 2 O-methylsterigmatocystin OR CYP621 1 CYP5080 1 
Benzoate-4-monoxygenase 
CYP5282 1 CYP53 1 CYP537 1 CYP548 1 CYP561 2 CYP570 1 CYP58 1 CYP625 1 CYP65 2 CYP682 1 CYP684 2    
Additionally, the 20 families seem to cluster into 5 clans (groups of CYP families that 
consistently cluster together on phylogenetic trees) in accordance to proposed biocatalytic 
functions. Similar cluster behaviour could be observed in Chen’s study of the 47 fungal 
CPYomes in which the families CYP52, CYP539 and CYP584 as well as CYP53, CYP58, 
CYP65, CYP528, CYP537, CYP548, CYP561, CYP570, CYP684 and CYP5080 form 
regular clans and are thus most likely linked to a common ancestor gene.[177] CYP505A1 
on the other hand forms a single clan with the self-sufficient fatty acid hydroxylase from 
Fusarium oxysporum (P450foxy) and its eukaryotic counterpart of P450BM3 from Bacillus 
megaterium, undermining the close relationship between these natural fusions. 
After careful consideration, sequences coding for CYP505A1 and 7 P450s with possible 
alkane hydroxylase function were picked for cloning and expression in E. coli since they 
are most likely encode active proteins. This assumption is substantiated by the fact that 5 
of the picked heme domains have high sequence similarity or identity to cytochrome P450 
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enzymes that are, according to a study from Pedrini et al., implicated in insect hydrocarbon 
degradation in Beauveria bassiana.[203] Moreover, the selected P450s are expected to 
catalyse oxidation of hydrophobic substrates due to their similarity to alkane hydroxylases. 
In addition, they are, with regard to substrate screening, probably easier to analyse. The 
selected heme domain CYP52G8, which is identical to one of the heme domains 
investigated by Pedrini and co-workers (CYP52X1), has already been reported to catalyse 
lauric acid hydroxylation and thus facilitates activity assays.[217]   
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4. Construction of a library of B. bassiana P450 genes and their expression in E.coli 
4.1 Materials and Methods 
4.1.1 Modification of P450s in preparation of synthesis  
Eukaryotic P450s are usually membrane associated through an N-terminal hydrophobic 
membrane anchor of around 25 to 70 amino acids. The association to the membrane is the 
main cause of the insolubility of these proteins when expressed in E. coli. The removal of 
the N-terminus potentially leads to an increase in solubility without reducing the enzyme 
activity due to the fact that the catalytic centre is situated in the cytoplasm.[244-245] 
In order to increase the solubility of expressed proteins, transmembrane areas predicted by 
software like TMpred[246] and SOSUI [247-249] were removed in the selected heme-domains. 
Table 4.1 shows the calculated transmembrane regions and protein properties of the 
selected P450s. It should be mentioned that, in accordance with the predicted 
transmembrane domain for CYP505A1, the first 73 aa should have been cut off. Alignment 
analysis with P450foxy, however, showed a lack of the first 165 aa in F. oxysporum. 
Therefore, the first 165 aa were cut off CYP505A1 instead of only 73aa. The prepared raw 
sequences of the P450s were codon optimized (listed in Appendix B) as an attempt to 
improve the expression in E. coli and were send to GeneArt® to be synthesized. 
Table 4.1: Properties of selected heme-domains from B. bassiana for cloning and expression amino acid (aa) length, molecular weight (MW) in Dalton (Da) as well as software predicted transmembrane areas are shown for corresponding cytochromes P450. The N-terminal beginning and C-terminal end of the calculated hydrophobic membrane anchor is specified by numbers corresponding to the aa position within the protein. The complete transmembrane region for each P450 is represented as aa sequence.  CYP name Length (aa) MW (Da) Transmembrane region 
CYP52G6 528 59113.6 
N terminal transmembrane region aa C terminal 
1 MALTAILIGLVVVTFVLR 18 
 
CYP539B1 515 58720.4 
N terminal transmembrane region aa C terminal 
7 NTTTVALAIPVCLLLFVIVNWLT 29 
 
CYP52T1_1 534 58271.6 
N terminal transmembrane region aa C terminal 
1 MALHAAYLFIAATLVAVYLTRSI 23 
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 CYP name Length (aa) MW (Da) Transmembrane region 
CYP52T1_2 536 60519.7 
N terminal transmembrane region aa C terminal 
4 LSSSFAAVLLSAVIAAYILKVVW 26 
 
CYP52T1_3 541 61462.9 
N terminal transmembrane region aa C terminal 
5 PISTFLAGAAILYLARWVCIEIN 27 
 
CYP52G8 528 59480.6 
N terminal transmembrane region aa C terminal 
6 VISLPALLVSLTVAFILLQVIEY 28 
 CYP584E2 528 59929.2 Soluble Protein 
CYP505A1 1232 136465.7 
N terminal transmembrane region aa C terminal 
51 PYAMVAMVAMVAMVAMEAMVSEA 73 
 
4.1.2 Cloning of P450s 
Truncated versions (truncation of hydrophobic N-terminal region) of the 7 codon 
optimised B. bassiana P450s were amplified using KOD hot start polymerase (2.5.5) and 
corresponding primers (Table 4.2) before cloning into the LICRED-vector (2.5.6). Cloning 
of the self-sufficient P450 (CYP505A1) in form of a truncated and a natural state version 
was also performed using the ligation independent method but employing the LIC-3C 
vector, as there is no additional reductase required for electron shuttling. The primers used 
for CYP505A1 amplification resulting in a PCR product incorporating the transmembrane 
area (CYP505A1_w_FWD) or a PCR product without N-terminal anchor 
(CYP505A1_wo_FWD) are listed in Table 4.2. 
Table 4.2: Primer used for PCR amplification 
Primer Sequence CYP52G6_F CCAGGGACCAGCAATGCGTGTTCTGGAAAGCCTGCGTCATGC CYP52G6_R GAGGAGAAGGCGCGCACTGCTTCATGGACACGAACTTTAAC CYP52G8_F CCAGGGACCAGCAATGGTTCGTTTTCGTAGCAAAGCAGCACGT CYP52_G8_R GAGGAGAAGGCGCGTTCATCAAAGTGAACTTTCAGGGTAAC CYP52T1_F CCAGGGACCAGCAATGCATTGGCTGTTTGCACGTAAACTGGGT CYP_52T1_R GAGGAGAAGGCGCGCAGCTGTGCTGCTTCAGAAAAACGAAC CYP52T1_2_F CCAGGGACCAGCAATGCGTCAGGTTAGCTATCAGAGCCTGGC CYP52T1_2_R GAGGAGAAGGCGCGATTTGCCTGCTGCAGACGAACGGCAAC CYP52T1_3_F CCAGGGACCAGCAATGCGTAGCATTCAGCGTCGTAATGCACG CYP52T1_3_R GAGGAGAAGGCGCGGCTGCTATTACCCAGGCTCACCGGAAC CYP539B1_F CCAGGGACCAGCAATGGTTGCCTATAAAGTTGCAAAAAGCAGC CYP539B1_R GAGGAGAAGGCGCGGGCCGTTTTTTCATCGGTTTTTTCCGG CYP584E2_F CCAGGGACCAGCAATGGCACTGGGTCAGCTGGCACCGACCGTT 
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Primer Sequence CYP584E2_R GAGGAGAAGGCGCGGTTTTTGGCACGGGTCAGTTTACAATT CYP505A1_wo_F CCAGGGACCAGCAATGGCAGAAAGCATTCCGATTCCGGAACCGC CYP505A1_w_F CCAGGGACCAGCAATGGATGTTGATCAGATTGCCTTTCGTTAT CYP505A1_R GAGGAGAAGGCGCGTCAGTCAAACACATCGGCCATAAAACG 
4.1.3 Protein characterization 
4.1.3.1 Spectrophotometric characterisation 
Purified enzyme or concentrated cell lysate was employed for spectrophotometric 
investigation. Analysis has been performed at room temperature using a Varian Cary 50 
BioUV/Vis Spectrophotometer (Agilent Technologies) and UV-transparent disposable 
cuvettes (ultra-micro, 15 mm window height, BrandTech Scientific). Absorption 
measurements took place between the wavelength 200 and 600 nm with one point for each 
nanometre. 
4.1.3.2 Whole cell activity assay 
Cells were grown as described in 2.7.1.2 and resuspended in a relevant volume of buffer A 
(50 mM Tris/HCl pH 7.5, 300 mM NaCl) to yield a suspension of 100gcww /l. Assays have 
been performed in a total volume of 6 ml containing no more than 0.2 mg/ml of substrate. 
Incubation took place in a 50 ml Erlenmeyer flask at 37 °C (shaking at 180 r.p.m.). 300 l 
samples were taken at time point 0 and after 1, 2, 4 and 22 h, and were prepared for GC 
analysis (4.1.3.3). Cells containing empty LIC-3C or LICRED vector have been used as 
negative control. 
4.1.3.3 Gas chromatography 
300 l samples taken from whole cell activity assays (4.1.3.2) were prepared as follows: 
First, transfer of sample to an Eppendorf tube filled with 500 l volume of ethyl acetate 
and vortexing at maximum speed; secondly, 2 min centrifugation (Sigma 2k15 centrifuge) 
at room temperature and 13,000 r.p.m. to facilitate phase separation; and finally, transfer of 
the upper organic phase into a screw top vial (Agilent Technologies) to be analysed using 
GC. 
When using lauric acid as substrate a second extraction round was performed followed by 
evaporation and derivatisation with 60 µl of N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) and 60 µl of methyl tert-butyl ether (MTBE) for 30 min at 70 ˚C, subsequently. 
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Analysis of substrates was performed using a Agilent 6890N network gas chromatograph 
with a flame ionization detector (FID). Helium served as carrier gas and a Agilent J&W 
HP-5 column (0.32 mm, 0.25 µm) was used for separation. Data analysis took place using 
Agilent ChemStation software. 
4.2 Results 
4.2.1 Cloning into LICRED and LIC-3C 
The B. bassiana P450foxy homolog (CYP505A1) was cloned into LIC-3-C vector which 
lacks the additional reductase but follows the same principles as the LICRED cloning used 
for the establishment of the P450 – fusion library. Figure 4.1 shows the success of PCR 
(P450 heme-domains: lane 5-11; CYP505A1 without transmembrane-domain: lane 3; 
CYP505A1 with transmembrane domain: lane 4). 
After annealing of prepared vector and insert (2.5.6) and subsequent transformation into 
NovaBlue Single competent cells (2.2.1), several colonies were picked for an initial screen 
of positive transformants by control digest with XbaI and NheI (2.5.1) prior to the final 
confirmation using sequencing. Positive clones for all LICRED constructs are shown in 
Figure 4.2 and Figure 4.3. The images display 2 selected clones for each P450 fusion 
construct containing the empty LICRED-vector and the insert of the expected length after 
digest. Sequencing by GATC confirmed the success of the cloning process. 
 Figure 4.1: linearized LICRED vector and PCR products after gel extraction  lane 1: 1 kb DNA ladder; lane 2: linearized LICRED-vector consisting of 6386 bp; lane 3: CYP505A1_without transmembrane domain (3231 bp); lane 4: CYP505A1_with transmembrane domain (3726 bp); lane 5: CYP539B1 (1491 bp); lane 6: CYP52T1 (1575 bp); lane 7: CYPT1_3 (1575 bp); lane 8: CYPT1_2 (1535 bp); lane 9: CYP52G6 (1563 bp); lane 10: CYP52G8 (1533 bp); lane 11: CYP584E2 (1614 bp) 
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CYP505A1 has been cloned into the LIC-3C vector once without the transmembrane-
domain (CYP505A1_wo_LIC-3C) and once comprising the whole gene sequence 
(CYP505A1_w_LIC-3C). Potential positive clones were picked and screened in the same 
manner as described for the LICRED system. Figure 4.4 illustrates the successful insertion 
of gene sequences with the calculated bp length into the vector which could be confirmed 
by sequencing data received from GATC. 
Figure 4.2: Initial screen of positive transformants using restriction enzymes XbaI and NheI lane 1: 1 kb DNA ladder; lane 2: CYP52G8_p1_LICRED (2636 bp); lane 3: CYP52G8_p2_LICRED (2636 bp); lane 4: CYP52T1_3_p1_LICRED (2678 bp); lane 5: CYP52G6_p1_LICRED (2666 bp); lane 6: CYP52G6_p2_LICRED (2666 bp) 
Figure 4.3: Initial screen of positive transformants using restriction enzymes XbaI and NheI lane 1: 1 kb DNA ladder; lane 2: CYP539B1_p1_LICRED (2594 bp); lane 3: CYP539B1_p2_LICRED (2594 bp); lane 4: CYP52T1_p1_LICRED (2678 bp); lane 5: CYP52T1_p2_LICRED (2678 bp); lane 6: CYP584E2_p1_LICRED (2717 bp); lane 7: CYP584E2_p2_LICRED (2717 bp); lane 8: CYP52T1_2_p1_LICRED (2636 bp); lane 9: CYP52T1_2_p2_LICRED (2636 bp) 
Figure 4.4: Initial screen of positive transformants using restriction enzymes XbaI and NheI lane 1: 1 kb DNA ladder; lane 2: CYP505A1_w_LIC-3C_p1 (3726 bp); lane 3: CYP505A1_w_LIC-3C_p2 (3726 bp); lane 4: CYP505A1_wo_LIC-3C_p1 (3231 bp); lane 5: CYP505A1_wo_LIC-3C_p2 (3231 bp) 
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4.2.2 Expression test 
In order to confirm overexpression of selected P450s, small scale expression tests were 
performed as described in 2.7.1.1. Unfortunately, no signal was noticeable in SDS-PAGE 
(data not shown), neither in soluble nor insoluble fraction. Therefore, the high sensitive 
method of Western blotting (2.7.4) was used to verify overexpression. 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Western blot analysis of selected P450s Insoluble fractions are marked with ins while soluble fractions are labelled sol: lane 1: Low-Range-Marker; lane 2: CYP52G8_LICRED_ins (94.5 kDa); lane 3: CYP52G8_LICRED_sol (94.5 kDa); lane 4: CYP52G6_LICRED_ins (95.4 kDa); lane 5: CYP52G6_LICRED_sol (95.4 kDa); lane 6: CYP52T1_3_LICRED_ins (94.1 kDa); lane 7: CYP52T1_3_LICRED_sol (94.1 kDa); lane 8: CYP52G8_LICRED _ins_uninduced; lane 9: CYP52G8_LICRED _sol_uninduced 10: positive control 
Figure 4.6: Western blot analysis of selected P450s Insoluble fractions are marked with ins while soluble fractions are labelled sol: lane 1: Low-Range-Marker; lane 2: CYP539B1_LICRED_ins (93.5 kDa); lane 3: CYP539B1_LICRED_sol (93.5 kDa); lane 4: CYP52T1_LICRED_ins (94.2 kDa); lane 5: CYP52T1_LICRED_sol (94.2 kDa); lane 6: CYP52T1_2_LICRED_ins (95.7 kDa); lane 7: CYP52T1_2_LICRED_sol (95.7 kDa); lane 8: CYP584E2_LICRED _ins (97.8 kDa); lane 9: CYP584E2_LICRED _sol (97.8 kDa) lane 10: positive control 
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Clear signals of protein expression of predicted molecular weight could be detected (Figure 
4.5) for CYP52G8 (lane 2) and CYP52G6 (lane 4) as well as a weak signal in case of 
CYP52T1_3 (lane 6), while there was no signal in uninduced cells. Unfortunately, none of 
these proteins seemed to be expressed solubly since bands of the expected length only 
occur in lanes containing insoluble samples. Furthermore, CYP52G8 possesses several 
bands below 90 kDa indicating that the protein gets easily degraded or is unstable. The 
same applies to CYP52G6 which appears to have 2 distinctive cleavage sites, resulting in 
to 2 additional signals that appear at about 35 kDa. 
Figure 4.6 displays the outcomes of Western blotting for CYP539B1, CYP52T1, 
CYP52T1_2 and CYP584E2. There is no expression detectable in the case of CYP584E2 
either in the soluble or in the insoluble fraction. A rather strong band corresponding to 
anticipated molecular weight can be seen in lane 2 containing the insoluble phase of 
CYP539B1 and 2 weaker signals are visible in lane 4 (insoluble fraction of CYP52T1) and 
6 (insoluble fraction of CYP52T1_2). Like in CYP52G8 and CYP52G6 shown above, 
other bands lower than 90 kDa also appear in the insoluble phase of CYP539B1 leading to 
the conclusion that this protein gets easily degraded as well. Also cleavage at the linker 
area between P450 domain and reductase domain (16 aa linker) might contribute to the 
degradation process and unstability of the chimeric fusion proteins. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Western blot analysis of selected P450s Insoluble fractions are marked with ins while soluble fractions are labelled sol: lane 1: Broad-Range-Marker; lane 2: CYP505A1_wo_LIC-3C_ins (120.6 kDa); lane 3: CYP505A1_wo_LIC-3C_sol (120.6 kDa); lane 4: CYP505A1_wo_LIC-3C_ins (120.6 kDa); lane 5: CYP505A1_wo_LIC-3C_sol (120.6 kDa); lane 6: CYP505A1_w_LIC-3C_ins (139 kDa); lane 7: CYP505A1_w_LIC-3C_sol (139 kDa); lane 8: CYP505A1_wo_LIC-3C_ins_uninduced; lane 9: CYP505A1_wo_LIC-3C_sol_uninduced; lane 10: positive control 
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Western blot analysis of E. coli strains expressing CYP505A1 (with and without 
transmembrane domain) shown in Figure 4.7 confirm overexpression. Bands above 
110 kDa can clearly be seen in lanes 2 (without TM; insoluble), 4 (without TM; insoluble) 
and 6 (with TM; soluble) while there are no bands in the uninduced negative control 
displayed in lane 8 and 9. As already pointed out earlier for P450 Rhf fusion proteins, there 
is also no soluble expression for any of the LIC-3C constructs in E. coli. Furthermore, all 
insoluble expressed proteins appear to be particularly degraded, signified by rather strong 
signals below the 110 kDa mark. 
Since signals observed in insoluble phases are fairly strong, exposure time while detecting 
the Western blot was limited and as a result, very weak signals couldn’t be visualized. In 
order to ultimately confirm that no soluble expression has been conducted by any of the 
strains Western blotting comprising only the soluble phases was carried out (data not 
shown). Unfortunately, most signals detected are unspecific (background signals) and 
don’t agree with the predicted molecular weight. 
In summary, it can be said that all P450 fusions were expressed insolubly, except for 
CYP584E2, but no signals could be spotted when analysing the soluble phases. The same 
applied for B. bassiana P450foxy homolog cloned into LIC-3C vector. 
4.2.2.1 Media optimization 
The expression system used in this project is based on a pET system which contains 
components of the lac operon. The lac operon can be regulated in a positive and a negative 
way. Negative regulation is mediated by a lac repressor, which binds to the lac operator - a 
specific DNA sequence between the promoter and the coding regions - in the operon. This 
event can be prevented by adding specific inducers of the lac operon (e.g., IPTG) to the 
expression system. IPTG binds to the lac repressor and substantially decrease its binding 
affinity to the lac operator. Positive regulation on the other hand requires the presence of 
cyclic AMP (cAMP) and cyclic AMP receptor protein, called CRP or CAP. The 
CAP/cAMP complex is able to stimulate transcription by binding to an element upstream 
of the lac promoter. Hence, the level of cAMP is a decisive factor of effective expression 
and is strongly influenced by the carbon source present in the medium. In the present of 
glucose an effect shared by a number of E. coli operons called catabolite repression occurs 
which leads to low cAMP levels and therefore poor transcription from the lac promoter.[250]  
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Cultures for small scale expression trails (2.7.1.1) have so far only been grown in M9 
medium (2.3.1) containing 4 mg/ml glucose as sole carbon source. In order to increase 
expression of anticipated proteins various alternative carbon sources have been tested to 
raise the cAMP level and therefore transcription.  
Arabinose or glycerol was tested as sole carbon source in the medium. Both have been 
supplemented from a 20 % (w/v) stock solution to ensure a final concentration of 4 mg/ml 
in the M9 medium. In addition, a combination of arabinose and glycerol or glucose and 
arabinose was tested. Carbon sources tested in combination had a final concentration of 
2 mg/ml each in the medium.  
Table 4.3 summarizes the relative expression levels seen after Western blot analysis for 
each protein and Figure 4.8 to Figure 4.12 show P450s after SDS gel separation. Data for 
arabinose expression are not shown, because cells didn’t grow when used as only carbon 
source.  
 
 
 
 
 
 
 
Figure 4.8: SDS gel of in E. coli expressed CYP52G6 and CYP52G8 grown on variable carbon sources Glc = Glucose; Ara = Arabinose; Gly = Glycerol; lane 1: Low-Range-Marker; lane 2-4: insoluble expressed CYP52G6_LICRED (94.5 kDa) grown in medium containing Glc & Ara (lane 2), Gly (lane 3), and Gly & Ara (lane 4); lane 5-7: insoluble expressed CYP52G8_LICRED (94.5 kDa) grown in medium containing Glc & Ara (lane 5), Gly (lane 6), and Gly & Ara (lane 7); lane 8: Low-Range-Marker; lane 9-11: soluble expressed CYP52G6_LICRED (94.5 kDa) grown in medium containing Glc & Ara (lane 9), Gly (lane 10), and Gly & Ara (lane 11); lane 12-14: soluble expressed CYP52G8_LICRED (94.5 kDa) grown in medium containing Glc & Ara (lane 12), Gly (lane 13), and Gly & Ara (lane 14). 
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Clear visible bands of proteins with predicted molecular weight could already be detected 
in SDS gels for insoluble fractions whether cells are grown only in glycerol or in 
combination with either glucose or arabinose. The only exceptions were CYP584E2 and 
CYP52T1_2 which only showed a moderate to no expression improvement at all. 
Figure 4.9: SDS gel of in E. coli expressed CYP584E2 and CYP52T1 grown on variable carbon sources Glc = Glucose; Ara = Arabinose; Gly = Glycerol; lane 1: Low-Range-Marker; lane 2-4: insoluble expressed CYP584E2_LICRED (97.8 kDa) grown in medium containing Glc & Ara (lane 2), Gly (lane 3), and Gly & Ara (lane 4); lane 5-7: insoluble expressed CYP52T1_LICRED (94.2 kDa) grown in medium containing Glc & Ara (lane 5), Gly (lane 6), and Gly & Ara (lane 7); lane 8: Low-Range-Marker; lane 9-11: soluble expressed CYP584E2_LICRED (97.8 kDa) grown in medium containing Glc & Ara (lane 9), Gly (lane 10), and Gly & Ara (lane 11); lane 12-14: soluble expressed CYP52T1_LICRED (94.2 kDa) grown in medium containing Glc & Ara (lane 12), Gly (lane 13), and Gly & Ara (lane 14). 
Figure 4.10: SDS gel of in E. coli expressed CYP52T1_2 and CYP52T1_3 grown on variable carbon sources Glc = Glucose; Ara = Arabinose; Gly = Glycerol; lane 1: Low-Range-Marker; lane 2-4: insoluble expressed CYP52T1_3_LICRED (94.1 kDa) grown in medium containing Glc & Ara (lane 2), Gly (lane 3), and Gly & Ara (lane 4); lane 5-7: insoluble expressed CYP52T1_2_LICRED (95.7 kDa) grown in medium containing Glc & Ara (lane 5), Gly (lane 6), and Gly & Ara (lane 7); lane 8: Low-Range-Marker; lane 9-11: soluble expressed CYP52T1_3_LICRED_sol (94.1 kDa) grown in medium containing Glc & Ara (lane 9), Gly (lane 10), and Gly & Ara (lane 11); lane 12-14: soluble expressed CYP52T1_2_LICRED (95.7 kDa) grown in medium containing Glc & Ara (lane 12), Gly (lane 13), and Gly & Ara (lane 14).  
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However, none of the P450 constructs revealed visible bands in the soluble fraction when 
run on a SDS gel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: SDS gel of in E. coli expressed CYP539B1 grown on variable carbon sources Glc = Glucose; Ara = Arabinose; Gly = Glycerol; lane 1: Low-Range-Marker; lane 2-4: insoluble expressed CYP539B1_LICRED (93.5 kDa) grown in medium containing Glc & Ara (lane 2), Gly (lane 3), and Gly & Ara (lane 4); lane 5: Low-Range-Marker; lane 6-8: soluble expressed CYP539B1_LICRED (93.5 kDa) grown in medium containing Glc & Ara (lane 6), Gly (lane 7), and Gly & Ara (lane 8) 
Figure 4.12: SDS gel of in E. coli expressed CYP505A1 without and with transmembrane domain grown on variable carbon sources Glc = Glucose; Ara = Arabinose; Gly = Glycerol; wo = without transmembrane; w = with transmembrane lane 1: Broad-Range-Marker; lane 2-4: insoluble expressed CYP505A1_LIC-3C without transmembrane domain (120.6 kDa) grown in medium containing Glc & Ara (lane 2), Gly (lane 3), and Gly & Ara (lane 4); lane 5-7: insoluble expressed CYP505A1_LIC-3C with transmembrane domain (139 kDa) grown in medium containing Glc & Ara (lane 5), Gly (lane 6), and Gly & Ara (lane 7); lane 8: Broad-Range-Marker; lane 9-11: soluble expressed CYP505A1_LIC-3C without transmembrane domain (120.6 kDa) grown in medium containing Glc & Ara (lane 9), Gly (lane 10), and Gly & Ara (lane 11);  lane 12-14: soluble expressed CYP505A1_LIC-3C with transmembrane domain (139 kDa) grown in medium containing Glc & Ara (lane 12), Gly (lane 13), and Gly & Ara (lane 14)  
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Table 4.3: Relative soluble and insoluble expression of Cytochrome P450s in the presence of different carbon sources at 16 ˚C. increased expression is indicated by the symbol + whereas the intensity of the increase is linked to the rising amount of the + symbols; unvaried expression is symbolized by 0. 
Cytochrome P450s Insoluble Expression Soluble Expression Glucose & Arabinose Glycerol Glycerol & Arabinose Glucose & Arabinose Glycerol Glycerol & Arabinose 
CYP52G6_LICRED  (95.4 kDa)  ++ +++ ++ 0 0 0 
CYP52G8_LICRED  (94.5 kDa) ++ +++ +++ 0 0 0 
CYP52T1_LICRED  (94.1 kDa) ++ +++ +++ 0 0 0 
CYP52T1_2_LICRED (95.7 kDa) 0 0 0 0 0 0 
CYP52T1_3_LICRED (96.5 kDa) + ++ ++ 0 0 0 
CYP539B1_LICRED (93.5 kDa) ++ +++ +++ 0 0 0 
CYP584E2_LICRED (97.8 kDa) 0 0 0 0 0 0 
CYP52A1_w_LIC-3C  (139 kDa) 0 + + 0 0 0 
CYP52A1_wo_LIC-3C  (120.6 kDa) ++ ++ ++ 0 0 0 
 
Western blot analysis confirmed the observations made by SDS PAGE analysis for 
insoluble and also soluble expression. No distinct signal could be detected to prove an 
increase in soluble expression. Nevertheless, an increase of expression in general could be 
evidently verified, especially if glycerol is the only carbon source applied during cell 
growth. 
4.2.2.2 Co-expression with chaperones 
Co-expression of chaperones is an approach known to increase not only insoluble but also 
soluble expression. In 1996 Mayhew et al. were able to show that co-expressing with the 
GroEL/ES chaperon system enhances correct protein folding and therefore protein 
yield.[251] For most prokaryotic CYPs as well as for CYP505A1 (P450foxy), co-expression 
of GroEL/ES greatly improved the P450 concentration in the soluble protein fraction as 
well.[252] 
81 
A commercially available pGro7 plasmid set (2.2.3) coding groES-groEL was used to 
transform in BL21 (DE3) competent cells (2.2.1) following the protocol described in 2.6.2. 
In order for the transformed BL21 (DE3) cells to take up expression plasmid for the target 
protein, competency was induced by using CaCl2 (2.6.1). After transformation with both 
plasmids, small scale expression tests (2.7.1.1) have been conducted in M9 medium with 
glycerol or glucose as carbon source and necessary antibiotics (2.3.1; 2.3.3). Furthermore, 
supplement of L-arabinose (3  mg/ml) to the medium is required to induce chaperone 
expression.  
Figure 4.13 to Figure 4.15 display SDS gel analysis of all P450 fusions as well as 
CYP505A1 (Figure 4.15).  
 
 
 
 
 
 
The overexpression of chaperones is clearly visible in the soluble fractions indicated by 
strong bands around 57 kDa corresponding to GroEL. Bands correlating to P450s of 
expected molecular weight could only be detected in the insoluble fractions except for 
CYP584E2. Furthermore, these bands appear to be stronger for P450s that have been 
expressed with glucose as carbon source. However, no distinct signals could be detected in 
SDS gels for soluble expressed P450s. Western blot analysis where therefore conducted for 
soluble fractions. 
Figure 4.13: SDS gel of CYP52G6, CYP52G8 and CYP52T1_3 co-expressed with chaperones in E. coli grown on variable carbon sources Glc = Glucose; Gly = Glycerol; lane 1: Low-Range-Marker; lane 2-3: insoluble expressed CYP52G6_LICRED (94.5 kDa) grown in medium containing Glc (lane 2) or Gly (lane 3); lane 4-5: insoluble expressed CYP52G8_LICRED (94.5 kDa) grown in medium containing Glc (lane 4) or Gly (lane 5); lane 6-7: insoluble expressed CYP52T1_3_LICRED (94.1 kDa) grown in medium containing Glc (lane 6) or Gly (lane 7); lane 8: Low-Range-Marker; lane 9-10: soluble expressed CYP52G6_LICRED (94.5 kDa) grown in medium containing Glc (lane 9) or Gly (lane 10); lane 11-12: soluble expressed CYP52G8_LICRED (94.5 kDa) grown in medium containing Glc (lane 11) or Gly (lane 12); lane 13-14: soluble expressed CYP52T1_3_LICRED (94.1 kDa) grown in medium containing Glc (lane 13) or Gly (lane 14). 
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Figure 4.14: SDS gel of CYP52T1_2, CYP52T1 and CYP584E2 co-expressed with chaperones in E. coli grown on variable carbon sources Glc = Glucose; Gly = Glycerol; lane 1: Low-Range-Marker; lane 2-3: insoluble expressed CYP52T1_2_LICRED (95.7 kDa) grown in medium containing Glc (lane 2) or Gly (lane 3); lane 4-5: insoluble expressed CYP52T1_LICRED (94.2 kDa) grown in medium containing Glc (lane 4) or Gly (lane 5); lane 6-7: insoluble expressed CYP584E2_LICRED (97.8 kDa) grown in medium containing Glc (lane 6) or Gly (lane 7); lane 8: Low-Range-Marker; lane 9-10: soluble expressed CYP52T1_2_LICRED (95.7 kDa) grown in medium containing Glc (lane 9) or Gly (lane 10); lane 11-12: soluble expressed CYP52T1_LICRED (94.2 kDa)  grown in medium containing Glc (lane 11) or Gly (lane 12); lane 13-14: soluble expressed CYP584E2_LICRED (97.8 kDa) grown in medium containing Glc (lane 13) or Gly (lane 14). 
Figure 4.15: SDS gel of CYP539B1 and CYP505A1 co-expressed with chaperones in E. coli grown on variable carbon sources Glc = Glucose; Gly = Glycerol; lane 1: Broad-Range-Marker; lane 2-5: insoluble expressed CYP539B1_LICRED (93.5 kDa, lane 2), CYP505A1_LIC-3C with transmembrane domain (139 kDa, lane 3), and CYP505A1_LIC-3C without transmembrane domain (120.6 kDa, lane 4) grown in medium containing Glc; lane 5-7: soluble expressed CYP539B1_LICRED (93.5 kDa, lane 5), CYP505A1_LIC-3C with transmembrane domain (139 kDa, lane 6), and CYP505A1_LIC-3C without transmembrane domain (120.6 kDa, lane 7) grown in medium containing Glc; lane 8: Broad-Range-Marker; lane 9-11: : insoluble expressed CYP539B1_LICRED (93.5 kDa, lane 9), CYP505A1_LIC-3C with transmembrane domain (139 kDa, lane 10), and CYP505A1_LIC-3C without transmembrane domain (120.6 kDa, lane 11) grown in medium containing Gly; lane 12-14: soluble expressed CYP539B1_LICRED (93.5 kDa, lane 12), CYP505A1_LIC-3C with transmembrane domain (139 kDa, lane 13), and CYP505A1_LIC-3C without transmembrane domain (120.6 kDa, lane 14) grown in medium containing Gly. 
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Figure 4.16 displays Western blot analysis of all P450 constructs co-expressed with 
GroEL/ES in M9 medium containing glucose as carbon source whereas Figure 4.17 shows 
the equivalent expressed in glycerol as carbon source. 
 
 
 
 
 
 
 
 
 
 
In both cases soluble expression was detectable for all P450s after only 30 s of exposure, 
except for CYP584E2 which didn’t show any traceable signal of the expected size. 
Figure 4.16: Western blot of soluble expressed P450s using the GroEL/ES chaperon system and glucose as carbon source  lane 1:Broad-Range-Marker; lane 2: CYP505A1_wo_LIC-3C (120.6 kDa); lane 3: CYP505A1_w_LIC-3C (139 kDa); lane 4:CYP539B1_LICRED (93.5 kDa); lane 5: CYP52G6_LICRED (95.4 kDa); lane 6: CYP52G8_LICRED (94.5 kDa); lane 7: CYP52T1_3_LICRED (96.5 kDa); lane 8: CYP52T1_2_LICRED (94.7 kDa); lane 9:CYP584E2_LICRED (97.8 kDa); lane 10: CYP52T1_LICRED (94.1 kDa); lane 11:Low-Range-Marker 
Figure 4.17: Western blot of soluble expressed P450s using the GroEL/ES chaperon system and glycerol as carbon source lane 1: Broad-Range-Marker; lane 2: CYP505A1_wo_LIC-3C (120.6 kDa); lane 3: CYP505A1_w_LIC-3C (139 kDa); lane 4:CYP539B1_LICRED (93.5 kDa ); lane 5: CYP52G6_LICRED (95.4 kDa); lane 6: CYP52G8_LICRED (94.5 kDa); lane 7: CYP52T1_3_LICRED (96.5 kDa); lane 8: CYP52T1_2_LICRED (94.7 kDa); lane 9: CYP584E2_LICRED (97.8 kDa); lane 10: CYP52T1_LICRED (94.1 kDa); lane 11: Low-Range-Marker 
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CYP52T1_LICRED, CYP52T1_2_LICRED, CYP52T1_3_LICRED and 
CYP505A1_wo_LIC-3C obtained the highest level of insoluble expression when grown 
with glucose in comparison to CYP539B1_LICRED, CYP52G6_LICRED and 
CYP52G8_LICRED which bands seem to be much weaker in Western blot analysis. 
Expression levels of P450s grown in M9 medium containing glycerol, surpassed 
expression levels of P450s grown with glucose many times over, when detected with the 
same exposure time in Western blot analysis. Highest expression level have been reached 
by CYP52G6_LICRED (lane 5) and CYP52T1_LICRED (lane 10). Nevertheless, 
respectable overexpression could also be detected for CYP505A1_wo_LIC-3C, 
CYP539B1_LICRED (lane 4), CYP52T1_3_LICRED (lane 7) and CYP52T1_2_LICRED 
(lane 8). CYP52G8_LICRED (lane 6) revealed only a weak band in Western blot whereas 
CYP584E2_LICRED didn’t show any signal. 
In summary, it can be said that the soluble expression level of all P450 fusions could be 
improved using the GroEL/ES chaperon system. Only exceptions are CYP505A1 
expressed with the transmembrane anchor and CYP584E2_LICRED which generally 
seemed to express rather poorly as indicated by earlier expression tests. Highest expression 
level could be reached by GroEL/ES co-expression and cell growth in M9 media using 
glycerol as carbon source. Hence, cell cultivation for whole cell activity assays, 
spectrophotometric characterization and purification were performed applying designated 
condition.    
4.2.3 Whole cell activity assay 
Even though the native substrates of Beauveria bassiana’s P450s are unknown so far, 
substrates were picked for initial activity testing. Whole cells were tested against 
N-benzylpyrrolidine as classical hydroxylation substrate for Beauveria, as well as 
N-benzoylpiperidine (Beauveria is known for catalysing the hydroxylation of N-protected 
heterocycles[219]) and limonene for the reason that alkane hydroxylases have been reported 
to show activity towards monterpene molecules.[253] Furthermore CYP52G8_LICRED was 
tested in whole cell activity assays against different concentrations (lowest concentration 
of 50 M) of lauric acid as it has been shown to hydroxylate lauric acid with strict 
regioselectivity on the terminal methyl by Zhang et al.[217]  
Assays were performed as described in 4.1.3.2 and analysed by GC (4.1.3.3). No activity 
could be detected for any of the P450s when tested against limonene (data not shown) and 
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N-benzoylpiperidine. The initial test against N-benzylpyrolidine on the other hand seemed 
promising. Absorption peaks that didn’t appear in the negative control could be identified 
for most P450s and a general increase of products was observed (data not shown). 
However, the mentioned result couldn’t be successfully reproduced. All peaks that 
appeared in P450 GC samples were also noticeable in the negative control. The first round 
of positive hits was therefore most likely the result of contaminated samples. Moreover, no 
conversion of lauric acid to 12-hydroxylauric acid by CYP52G8_LICRED could be shown, 
leading to the conclusion that the chimeric fusion is possibly inactive. Spectrophotometric 
analysis substantiates (4.2.4) this possibility.  
4.2.4 Spectrophotometric characterisation 
Cytochromes P450 have, in comparison to other cytochromes, rather uncommon spectral 
properties that allow for simple identification of active proteins using spectrophotometric 
analysis. Unreduced P450s have typically an absorption maximum at 420 nm which shifts 
of about 30 nm to 450 upon reduction and subsequent CO binding.[254]  
Concentrated E. coli cell lysate with expressed P450s cultivated as described in 2.7.1.2 was 
reduced with sodium dithionite and then bubbled with carbon monoxide. 
Spectrophotometric analysis was performed for every step subsequently, as described in 
4.1.3.1. 
 
Figure 4.18: UV-visible absorbance spectra for CYP539B1_LICRED oxidised form: blue line; sodium dithionite reduced form: red line; reduced, CO-bound form: green line. 
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Figure 4.18 displays the recorded CO-difference spectra for CYP539B1_LICRED as 
representative for the other Beauveria P450 fusions. Instead of an absorption maximum at 
420 nm when unreduced, a rather broad peak at around 400 - 410 nm was observed for all 
strains. This absorption maximum shifted after reduction with sodium dithionite to a more 
distinct peak at 425 - 430 nm and seemed to move back to 420 nm upon CO binding. Host 
E. coli proteins in the cell lysate or not properly folded protein and therefore inactive 
protein might have been the reason of this untypical CO-difference spectra. 
4.2.5 Purification of CYP539B1_LICRED 
In order to preclude interference of external influences (e.g. host E. coli proteins and 
chaperones) CYP539B1_LICRED was chosen to be purified and subsequently be tested 
for the characteristic absorption peak upon reduction and CO binding at 450 nm. 
Purification was performed as described in 2.7.2.  
 
 
Figure 4.19: Nickel affinity chromatography chromatogram for the purification of 539B1_LICRED. blue line: UV absorbance at 280 nm; green line: imidazole concentration gradient; Fraction A1-B6 are displayed along the x axis. 
A distinct peak after nickel affinity chromatography could be verified for 539B1_LICRED 
as shown in Figure 4.19. Analysis of the collected fractions using SDS gel electrophoresis, 
however, revealed that the peak corresponded only to overexpressed chaperones (Figure 
4.20) while no bands of the expected length could be detected for 539B1_LICRED.  
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Figure 4.20: SDS-PAGE analysis of CYP539B1_LICRED fractions after nickel affinity chromatography lane 1: 1 kb DNA ladder; lane 2: insoluble fraction; lane 3-4: collected fractions after washing of column with buffer A; lane 5: flow-through after column loading; lane 6-15: samples corresponding to the fractions A4, A5, A6, A7, A8, A9, A10, A11, A12, and B12 collected in nickel affinity chromatography (Figure 4.19).  Therefore, purification wasn’t possible using nickel affinity chromatography, either 
because of steric hindrance of the polyhistidine-tag by the fusion-protein itself or as a 
result of strong interaction with the co-expressed chaperones. 
4.3 Discussion 
E. coli was initially selected for heterologous expression of B. bassiana P450s as it 
provides advantages such as low cost of maintenance, ease of use, usually high yield of 
protein in comparison to yeast and mammalian cells and the lack of endogenous P450s.[255] 
Despite these advantages, the use of bacterial cells for the expression of CYPs has until 
recently been limited primarily to the soluble prokaryotic CYPs as the expression of 
membrane-bound cytochrome P450s can cause expression problems due to different codon 
bias and protein misfolding. However, advances of more efficient techniques and methods 
led to well established systems capable of producing large yields of catalytically active 
protein.  
N-terminal modification, for example, is an important tool for heterologous expression of 
cytochromes P450. With regard to the expression objective there are two categories of 
N-terminal modification: (1) modification to direct expression to the plasma membrane of 
E. coli and (2) modification to localize the protein in the cytoplasm. The first modification 
form is usually applied in order to retain the membrane binding characteristics. Membrane 
bound proteins possess signal sequences at the N-terminus (several hydrophobic aa) which 
are recognized by a signal recognition particle (SRP) and determine their membrane 
localization within the cell.[256] Although prokaryotes have analogous systems for directing 
protein to the membrane (plasma membrane), foreign signal sequences from eukaryotic 
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P450s are usually not recognized by bacterial systems and require further changes to 
increase expression levels as well as to obtain catalytically active protein.[257] Ways to 
achieve this include: altering (mutating) the native N-terminus in order to increase 
recognition of host SRP[258], insertion of previously established sequences to the N-
terminus[259] and combination of truncation and substitution with a modified sequence.[260] 
The number of variations using this system is vast and has to be regarded separately for 
every P450. It was therefore more reasonable to select the second modification system for 
this project and simply truncate the N-terminal region in order to obtain soluble expressed 
proteins. Furthermore, in the event of soluble expressed protein, structural information 
could have been obtained using crystallization. However, CYP expression applying 
N-terminal truncation of the anchor sequence has been reported with varying results and is 
no guarantee for soluble expression as the F-G helices of cytochrome P450s are also 
involved in membrane association. Li and coworker, for example, were able to express 
85% truncated rat hepatic cholesterol 7a-hydroxylase in the cytosol[261] while 50% of 
expressed truncated CYP46A1 by Mast and coworkers remained membrane bound.[262]  
As mentioned above, E.coli lacks P450s and although it has endogenous electron transport 
systems it can’t support the full catalytic activity of a heterologously expressed P450 
without an additional CYP reductase. In order to bypass the necessity to express and 
process multiple proteins separately, P450 heme domains were fused to a redox partner, 
except for CYP505A1 which is a natural fusion already. Another advantage of the fusion 
system is that it simplifies the control of relative expression levels as P450 and reductase 
are produced in equivalent amounts and may also improve catalytic performance. In this 
project a non-natural redox partner from P450-Rhf was employed as it has been reported to 
be a versatile fusion partner. Although artificial fusion constructs utilising the P450-Rhf 
reductase (RhfRED) have been described by several different research groups[263-265] the 
LICRED system[227] developed by Sabbadin and coworkers appeared to be the most useful 
system, since it was generated as a high throughput tool for novel P450s and it was readily 
available in the university of York. The utility of this system was demonstrated for various 
bacterial targets and showed also promising results beyond class I type fusions. Schückel 
applied the LICRED system creating the first active bacterial–plant fusion P450 enzyme by 
fusing an N-terminally modified IFS1 (membrane anchor removed) to RhfRED.[266] 
Furthermore, the LICRED vector is based on the pET plasmid which is one of the most 
frequently used vectors for protein expression in E. coli and provided therefore a reliable 
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and controllable design for the LICRED system. A T7 RNA polymerase is needed for 
transcription of the gene of interest as it recognizes the T7 viral promoter resulting in 
selective high-level expression. This polymerase is, however, not naturally produced by 
bacterial cells and must be introduced into the host chromosome.[267] Thus, E. coli BL21 
(DE3) and E. coli Rosetta (DE3) were used in this project since they are suitable for T7-
expression systems. 
Another factor to consider when expressing eukaryotic proteins in E. coli is the codon 
usage. Codons used in eukaryotes can differ from codons used in E. coli and as elongation 
proceeds it may happen that the ribosomes fail to recognize particular codon sequences due 
to the lack of corresponding available tRNA which can in turn influence the transcription 
rate and extent of heterologously expressed genes.[268] Furthermore, formation of 
secondary mRNA structures may hinder ribosomal binding but could be prevented by 
simple replacement of key nucleotides. Silent mutations offer therefore a simple method to 
increase the expression yield without altering the protein’s integrity. Thus, for this project 
genes have been synthesized for expression with regard to codon optimisation for E. coli.  
Expression problems can also occur through protein misfolding due to the absence of post-
translational machinery in E. coli and misfolded proteins tend to be rapidly degraded.[269] 
The GroEL-ES system has therefore been employed in this study in order to assist the 
correct folding of unfolded proteins by providing the appropriate hydrophilic environment. 
This system was especially interesting as it has been reported to greatly improve fungal 
cytochrome P450 concentration in the soluble protein fraction[252] and to increase yields of 
eukaryotic cytochrome P450 proteins as well. Yamasaki and coworkers, for example, were 
able to increase CYP2J3 protein yields twelve-fold by simply adding the GroES-GroEL 
chaperone expression plasmid.[270] 
Although all the above mentioned factors were considered, soluble expression of active 
proteins wasn’t possible in E. coli. Nonetheless, insoluble expression levels could be 
greatly improved by modifying the expression medium using different carbon sources. It is 
arguable wether the insolubility of the chimeric fusions was caused by the eukaryotic 
nature of the heme domains or may be triggered by the addition of a bacterial reductase 
domain. Experiments expressing solely the truncated heme domains CYP539B1 and 
CYP52G8 employing the LIC-3C vector (data not shown), however, had similar results 
when using the same expression conditions. No soluble expression could be verified for 
heme domains leading to the assumption that the general insolubility of the chimeric fusion 
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is owed to the eukaryotic nature of the heme domain rather than to the fused bacterial Rhf 
reductase domain. Thus, further changes in the expression strategy were required in order 
to improve solubility.   
Although soluble expression of chimeric fusions as well as truncated CYP505A1 could be 
increased by introduction of chaperonin GroEL-GroES, the increase in solubility seemed to 
be mainly caused through strong interaction between the P450 protein and the chaperones. 
As a result, the GroEL-GroES complex appeared to be permanently attached to the P450 
and thus, forced solubility as the fusions were impeded to either interact with the plasma 
membrane or form aggregates. This is substantiated by the purification results of 
539B1_LICRED which was co-expressed with chaperones. Furthermore, protein integrity 
checks using CO-different spectra of crude lysate containing P450s co-expressed with 
chaperones indicated the loss of activity of P450 enzymes as it was only possible to 
measure wavelength maxima at 420 nm instead of 450 nm. Moreover, whole cell activity 
assays failed to confirm the presence of catalytically active protein. It is arguable that the 
absence of product formation could be not only caused by inactivity of the proteins but 
also the lack of binding affinity of the P450s to deployed substrates. However, in the case 
of the CYP52G8 chimera, active protein should have been able to convert lauric acid to 
12-hydroxylauric acid. The reason for this assumption is given by the fact that native 
CYP52G8 is identical to a by Zhang et al. published B. bassiana P450 (CYP52X1) that has 
been shown to perform this reaction. [217]  
In conclusion, the E.coli expression system wasn’t suitable for soluble expression of 
neither natural and truncated chimeric B. bassiana fusions nor sole B. bassiana heme 
domains. Further changes would have had to be applied to this system in order to improve 
protein expression and cellular distribution regarding each P450 individual. In 
consideration of remaining project time and number of variables to be accounted for in 
order to improve the E. coli expression system it was decided to simply move on to an 
eukaryotic expression host that was already reported to express B. bassiana P450s[217] 
instead of improving the bacterial host system. 
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5. Construction of library of a B. bassiana P450s in pYeDP60 and expression in Saccharomyces cerevisiae WAT11 
Heterologous expression of eukaryotic P450s using bacterial hosts such as E. coli can be 
very challenging. A major issue that leads to often poor or no soluble expression is due to 
the interference of the N-terminal anchor. In order to provide conditions that enhance the 
probability of soluble protein expression in E. coli, genes of the B. bassiana P450 domains 
have been synthezised without the N-terminal anchor as described in 4.1.1. However, 
cytochrome P450 expression in S. cerevisiae requires in comparison to expression in 
E. coli N-terminal structures that drive localisation of the protein to the endoplasmic 
reticulum (ER) membranes. It is important to integrate cytochromes P450 in the ER 
membranes of the organism in order to enable interaction with the membrane bound 
cytochrome P450 reductase which acts as redox partner and supplies the P450 with 
electrons for biocatalysis.[60] Furthermore, the redox-environment created in the 
S. cerevisiea ER is more similar to the natural surroundings of membrane bound P450 
enzymes and thus may have a positive impact on the protein integrity and activity. It was 
therefore necessary to reintroduce the N-terminal anchor for yeast expression.   
5.1 Materials and Methods 
5.1.1 Reintroduction of the N-terminal region 
The sequences of the removed N-terminal regions (4.1.1) were send to GeneArt® to be 
synthesized. Amplification of the anchor regions (see sequences in Appendix B) and the 
truncated P450 heme domains took place using KOD hot start polymerase (2.5.5) and 
corresponding primers (Appendix A, Table A.3). PCR product of the N-terminal anchor, 
PCR product of appropriate P450 heme domain and the linearized pYeDP60 vector (2.2.3) 
were then combined in one reaction using the In-Fusion® HD Cloning System (2.5.7). 
Sequencing by GATC confirmed the success of the reintroduction process and the vector 
containing the full length sequence of the B. bassiana P450 heme domain could be used as 
template for the actual cloning described below. 
5.1.2 Cloning of P450 
The 7 selected B. bassiana P450 heme domains were amplified in full length using KOD 
hot start polymerase (2.5.5) and corresponding primers (Table 5.1, Table 5.2, and 
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Table 5.3). Amplification products deployed for cloning incorporated either a N-terminal 
his-tag, C-terminal his-tag or no his-tag. The full length self-sufficient P450 (CYP505A1) 
was amplified with addition of a C-terminal his-tag only. PCR products were cloned into 
the linearized pYeDP60 vector (2.2.3) using the In-Fusion® HD Cloning System (2.5.7). 
The pYeDP60 vector was linearized by double digest with BamHI and KpnI and serves as 
a shuttle vector for cloning in E. coli and expression in yeast.[228] 
Table 5.1: Primer pairs used for PCR amplification incorporating a N-terminal his tag 
Primer Sequence 52G6_DP60_n-tag_F CTAAATTACCGGATCCATGCATCATCACCATCACCAC 52G6_DP60_n-tag_R GCGAATTCGAGCTCGGTACCTTACACTGCTTCATGCAGACG 52G8_DP60_n-tag_F CTAAATTACCGGATCCATGCATCATCACCATCACCAC 
52G8_DP60_n-tag_R GCGAATTCGAGCTCGGTACCTTATTCATCAAAGTGAACTTTCAGG 52T1_DP60_n-tag_F CTAAATTACCGGATCC ATGCATCATCACCATCACCAC 52T1_DP60_n-tag_R GCGAATTCGAGCTCGGTACCTTAGCTGCTATTACCCAGG 52T1_2_DP60_n-tag_F CTAAATTACCGGATCCATGCATCATCACCATCACCAC 52T1_2_DP60_n-tag_R GCGAATTCGAGCTCGGTACCTTAATTTGCCTGCTGCAGACG 52T1_3_DP60_n-tag_F CTAAATTACCGGATCCATGCATCATCACCATCACCAC 52T1_3_DP60_n-tag_R GCGAATTCGAGCTCGGTACCTTACAGCTGTGCTGCTTCACA 539B1_DP60_n-tag_F CTAAATTACCGGATCCATGCATCATCACCATCACCA 539B1_DP60_n-tag_R GCGAATTCGAGCTCGGTACCTTAGGCCGTTTTTTCATCG 584E2_DP60_n-tag_F AAATTAATAATGACCGGATCCATGGGCAGCAGCCATCATC 584E2_DP60_n-tag_R CGCGAATTCGAGCTCGGTACCTTAGTTTTTGGCACGGGTCAG  
Table 5.2: Primer pairs used for PCR amplification incorporating a C-terminal his tag 
Primer Sequence 52G6_DP60_c-tag_F CTAAATTACCGGATCCATGGCGCTCACTGCTATCC 
52G6_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGCACTGCTTCATGCAG 52G8_DP60_c-tag_F CTAAATTACCGGATCCATGGCGGTACTATCCGTTA 
52G8_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGTTCATCAAAGTGAAC 52T1_DP60_c-tag_F CTAAATTACCGGATCCATGGCTCTCCACGCTGCC 
52T1_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGGCTGCTATTACCCAG 52T1_2_DP60_c-tag_F CTAAATTACCGGATCCATGAACTTGTTGTCATCGTCTT 
52T1_2_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGATTTGCCTGCTGCAG 52T1_3_DP60_c-tag_F CTAAATTACCGGATCCATGACTCTCTCGCCTATTTCTAC 
52T1_3_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGCAGCTGTGCTGCTTC 539B1_DP60_c-tag_F CTAAATTACCGGATCCATGCTTATCGAGGCTGTCA 
539B1_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGGGCCGTTTTTTCATC 584E2_DP60_c-tag_F AAATTAATAATGACCGGATCCATGGCACTGGGTCAGCTG 
584E2_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGGTTTTTGGCACGGGT 
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Primer Sequence 505A1_DP60_c-tag_F CTAAATTACCGGATCCATGGATGTTGATCAGATTGC 
505A1_DP60_c-tag_R CGAGCTCGGTACCTTAGTGGTGATGGTGATGATGGTCAAACACATCGGC  Table 5.3: Primer pairs used for PCR amplification incorporating no additional his tag 
Primer Sequence 52G6_DP60_F CTAAATTACCGGATCCATGGCGCTCACTGCTATCC 52G6_DP60_R GCGAATTCGAGCTCGGTACCTTACACTGCTTCATGCAGACG 52G8_DP60_F CTAAATTACCGGATCCATGGCGGTACTATCCGTTA 52G8_DP60_R GCGAATTCGAGCTCGGTACCTTATTCATCAAAGTGAACTTTCAGG 52T1_DP60_F CTAAATTACCGGATCCATGGCTCTCCACGCTGCC 52T1_DP60_R GCGAATTCGAGCTCGGTACCTTAGCTGCTATTACCCAGG 52T1_2_DP60_F CTAAATTACCGGATCCATGAACTTGTTGTCATCGTCTT 52T1_2_DP60_R GCGAATTCGAGCTCGGTACCTTAATTTGCCTGCTGCAGACG 52T1_3_DP60_F CTAAATTACCGGATCCATGACTCTCTCGCCTATTTCTAC 52T1_3_DP60_R GCGAATTCGAGCTCGGTACCTTACAGCTGTGCTGCTTCACA 539B1_DP60_F CTAAATTACCGGATCCATGCTTATCGAGGCTGTCA 539B1_DP60_R GCGAATTCGAGCTCGGTACCTTAGGCCGTTTTTTCATCG 584E2_DP60_F AAATTAATAATGACCGGATCCATGGCACTGGGTCAGCTG 584E2_DP60_R CGCGAATTCGAGCTCGGTACCTTAGTTTTTGGCACGGGTCAG 
5.1.3 Expression 
Expression was performed under conditions requiring appropriate sterilization of media 
and consumables by autoclaving.  
S. cerevisiae colonies containing relevant plasmid were restreaked on a selective plate 
(SGI, 2.3.2) as shown in Figure 5.1 in order to harvest a reasonable amount of cell mass 
that could serve as inoculum for the SGI liquid preculture. Colonies used for expression 
tests have been analysed by colony PCR (2.5.5) prior to inoculation to ensure the presence 
of the CYP_pYeDP60 construct. The designed primers (Table 5.4) correspond to internal 
vector sequences resulting in PCR products incorporating 203 nucleotides in front of the 
cloned gene sequence and 84 nucleotides behind. 
 Figure 5.1: S. cerevisiae colonies on SGI plate. Cell amount serving as inoculum for preparation of preculture for expression is circled in red. 
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Table 5.4: Primer pair used for colony PCR 
Primer Sequence FWD_pYeDP60_int TAGTGCTGACACATACAGGC REV_pYeDP60_int CCTGGCAATTCCTTACCTTC  For expression, 20 ml of SGI liquid medium (2.3.2) was inoculated with positive 
transformants, as described above, and incubated for 18 h at 28 °C (160 r.p.m.). The OD600 
of the overnight culture was measured the following morning in a 1:10 dilution to calculate 
the appropriate volume of overnight culture necessary to inoculate 200 ml YPGE (2.3.2) 
main culture to an OD600 of 0.15. Main cultures were incubated shaking (160 r.p.m.) at 
28 °C. After 30 h incubation, the main source of carbon in the medium (glucose) which is 
responsible for the repression of transcription should be used up, and thus forcing the yeast 
to switch metabolism towards ethanol. In order to induce transcription 10 ml galactose 
(2.3.3) were added to each flask and incubated shaking (160 r.p.m.) for 18 h at 18 °C. In 
presence of the inducer (galactose) Gal4p, a regulatory protein, binds to sites in the UAS 
(upstream activation sequence) and activates transcription. The yeast was then harvested 
and the microsomes isolated (5.1.4). 
5.1.4 Microsome preparation 
Microsomes were prepared by differential centrifugation.[228] Yeast cells were harvested by 
centrifugation at 4250 r.p.m. (Sorvall RC 5B plus centrifuge, F10-6x500 rotor) for 10 min 
at 4 °C. The cell pellet was then resuspended in 30 ml ice-cold TEK buffer and recovered 
by additional centrifugation. Cells were resuspended in 2 ml TES buffer and glass beads 
(glass beads, 0.40-0.60 mm, Sartorius) were added up to the level of cell suspension. The 
cell walls were disrupted mechanically by hand shaking in 6 x 1 min intervals with 1 min 
delay between each interval on ice. Glass bead suspension was washed three times with 
20 ml TES buffer and the washings were transferred into fresh tubes. The solution was 
centrifuged (Sorvall Evolution RC centrifuge, SLC-3000 rotor) for 20 min at 7500 r.p.m. 
(4 °C) to remove cell membranes, leaving membrane fractions and soluble proteins in the 
supernatant. The supernatant was filtered through miracloth (Calbiochem, Merck) to 
remove all glass beads and then ultracentrifuged at 35000 r.p.m. at 4 °C (Beckman Avanti 
J-HC ultracentrifuge, 45 Ti-rotor) for 1 – 2 h to pellet the microsomes. The pellet was 
transferred into a potter homogeniser, 500 µl TEG added and homogenised on ice avoiding 
the build up of air bubbles.  
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To test the presence of active P450, sodium dithionite and CO was added by bubbling the 
microsome solution in the cuvette for 30 s in order to create the reduced CO bound form of 
the P450. Absorption was measured between 200 and 500 nm. 
TEK buffer  2M Tris-HCl (pH 7.5)  12.5 ml 0.5M EDTA (pH 8.0) 1 ml KCl 3.7 g H2O fill up to 500 ml 
TES buffer  2M Tris-HCl (pH 7.5)  25 ml 0.5M EDTA (pH 8.0) 2 ml Sorbitol 109 g H2O fill up to 1000 ml 
10 g BSA and 120 µl β-mercaptoethanol were added to 1 l buffer on the day of use. 
TEG buffer  2M Tris-HCl (pH 7.5)  2.5 ml 0.5M EDTA (pH 8.0) 100 µl  Glycerol 30 ml H2O fill up to 100 ml 
5.2 Results 
5.2.1 Cloning into pYeDP60 
7 B. bassiana heme domains were cloned into the pYeDP60 plasmid as described in 5.1.2. 
Figure 5.2 shows the success of PCR for all amplification products that incorporate the 
C-terminal his-tag.  
 Figure 5.2: PCR products incorporating the C-terminal his-tag after gel extraction lane 1: 1 kb DNA ladder; lane 2: CYP52G6; lane 3: CYP52G8; lane 4: CYP52T1_2; lane 5: CYP52T1_3; lane 6: CYP52T1; lane 7: CYP539B1; lane 8: CYP584E2; lane 9: CYP505A1; lane 10: 1 kb DNA ladder 
PCR results comprising DNA sequences without his-tag and with N-terminal his-tag are 
not shown as the individual sequence length of the corresponding gene is very similar to 
the C-terminal his-tagged amplification product and would not show differences on an 
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agarose gel. Table 5.5 lists the relative nucleotide length for all amplification products in 
correspondence to molecular changes. 
Table 5.5: Relative nucleotide length of amplification products 
Template sequence base pair length of nucleotide sequence Without his-tag N-terminal his-tag C-terminal his tag CYP52G6 1623 1641 1634 CYP52G8 1623 1641 1634 CYP52T1 1641 1659 1652 CYP52T1_2 1647 1665 1658 CYP52T1_3 1662 1680 1673 CYP539B1 1584 1602 1595 CYP584E2 1630 1648 1639 CYP505A1 - - 3746 
After annealing of prepared vector and insert and subsequent transformation into 
NovaBlue Single competent cells (2.6.3), several colonies were picked for an initial screen 
of positive transformants by control digest with BamHI and KpnI (2.5.1) prior to the final 
confirmation using sequencing. Positive clones for all constructs containing the C-terminal 
his-tag are shown in Figure 5.3.  
 
Figure 5.3: Initial screen of positive transformants containing a C-terminal his-tag using restriction enzymes BamHI and KpnI lane 1: 1 kb DNA ladder; lane 2: CYP52G6_DP60; lane 3: CYP52G8_DP60; lane 4: CYPT1_2_DP60; lane 5: CYPT1_3_DP60; lane 6: CYP52T1_DP60; lane 7: CYP539B1_DP60; lane 8: CYP584E2_DP60; lane 9: CYP505A1_DP60; lane 10: empty pYeDP60 
The image displays 1 selected clone for each P450 construct with C-terminal his-tag 
containing the empty pYeDP60 vector and the insert of the expected length after digest. 
The nucleotide length of the inserts after digest is similar to the nucleotide length of the 
individual amplification products listed in Table 5.5 since the restriction sites flank the 
inserted DNA sequences directly. CYP52G6_DP60, CYPT1_2_DP60 and 
CYP505A1_DP60 each possess a binding site for the applied restriction enzymes and thus 
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display 2 fragments in agarose gel (CYPT1_2_DP60’s second fragment is too small to see 
in agarose gel). Sequencing by GATC confirmed the success of the cloning process. 
5.2.2 Transformation into S. cerevisiae 
Transformation was performed as described in 2.6.4. In order to confirm the insertion of 
the correct pYeDP60 construct, individual S. cerevisiae colonies were picked using a 
sterile pipette tip and restreaked on a selective plate (SGI, 2.3.2) as shown in Figure 5.1. 
On the pipette tip remaining cell material was then used for colony PCR (2.5.5). Figure 5.4 
and Figure 5.5 display the colony PCR of two to three selected transformants for each 
P450 construct incorporating a C-terminal his-tag. Colony PCR results for P450 constructs 
containing no his-tag or an N-terminal his-tag are not displayed for the same reason 
mentioned in 5.2.1.  
Positive transformation could not be verified for all selected colonies. In case of 
CYP52G6_DP60, for example, only one out of three colonies was tested positive using 
colony PCR. S. cerevisiae that wasn’t transformed should not be able to grow on selective 
agar plates and S. cerevisiae transformed with the original vector (without insert) would 
have shown a band of around 300 bp on the agarose gel. This, however, was not the case 
leading to the assumption that too much employed cell material and therefore high 
concentrations of DNA obstructed the PCR.  
 
Figure 5.4: Colony PCR of transformed S. cerevisiae (pYeDP60 constructs containing genes of interest with C-terminal his-tag) lane 1: CYP52G6_DP60_p1; lane 2: CYP52G6_DP60_p2; lane 3: CYP52G6_DP60_p3; lane 4: CYPT1_3_DP60_p1; lane 5 CYPT1_3_DP60_p2; lane 6: 1kb DNA ladder; lane 7: CYPT1_DP60_p1; lane 8: CYPT1_DP60_p2; lane 9: CYP505A1_DP60_p1; lane 10: CYP505A1_DP60_p2; lane 11: CYP505A1_DP60_p3 
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Figure 5.5: Colony PCR of transformed S. cerevisiae (pYeDP60 constructs containing genes of interest with C-terminal his-tag) lane 1: CYP52G8_DP60_p1; lane 2: CYP52G8_DP60_p2; lane 3: CYP52G8_DP60_p3; lane 4: 1kb DNA ladder; lane 5 CYP584E2_DP60_p1; lane 6: CYP584E2_DP60_p2; lane 7: CYPT1_2_DP60_p1; lane 8: CYPT1_2_DP60_p2; lane 9: CYP539B1_DP60_p1; lane 10: CYP539B1_DP60_p2;  
Table 5.6 lists the relative nucleotide length for all amplification products expected after 
colony PCR in correspondence to molecular changes. 
Table 5.6: relative nucleotide length of colony PCR amplification products 
Template sequence base pair length of nucleotide sequence Without his-tag N-terminal his-tag or C-terminal his tag 
CYP52G6 1874 1892 CYP52G8 1874 1892 CYP52T1 1892 1910 CYP52T1_2 1898 1916 CYP52T1_3 1913 1931 CYP539B1 1835 1853 CYP584E2 1874 1892 CYP505A1 - 4004 
5.2.3 Expression test in Saccharomyces cerevisiae WAT11 
Colonies used for expression tests have been analysed by colony PCR prior to inoculation 
as described in 5.1.3 in order to unsure the presence of the CYP_pYeDP60 constructs. 
After the harvest of cells (5.1.3) microsomes were prepared using differential 
centrifugation (5.1.4). Membrane-bound P450s expressed in microsomes have usually a 
rather low concentration and are therefore not easily verified via SDS page. No signals of 
the expected sizes could be detected in SDS page (data not shown). Thus, other 
identification methods had to be applied in order to confirm the presence of overexpressed 
P450s in the microsome fractions. Spectrophotometric analysis (CO-difference spectra) 
and the high sensitive method of Western blotting are suitable for this task and have been 
used in this study. 
A 1:4 dilution of the microsome fraction in TEG buffer was reduced with sodium 
dithionite and then bubbled with carbon monoxide. Absorption for unreduced and reduced, 
CO treated microsome solution was measured between 200 and 600 nm. Figure 5.6 
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displays the recorded CO-difference spectra for CYP52T1 as representative for the other 
Beauveria P450s. Membrane fractions of induced S. cerevisiae containing the empty 
pYeDP60 have been analysed as a negative control in order to judge the influence of 
endogenously expressed P450s (Figure 5.6 A). Here, only a small peak around 425-430 nm 
could be detected after reduction and subsequent CO-treatment. No typical 450 nm peak 
was visible leading to the assumption that the expressed endogenous P450s are most likely 
not correctly folded and therefore inactive. The same applies for all microsome fractions 
that should contain overexpressed fungal P450s (Figure 5.6 B, Figure 5.6 C, and Figure 
5.6 D). In fact, considering peak position, height and width, the CO-difference spectra 
appear suspiciously similar to the CO-difference spectrum of microsome fractions 
containing only endogenous P450s and therefore, signifying no expression at all. However, 
CO-difference spectra are not always dependable. Thus, the more sensitive and reliable 
method of Western blotting was performed for final validation. Unfortunately, Western 
blot analysis confirmed the results indicated by the spectrophotometric analysis. No signals 
of expressed proteins with the predicted molecular weight could be detected (data not 
shown). 
 
Figure 5.6: UV-visible absorbance spectra for CYP52T1_DP60 containing either no his tag, N-terminal his-tag or C-terminal his-tag in comparison to empty pYeDP60 oxidised form: blue line; reduced, CO-bound form: red line. The microsome fraction from induced S. cerevisiae containing the empty pYeDP60 vector (A) and microsome fractions expressing CYP52T1 without his-tag (B), N-terminal his-tag (C) and C-terminal his-tag (D) are shown. 
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5.3 Discussion 
The reason to select S. cerevisiae as aeukaryotic heterologous expression host for 
B. bassiana P450s is reflected by its obvious advantages. First of all, Saccharomyces 
cerevisiae is the first system reported to successfully express mammalian[34] and plant[271] 
P450 proteins and has advanced to the most frequently used system for functional 
expression of plant P450s.[272] Furthermore, it shows great promise for expression of 
functional fungal cytochrome P450 heme domains.[273-274] The most important advantage 
of the yeast system in comparison to other eukaryotic expression systems is, however, the 
combination of prokaryotic simplicity of growth (e.g., low cost culture media, rapid 
growth) and manipulation (optimized yeast systems for P450 expression) with eukaryotic 
complexity of protein machinery (e.g., posttranslational folding) and the presence of an ER 
membrane environment.  
The pYeDP60 vector system[228], which has so far been the most successfully used for 
cytochrome P450, and the WAT11 yeast strain were selected for the expression of the 
B. bassiana P450s. S. cerevisiae WAT11 has been initially developed for expression of 
plant P450s as it contains a chromosomally integrated Arabidopsis P450 reductase gene 
(ATR1) to overcome coupling deficiencies with the endogenous S. cerevisiae P450 
reductase and thus provides a redox environment that is optimal for plant P450 activities. 
Despite that, utilisation of the WAT11 strain in combination with the pYeDP60 vector 
system was still considered the most promising strategy for functional expression of 
B. bassiana P450s as it was already successfully applied for 5 B. bassiana P450s by 
Pedrini and co-worker.[274] Moreover, 2 (CYP52X1, CYP5337A1) of these 5 P450s 
possess identical amino acid sequences with CYP52G8 and CYP52T1 which were selected 
in this study and should have therefore been successfully expressed when using the same 
expression system and conditions.  
P450s expressed by Pedrini et al. have either been cloned with an N-terminal his-tag or 
C-terminal his-tag. Although the insertion of a N-terminal his-tag is usually arguable since 
it is expected to be cleaved together with the signal sequence which conveys protein 
localization to the membrane, P450s are processed differently in comparison to other 
proteins as their N-terminal region is recognized by the signal recognition particle but not 
cleaved.[257] Thus, it was decided to use both systems for this study as well as untagged 
P450s in order to determine possible differences with regard to substrate assay 
performances of functional expressed P450s. Unfortunately, no expression could be 
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detected for any of the P450 constructs. Although the absence of a typical CO difference 
spectral shift is not necessarily proof for a lack of expression, as shown for 4 out of 5 
expressed B. bassiana P450s by Pedrini et al.,[274] the absence of protein bands in Western 
blot analysis on the other hand is evident. 
The nature of the utilized pYeDP60 vector system presents one possible explanation. In 
this system, the GAL10-CYC1 promoter is fully repressed by the glucose in the medium 
and derepression is only achieved when glucose is exhausted and cells are forced to rely on 
ethanol utilization for growth followed by full induction of protein expression through the 
addition of galactose.[228] It seemed possible that not all of the glucose was consumed by 
the time of induction and thus no expression was induced. However, the exchange of 
glucose containing medium at the end of the exponential growth phase with induction 
medium containing galactose instead led to similar results in the UV-visible absorbance 
spectra and Western blot analysis. 
A more reasonable explanation can be found when looking at the nucleotide sequences of 
the cloned genes. As already mentioned for the E. coli expression system, codon bias of the 
expression host can affect the efficiency of translation, often resulting in proteins being 
poorly expressed or mistranslated in heterologous organisms. In the case of the in this 
study selected P450 enzymes, template sequences for PCR and additional cloning derived 
from E. coli optimised synthesised genes whereas Pedrini et al. were using the original 
fungal cDNA as template for PCR. Although the average GC content of the fungal P450s 
(ranging from 49.8% for CYP539B1 to 61.7% for CYP52G8) has been decreased to about 
48-50% and as a consequence is significantly closer to the average GC content of yeast 
genes (40%)[275] the codon bias in yeast is very different.  
Table 5.7: comparison of codon usage of 4 major aa in E. coli and S. cerevisiae 
Amino acid Codon Codon usage in % E. coli S. cerevisiae 
Leucine (Leu, L) CTG 55 9 Serine (Ser, S) AGC 26 9 Proline (Pro, P) CCG 56 9 
Arginine (Arg, R) CGT 45 17 CGC 37 4 
    
Among the most unfavourable codons with reference to the bias in highly expressed genes 
in yeast, are the codons CTC for Leu, AGC for Ser, CCG for Pro and CGT or CGC for Arg 
(Table 5.7).[276] In CYP505A1 they represent 17.44 % of the total codons while the 
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percentage in the non-fusion genes is even higher (25-30 %). More alarming is the fact that 
100 % of the amino acids Leu and Arg are coded by rare codons. Low usage codons for 
Pro and Ser are utilized in a rate of 79-100 % (Table 5.8). It is therefore reasonable to 
assume that the presence of these low-usage codons have caused translational inhibition 
especially under consideration of the fact that protein sequence for 2 B. bassiana P450s as 
well as expression system and conditions have been identical to that of Pedrini et al.. 
Furthermore, it has been previously reported that codon bias in S. cerevisiae can have an 
enormous influence of protein expression.[277-278] Batard and coworkers, for example, were 
able to increase the expression of CYP73A17 to 300 pmol P450 mg-1 protein after recoding 
111 base pairs while no expression was detectable when using the original gene 
sequence.[278] In addition, it has to be mentioned that the B. bassiana genes were expressed 
using the very strong GAL10-CYC1 promotor that might have contributed to the 
translational inhibition by simply inducing the synthesis of a critical number of transcripts 
which could have then led to complete depletion in rare tRNA and thus an excessive 
slowing down of the ribosomes. 
Table 5.8: Proportion of low usage codons in gene-sequences of B. bassiana heme-domains optimised for E. coli expression 
Gene Codon (aa) Rare codon used for aa (%) Rare codon used in total aa sequence (%) Total rare codon usage (%) 
CYP505A1 
CTG  (Leu) 100 8.11 
17.44 AGC  (Ser) 88 2.76 CCG  (Pro) 93 2.59 CGT   (Arg) 100 3.98 CGC 
CYP52G6 
CTG  (Leu) 100 11.15 
26.55 AGC  (Ser) 81 3.9 CCG  (Pro) 79 4.3 CGT  (Arg) 100 7.2 CGC 
CYP52G8 
CTG  (Leu) 100 8.9 
26.78 AGC  (Ser) 85.3 5.48 CCG  (Pro) 100 4.9 CGT  (Arg) 100 7.5 CGC 
CYP52T1 
CTG  (Leu) 100 11.79 
30.61 AGC  (Ser) 85.71 6.74 CCG  (Pro) 93.54 5.34 CGT (Arg) 100 6.74 CGC           
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Gene Codon (aa) Rare codon used for aa (%) Rare codon used in total aa sequence (%) Total rare codon usage (%) 
CYP52T1_2 
CTG  (Leu) 100 9.8 
26.15 AGC  (Ser) 80 4.47 CCG  (Pro) 92 4.28 CGT (Arg) 100 7.6 CGC 
CYP52T1_3 
CTG  (Leu) 100 10.5 
25.28 AGC  (Ser) 82.35 5.2 CCG  (Pro) 91.3 3.87 CGT (Arg) 100 5.71 CGC 
CYP539B1 
CTG  (Leu) 100 7.75 
24.54 AGC  (Ser) 92.6 4.88 CCG  (Pro) 93.93 6.05 CGT (Arg) 100 5.86 CGC 
CYP584E2 
CTG  (Leu) 100 10.79 
28.95 AGC  (Ser) 95.45 3.97 CCG  (Pro) 79.31 4.35 CGT (Arg) 100 9.84 CGC  
In conclusion, the S. cerevisiae expression system was expected to deliver functionally 
expressed P450 because it has been demonstrated to be suitable for B. bassiana P450 
expression by Pedrini and coworkers.[274] Despite of the use of identical expression system 
and conditions, expression wasn’t successful which was most likely due to the codon bias 
in yeast as the gene sequences used for expression have been optimised for E. coli and not 
for S. cerevisiae. Consequently, new gene sequences would have had to be applied to this 
system in order to improve protein expression and carry out substrate assays. In 
consideration of remaining project time, however, it wasn’t possible to redo all the steps 
necessary to achieve functional fungal P450s in the microsomes of S. cerevisiae. 
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6. A P450 fusion library of heme domains from Rhodococcus jostii RHA1 and its evaluation for the biotransformation of drug molecules 
23 Rhodococcus jostii P450 domains that had already been cloned into the LICRED vector 
by Ralph Hyde (University of York) have been investigated in the interests of identifying 
activities for the transformation of drug molecules. In addition, the applicability of the 
LICRED system as a high throughput tool could be reevaluated.  
6.1 Introduction 
In order to gain an overview of the 25 annotated P450 enzymes from Rhodococcus jostii 
RHA1, a phylogenetic analysis of the putative gene targets was performed by Lindsay Eltis 
and is shown in Figure 6.1.[279] A list of the gene targets can be found in Appendix A 
(Table A.2).  
 
Figure 6.1: Phylogenetic tree constructed of Rhodococcus jostii RHA1 gene targets (blue) Included with the RHA1 P450 genes are various cytochromes P450 heme domains of known structure designated by their PDB codes 
R. jostii features one homolog of CYP51B (ro04671), which has been assigned the role of 
a sterol demethylase in strains of Aspergillus[280]; four homologs of CYP125 (ro04679, 
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ro04667, ro02651 and ro02355), including one that has been shown to initiate side-chain 
degradation in steroids through C26 hydroxylation (Figure 6.2 1)[224], and one of 
CYP257A1 (ro11069), which has been shown to catalyse the N-demethylation of the 
alkaloid dextromethorphan (Figure 6.2 3)[225].  
 
Figure 6.2: Oxidative activities attributed to P450 from Rhodococcus jostii RHA1  CYP125 catalyses the oxidation of sterols such as cholesterol 1 at the C26 position; CYP257A1 catalyses the N-demethylation of the alkaloid dextromethorphan 3 
Based on the phylogenetic analysis Ralph Hyde (University of York) created a 
P450RHA1-RhfRED fusion library for 23 of the R. jostii RHA1 targets by applying the 
LICRED technology (2.5.6) using genomic DNA as a template for the amplification. 
Primers for cloning can be found in Appendix A (Table A.4). Further investigations of the 
fusion library were commenced in this study. 
6.2 Material and Methods 
6.2.1 Screening for drug metabolites using resting whole cells 
All whole-cell biotransformation tests were carried out with resting cells in buffer A 
(50 mM Tris/HCl, 300 mM NaCl, pH 7.5). 1 mM stock solutions of all substrates were 
prepared in methanol prior to biotransformation experiments. Biotransformations of freshly 
harvested cells with a cell wet weight of 100 mg/ml were carried out by addition of 12 µM 
(3.6 l) of the relevant stock solution to give a total volume of 300 l.  
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Figure 6.3: experimental setup for E. coli whole cell activity assays and UPLC-MSE analysis RoX: E. coli strain transformed with LICRED containing R. jostii RHA1 heme domain X; resting whole cells with a cell wet weight of 100 mg/ml are incubated with 12 M of substrate X in 96-well plates; biotransformations of cells expressing the empty LICRED vector, overnight reactions of substrate X in buffer A and 40 % acetonitrile serve as negative controls  Reactions were incubated with constant vigorous shaking at room temperature in deep 
96-well plates (Thermo Scientific Nunc, USA) of 1 ml well volume. Samples of 50 l were 
taken at intervals: t = 0 h, t = 3 h and t = 18 h and transferred to a conical 96-well plate 
(Thermo Scientific, Denmark). The biological material was precipitated by the addition of 
100 l acetonitrile and the samples centrifuged at 4000 r.p.m. (Hettich, Germany) at 4° C 
for 20 min. 50 l of the supernatant was then transferred into 150 l 40% (v/v) acetonitrile 
in water and analysed by UPLC-MSE (6.2.4). Figure 6.3 illustrates the experimental setup 
described above. 
6.2.2 Screening for drug metabolites using purified Ro07-RhfRED 
150 M NADPH was added to a solution of pure Ro07-RhfRED (0.8 mg/ml, 9.4 M) 
containing 12 M of the drug compound, added from a 1 mM stock solution in methanol, 
to give a final reaction volume of 100 l. Each reaction was incubated with shaking at 
room temperature (22–25°C) in deep 96 well plates (Thermo Scientific Nunc, USA) of 
1 ml well volume. Samples were taken at time point t = 0 and t = 18 h. 25 l of the sample 
was then removed and the biological material precipitated by the addition of 50 l 100% 
acetonitrile, after which the sample was centrifuged at 4000 r.p.m. (Hettich, Germany) for 
20 min at 4 °C. 25 l of the supernatant was then transferred into 75 l 40% (v/v) 
acetonitrile in water and analysed by UPLC-MSE (6.2.4). 
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6.2.3 In vitro activity assays towards imipramine using purified Ro07-RhfRED 
The activity of Ro07-RhfRED was tested at different concentrations of imipramine ranging 
from 1-50 µM. All reactions were carried out in the biotransformation buffer A 
(50 mM Tris/HCl, 300 mM NaCl, pH 7.5). Reactions were prepared as listed in Table 6.1. 
Briefly, 0.15 mM of NADPH was added to 100 l volume of buffer A containing 1 mg/ml 
of the purified enzyme. 1–50 µM of imipramine was then added from a 0.06 mM stock in 
buffer A. The final reaction volume of 1 ml was obtained by adding buffer A. The 
reactions were incubated at 30 °C with constant shaking at 500 r.p.m.. Reactions were 
carried out in duplicates and reaction progress was measured at intervals t = 0 and 12 h. 
Reactions were stopped by addition of pure acetonitrile followed by the removal of 
precipitated proteins by centrifugation at 4 °C for 20 min at 4000 r.p.m... Subsequently, the 
reaction mixtures were quenched using solution of 40% acetonitrile (v/v) in water and 
analysed by UPLC-MSE (6.2.4). 
Table 6.1: experimental set up for imipramine kinetic assay with purified Ro07-RhfRED 
Sample name Imipramine (Conc. in µM) Enzym (10 mg/ml) (in µl) NADPH (3 mM) (in µl) BufferA (in µl) Substrate (0,06mM) (in µl) control (no enzym) 50 0 50 100 850 control (no NADPH) 50 100 0 50 850 1 0 100 50 850 0 
2 1 100 50 833 17 
3 2 100 50 816 34 
4 3 100 50 799 51 
5 4 100 50 782 68 
6 5 100 50 765 85 
7 7 100 50 731 119 
8 10 100 50 680 170 
9 25 100 50 425 425 
10 50 100 50 0 850 
6.2.4 Analysis using UPLC-MSE and data processing 
Samples (10 µL) were injected and analysed using a Waters ACQUITY UPLC liquid 
chromatography system coupled to a Waters Synapt HDMS instrument (Waters, Milford, 
MA, USA) and equipped with an electrospray ionisation (ESI) source. Chromatographic 
separation was carried using an ACQUITY UPLC BEH C18 column (130 Å, 1.7 µm × 2.1 
mm × 100 mm; Waters, Milford, MA, USA) at flow rate of 0.5 ml/min and column 
temperature of 45 °C. For separations using liquid chromatography mobile phases 
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consisting of ultra-pure water supplemented with formic acid (0.1% v/v; mobile phase A) 
and pure acetonitrile (mobile phase B) were employed. The gradient applied for separation 
was as follows: 0.0-6.0 min (10–70% mobile phase B); 6.0-6.7 min (70–90% mobile phase 
B), followed by a return to the initial mobile phase composition over 0.01 min. 
The MSE analysis was run on a Waters Synapt HDMS operating under positive 
electrospray ionization (ESI) conditions in V-mode. A generic method with two scan 
functions was used as follows: m/z 80–1000, cone voltage 20 V and 0.1 s scan time, the 
trap collision energy (CE) in function 1 was 20 V and in function 2 an energy ramp of 15–
45 V was applied, the transfer cell CE was 12 V. Data were collected in a centroid mode. 
Leucine-enkephaline was used as a lock mass (m/z 556.2771) for internal calibration at a 
concentration of 250 pg/ml and a flow rate of 0.04 ml/min.  
The MSE data were processed in MetaboLynx 4.1 (Waters, Milford, MA, USA) using both 
the mass defect filter (MDF) and the dealkylation tool. 
6.3 Results 
6.3.1 Expression test in E. coli 
In order to confirm overexpression of selected P450s, small scale expression tests were 
performed as described in 2.7.1.1. The strain E. coli Rosetta 2 (DE3) (2.2.1) was used to 
express R. jostii P450s cloned into the LICRED vector. Different conditions in respect of 
growth medium and expression temperature were tested. Initially, expression was tested in 
10 ml LB medium and confirmed via SDS-PAGE and Western blot (data not shown). 
Although the production of insoluble and partly even soluble protein could be verified in 
all 23 cases, expression in general proved to be more efficient using M9 minimal medium 
for growth. All results shown below are taken from Western blot analysis (2.7.4) with cells 
grown in M9 medium. The optimal expression temperature was determined by growing 
cells at 16˚C, 30˚C and 37˚C. Only experiments that took place in 16˚C showed any 
soluble expression. Figure 6.4 displays Western blot analysis for Ro08-RhfRED grown at 
varied temperatures as representative for the other R. jostii P450 fusions.   
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 Figure 6.4: Western blot analysis of Ro08-RhfRED expression carried out at varied temperatures lane 1: Low-Range-Marker; lane 2, 4, and 6: insoluble Ro08-RhfRED expressed at 16 ˚C (lane 2), 30 ˚C (lane 4), and 37 ˚C (lane 6); lane 3, 5 and 7: soluble Ro08-RhfRED expressed at 16 ˚C (lane 3), 30 ˚C (lane 5), and 37 ˚C (lane 7); lane 8: empty; lane 9: positive control.  
All P450 fusions, except Ro03-RhfRED, were expressed insolubly and displayed bands of 
the expected height corresponding to a molecular weight of about 80 to 87 kDa in Western 
blot analysis. Soluble expression could be verified for Ro04-RhfRED, Ro05-RhfRED, 
Ro08-RhfRED, Ro11-RhfRED, Ro18-RhfRED and Ro22-RhfRED. However, exposure 
time whilst detecting Western blot was limited to the signal strength of the insoluble phase. 
These signals were usually fairly strong and masked the whole blot when exposed too 
long. Thus, weaker signals occurring in the soluble fraction could not be detected. Western 
blotting of all soluble phases was carried out in order to check for additional weaker 
signals (Figure 6.5 and Figure 6.6). 
Significant signals of the predicted molecular weight (80 to 87 kDa) for soluble expressed 
fusions of RhfRED were detected by Western blot analysis for Ro01-RhfRED, Ro02-
RhfRED, Ro04-RhfRED, Ro05-RhfRED, Ro06-RhfRED, Ro07-RhfRED, Ro08-RhfRED, 
Ro09-RhfRED, Ro11-RhfRED, Ro12-RhfRED, Ro16-RhfRED, Ro18-RhfRED, Ro20-
RhfRED, Ro21-RhfRED and Ro22-RhfRED. Among these soluble expressed fusions, 
Ro01-RhfRED, Ro02-RhfRED and Ro09-RhfRED (Figure 6.5: lane 1, 2 and 11) as well as 
Ro16-RhfRED, Ro20-RhfRED, and Ro21-RhfRED (Figure 6.6: lane 6, 10 and 11) showed 
comparatively weak expression. The moderate (Ro04-RhfRED, Ro05-RhfRED, Ro06-
RhfRED, Ro07-RhfRED and Ro11-RhfRED; Figure 6.5: lane 6, 7, 8, 9 and 13) or strongly 
(Ro08-RhfRED, Ro12-RhfRED, Ro18-RhfRED and Ro22-RhfRED; Figure 6.5: lane 10 
and 14; Figure 6.6: lane 8 and 12) expressed genes on the other hand displayed evidence of 
110 
cleavage at the heme domain-reductase linkage illustrated by the blot response at 
approximately 45 and 55 kDa.  
 Figure 6.5: Western blot analysis of soluble expressed X-RhfRED fusions at 16C lane 1: Low-Range-Marker; lane 2: extract from non-induced cells; lane 3: Ro01-RhfRED; lane 4: Ro02-RhfRED; lane 5: Ro03-RhfRED; lane 6: Ro04-RhfRED; lane 7: Ro05-RhfRED; lane 8: Ro06-RhfRED; lane 9: Ro07-RhfRED; lane 10: Ro08-RhfRED; lane 11: Ro09-RhfRED; lane 12: Ro10-RhfRED; lane 13: R011-RhfRED; lane 14: Ro12-RhfRED 
 Figure 6.6: Western blot analysis of soluble expressed X-RhfRED fusions at 16C lane 1: Low-Range-Marker; lane 2: extract from non-induced cells; lane 3: Ro13-RhfRED; lane 4: Ro14-RhfRED; lane 5: Ro15-RhfRED; lane 6: Ro16-RhfRED; lane 7: Ro17-RhfRED; lane 8: Ro18-RhfRED; lane 9: Ro19-RhfRED; lane 10: Ro20-RhfRED; lane 11: Ro21-RhfRED; lane 12: Ro22-RhfRED; lane 13: Ro23-RhfRED 
7 of the 15 recombinant cell strains expressing soluble fusion proteins were picked to be 
further analysed with regard to their oxidative activity as whole-cell biocatalysts in the 
biotransformation of drugs. Homologs of CYP51B, CYP125 and CYP257A1 (see 
introduction: 6.1) are represented by Ro22-RhfRED, Ro05-RhfRED and Ro07-RhfRED, 
respectively. In addition, Ro04-RhfRED, Ro08-RhfRED, Ro11-RhfRED and Ro18-
RhfRED have been randomly selected for further investigation. 
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6.3.2 Screening for drug metabolites using resting whole cells 
Whole cells were grown as described in 2.7.1.2. After cell harvest, the cell pellet was 
washed twice with buffer A (50 mM Tris/HCl pH 7.5, 300 mM NaCl) and was 
subsequently resuspended in a proportionated volume of buffer A to give a cell wet weight 
of 100 mg/ml. Whole cells were then challenged with 65 commercially available drug 
compounds (provided by AstraZeneca; see list: Appendix D), including alkaloids (e.g., 
dextromethorphan), steroids (e.g., ethinylestradiol), anti-inflammatory- (e.g., amodiaquine, 
diclofenac, indomethacin), antidiabetic- (e.g., pioglitazone, rosiglitazone) and 
cardiovascular agents (e.g., clopidogrel, propranolol, verapamil) and natural antibiotics 
(e.g., erythromycin). Cells containing only the empty LICRED vector as well as overnight 
drug reaction in cell free buffer A and acetonitrile were used as negative control in order to 
exclude background reactions by either E. coli internal biotransformation or as part of drug 
interactions with buffer or acetonitrile. 
In order to obtain a first impression of the enzyme activity, cells were incubated with 
12 M compound as described in 6.2.1 and subsequently analysed using UPLC-MSE 
(6.2.4). Each of the 7 recombinant cell strains performed biotransformations including 
hydroxylation and N-demethylation reactions. The most promising biotransformations are 
listed in Table 6.2. Corresponding structures are shown in Figure 6.7.  
 
 
Figure 6.7: Drug molecules from the screen that showed significant levels of transformation against negative controls when incubated with P450RHA1-RhfRED fusions.   
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Table 6.2: Biotransformation spectra of heterologously expressed cytochrome P450 fusion proteins from R. jostii RHA1 in whole cells. Biotransformations of cells expressing the empty LICRED vector, overnight reactions in buffer A and 40 % acetonitrile were included as negative control; grey areas signify biotransformation processes.  
 Substrate 
Biocatalyst X-RhfRED 
Diltiazem Indomethacin Rosiglitazone Imipramine Zafirlukast Conversion (%) Demethylation Hydroxylation Demethylation Demethylation Hydroxylation 
Ro04 1.34 – 0.41 6.00 – Ro05 0.30 5.67 – 0.27 3.02 Ro07 9.52 – 2.75 8.53 - Ro08 1.07 11.41 0.44 0.56 6.15 Ro11 0.93 7.20 0.46 0.54 3.86 Ro18 1.45 8.32 0.17 0.73 6.24 Ro22 0.87 5.55 0.45 0.69 4.56 
LICRED 0.61 – 0.29 0.53 – 40% ACN – – – 0.17 – buffer A 0.18 – – 0.23 – 
 
With regard to enzyme activity it was noticeable that some of the fusions were more likely 
to perform hydroxylation reactions while others favoured N-demethylation reactions. 
Ro05-RhfRED, Ro08-RhfRED, Ro11-RhfRED, Ro18-RhfRED and Ro22-RhfRED 
hydroxylated indomethacin and zafirlukast with relatively high conversions but showed 
rather low N-demethylation activity towards diltiazem, rosiglitazone and imipramine. 
Ro07-RhfRED and Ro04-RhfRED on the other hand performed exclusively 
N-demethylation reactions. Ro07-RhfRED, however, was more successful in catalyzing 
demethylation reactions, giving a 9.5% and 8.5% conversion to demethylated metabolites 
of diltiazem and imipramine, respectively. It was, therefore, selected for a more detailed 
investigation, through studies of the pure enzyme. 
6.3.3 Purification and characterisation of Ro07-RhfRED 
Cells were grown to a total volume of 3 l and harvested as described in 2.7.1.2. Purification 
was mainly performed as described in 2.7.2. However, the imidazole gradient to elute 
Ro07-RhfRED from the column was optimised in accordance with previous purification 
trials. The loaded column was initially washed with about 12 column volumes buffer A. 
Impurities could be eluted by increasing the gradient of imidazole (within 20 min) from 
0-20 mM (Figure 6.8: ascending green line). Finally, desired protein could be eluted from 
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the column by raising the imidazole concentration from 20 mM to 100 mM (Figure 6.8: 
descending green line) in a timeframe of 60 min.  
 Figure 6.8: Nickel affinity chromatography chromatogram for the purification of Ro07-RhfRED  blue line: UV absorbance at 280 nm; green line: imidazole concentration gradient; Fractions are displayed along the x axis. 
The chromatogram for the purification of Ro07-RhfRED is shown in Figure 6.8. In order 
to verify the purity of these fractions SDS gel electrophoresis has been carried out (Figure 
6.9) and showed more than 90% purity.  
 Figure 6.9: SDS-PAGE analysis of Ro07 RhfRED fractions after nickel affinity chromatography lane 1: 1 kb DNA ladder; lane 2: insoluble fraction; lane 3: flow-through after column loading; lane 4-15: samples corresponding to the fractions X1, A5, A10, D7, D8, D11, E10, E7, E3, F2, F6, and F12 collected in nickel affinity chromatography (Figure 6.8). 
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In order to validate the integrity of the purified enzyme, CO-difference spectra were 
performed. Ro07-RhfRED was reduced with sodium dithionite and then bubbled with 
carbon monoxide. Spectrometric analysis was performed for every step subsequently, as 
described in 4.1.3.1.  
 Figure 6.10: UV-visible absorbance spectra of purified Ro07-RhfRED oxidised form: blue; sodium dithionite reduced form: red; reduced, CO-bound form: green 
Figure 6.10 displays the recorded CO-difference spectra for Ro07-RhfRED. Unreduced 
P450s have typically an absorption maximum at  420 nm which shifts of about 30 nm to 
450 nm upon reduction and subsequent CO binding. This characteristic Soret shift could be 
observed in all tested fractions containing purified protein, indicating that the chimeric 
fusion was correctly folded and had the ability to bind substrates with high affinity. 
Furthermore, the Soret shift could still be observed after 2 weeks of storage of the purified 
protein in the fridge and thus suggest high stability of the fusion protein. Comparative pure 
fractions have then been pooled and concentrated for further use. 
In order to validate the activity of the purified Ro07-RhfRED, it was challenged with the 
65 drugs used for the whole cell screening (6.3.2). Assays were performed as described in 
6.2.2. The results obtained with the purified Ro07-RhfRED confirmed its activity. 
Moreover, the conversion of imipramine to the N-demethylated product almost doubled 
when compared to the screening results with whole cells. Imipramine was therefore 
selected for more detailed investigation of the catalytic properties of the Ro07-RhfRED 
fusion.  
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6.3.4 Biotransformation of imipramine 
In order to exclude possible negative effects of additives like methanol on the enzyme, 
stock solutions of substrate, NADPH as well as purified Ro07-RhfRED were prepared in 
buffer A. Samples for conversion of imipramine (Figure 6.11 B 1) to N-desmethyl 
imipramine (Figure 6.11 B 2) were prepared as described in 6.2.3.  
 Figure 6.11: Biotransformation of imipramine with purified Ro07-RhfRED A: Conversion (%) of imipramine after 12 h by purified Ro07-RhfRED at different substrate concentrations; B: UPLC/MSE chromatogram of imipramine (25 µM) conversion after 12 h; blue: imipramine (1); green: demethylated metabolite (2) 
Conversion rates of up to 60 % could be detected at low substrate concentration (Figure 
6.11 A: 7 M). Imipramine conversion decreased once its concentration exceeded 7 M 
indicating substrate inhibition. However, conversion of high rates still took place with 
imipramine concentration of 50 M (40 %) and led to the best yield of N-desmethyl 
imipramine overall. Furthermore, N-demethylation did not only depend on the substrate 
concentration but was also influenced by enzyme concentration. Conversion experiments 
performed by Justyna Kulig in AstraZeneca using only 0.5 mg/ml enzyme in a total 
reaction volume of 300 l (0.15 mM NADPH) led to a dramatic decrease in conversion. 
The highest conversions of only 36.2 % and 35.4 % were measured for imipramine 
concentrations of 2.5 µM and 5 µM after 4 h incubation. In addition, no further conversion 
could be observed after the 4 h incubation.[279] 
6.4 Discussion 
Characterization of genomic sequences and thus identification of novel P450 enzymes has 
advanced rapidly in the last 20 years and created new challenges with regard to the 
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elucidation of these newly discovered proteins. New sequences are arising much faster 
than gene product function can be validated. R. jostii RHA1, for example, has a remarkable 
diversity of genes that encode oxidative enzymes of which the majority are, however, of 
unknown function. Inspired by natural P450-redox fusion proteins in which the electron 
supply components are fused to the P450 catalytic domain, researchers have focused on 
generating non-natural fusions of P450s as dealing with a single enzyme provides 
advantages in comparison to a multiprotein system and can simplify high throughput 
screening and therefore characterization procedures. P450BM3 (CYP101A2) from 
Bacillus megaterium[26] and P450Rhf from Rhodococcus sp. NCIMB 9784 (CYP116B2) [79] 
are well known examples of such naturally occurring fusion systems. The P450BM3 system, 
however, is not a very suitable tool for high throughput analysis as it relies on 
intermolecular electron transfer between two monomers and thus is only active as a 
dimer.[281] Chimeric fusions with BM3 and non-native heme domains show often a high 
degree of uncoupling[282] most likely owing to essential specific interactions between the 
domains of the two monomers not being formed. Chimeric fusions with RhfRED on the 
other hand were shown to transfer electrons from NADPH primarily intramolecularly to 
the P450 heme domain.[227] 
The first report of a non-natural fusion with RhfRED was by Misawa and colleagues who 
produced functional chimeras that acted on the natural substrates.[263] Other reports 
employing non-natural fusions of RhfRED with varying degrees of success were to follow. 
However, before the development of the LICRED vector by Sabbadin and colleagues, no 
methods had been available to generate libraries of P450 biocatalysts in a high throughput 
manner.[227] The LICRED vector contains the RhfRED gene downstream of a ligation 
independent cloning site, allowing for rapid insertion of P450 genes and generation of 
large libraries of P450-RhfRed fusions. Although, the utility of this system was already 
demonstrated by fusions with P450cam, XplA and 22 novel P450s isolated from Nocardia 
farcinica, [227] it provided the perfect basis to examine heterologous expressed genes for 
useful activities with simultaneous re-evaluation of the systems potential.  
By employing the LICRED system it was possible to create a fusion library of 23 
cytochrome P450 heme domains from R. jostii. 15 of them could be expressed soluble in 
E. coli Rosetta (DE3). 7 of these have been analysed in more detail in whole cell assays 
and revealed many different activities including hydroxylation and demethylation reactions 
when challenged with 65 commercially available drugs and thus proved the generic 
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applicability of the LICRED platform. One recombinant strain, expressing Ro07-RhfRED 
(homolog of CYP257A1), catalysed the N-demethylation of diltiazem and imipramine and 
could be successfully purified and further characterized. The N-demethylation activity 
presented by Ro07-RhfRED complies with previous observations of this enzyme‘s activity 
as a demethylase of alkaloid substrates (dextromethorphan).[225] Dextromethorphan itself, 
however, was not transformed in significant quantity by the Ro07-RhfRED fusion protein 
in whole cells or purified form. The reason for this might be the fused reductase domain 
itself which could have affected substrate specificity of the enzyme, as has been observed 
for P450MycG.[283] Nevertheless, Ro07-RhfRED was able to convert up to 63 % of 
imipramine when applied in cell-free biotransformations although its activity seemed to be 
strongly dependent on the substrate and enzyme concentration. Dependence on substrate 
concentration could also be demonstrated by Justyna Kulig through analysis of the 
biotransformation of diltiazem by cell-free Ro07-RhfRED (Figure 6.12).[279] 
As with imipramine most efficient reactions were obtained at low substrate concentrations 
of between 1.0 (26.0 %) and 7.5 µM (25.6 %), but the highest turnover was measured for 
concentration of 50 µM. Furthermore, no conversion was observed after 4 h either due to 
substrate inhibition or activity loss of the protein.  
Besides substrate screening it was also possible to investigate parameter of the N-
demethylase activity of Ro07-RhfRED in more detail as also shown by Justyna Kulig 
(Figure 6.13). 
The activity of Ro07-RhfRED towards analogues of imipramine demonstrated that the 
exchange of different chemical groups can have enormous influence on the N-demethylase 
activity. The introduction of hydroxy groups (Figure 6.13 2 and 7) or the presence of a 
second side chain in the substrate (Figure 6.13 10) and the corresponding rise of the polar 
surface area of the substrate, for example, reduced conversion rates dramatically. Substrate 
alteration that led to a lower polar surface area on the other hand didn’t seem to hinder N-
demethylation activity as drastically. In fact, the introduction of a methyl group in the alkyl 
chain (Figure 6.13 3) or a chlorine atom on the aromatic ring (Figure 6.13 4) had only little 
influence on the activity of Ro07-RhfRED. Furthermore, it could be observed that the 
chimeric fusion possesses clear stereoselective preferences when tested on enantiomeric 
substrates (Figure 6.13 8 and 9).  
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Figure 6.12: Biotransformation with purified Ro07-RhfRED of diltiazem at different substrate concentrations[279] substrate concentrations: –  – 1.0 µM, –  – 2.5 µM, –  – 5.0 µM, –  – 7.5 µM,                            –  – 10.0 µM, –  – 25.0 µM, –  – 50.0 µM 
 
 
Figure 6.13: Conversions of imipramine 1 and analogs 2-11 and their relationship to physico-chemical properties of the substrates catalysed by Ro07-RhfRED [279] ♦ = polar surface area (PSA); ○ = octanol-water partition coefficient (logP); □ = H-donors; yellow: negative influence of hydroxyl groups; green: neutral influence of chlorine; blue: slightly negative influence of additional methyl group; purple: 2-fold decrease with additional cyclopropane group; red: stereopreference; orange: no reaction with additional side chain 
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This study could clearly substantiate the applicability of the by Sabbadin and colleagues 
conceived LICRED plasmid as strategy to create and screen libraries of diverse P450 
fusions. Although the substrate specifity for natural substrates might have been affected by 
the fused reductase domain, as shown for Ro07-RhfRED, this system led to the 
identification of several enzymes from R. jostii competent to hydroxylate or demethylate 
various substrates of industrial interest and might be further applied in industry in order to 
screen for activities of use in other compounds of interest to medicinal chemistry. It could 
be further demonstrated that physico-chemical parameters like the polar surface area 
correlate with conversion rates and thus might be useful data for future selection of 
substrates prior to in vitro evaluation. However, the LICRED platform serves only as a 
screening tool for identifying useful P450 activities. Scale up processes of industrial 
relevance might need to be optimised for individual chimeras.  
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7. Final discussion 
Enzymes - a precious resource of incomparable value for industry, accounting for more 
than 500 industrial products today.[284] Even though the capacity of natural catalysts 
(enzymes) has been harnessed by humans for thousands of years, dating back to 
7000-6600 BCE with fermentation of sugars to alcohol by yeast[285], it wasn’t until the late 
19th century - spawned by the awareness of the existence of enzymes - that the curiosity 
and interest to elucidate biochemical pathways and enzyme mechanisms led to the 
development of enzyme-directed research. The implementation potential of natural 
catalysts transforming non-natural organic compounds in industry however, was mainly 
recognized during the 1980s, with the rise of enantioselective synthesis and the advance in 
molecular biology.[286] Since then, the number of on industrial scale performed 
biotransformations grew rapidly and is expected to continue growing as the demand for 
novel enzymes rises, impelled by a growing need for sustainable solutions. 
Oxygenases in particular are of enormous interest and are often used to synthesize 
compounds that are not accessible by chemical routes.[132] Among them, cytochrome P450s 
attracted probably the most attention due to their involvement in the biosynthesis of a 
broad range of bioactive natural products in all kingdoms of life, often mediated with 
remarkable regio- and stereoselectivity. Most P450s catalyse monooxygenase reactions 
with the assistance of a redox partner by utilizing molecular oxygen and a reducing co-
factor.[109] P450s that fulfil distinct roles in primary metabolism act with high catalytic 
efficiency and refined substrate selectivity abetting for the classical idea that enzymes have 
evolved to catalyse one particular chemical reaction. The majority of, and most likely the 
most striking P450s however, show more substrate ambiguity, usually as part of a 
protection mechanism to remove extrinsic natural products and thus allowing for an 
exceptional catalytic versatility.[287] P450s that mediate drug metabolism in the human 
liver, for example, show a remarkable substrate ambiguity and facilitate the clearance of 
almost 75 % of prescribed drugs.[288] Also many fungal P450s are suspected to act as 
multifunctional enzymes.[289] Although nature provides a vast amount of enzyme resources, 
the discovery and development of a suitable cytochrome P450 for biocatalysis is a 
demanding and time-consuming procedure. The classical biochemical approach represents 
a rather straightforward strategy starting with in vivo observations. These are then 
replicated in an in vitro assay that can be used to purify the enzyme of interest which in 
turn can be employed to obtain cDNA and determine the nucleotide sequence to identify 
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the corresponding gene.[290] However, enzyme discovery today has been revolutionised by 
various genome sequencing programs that led to an abundance of available nucleotide 
sequence data and thus resulting in the need for strategies to work backwards from gene to 
function. Especially microorganism that have already been applied in an industrial context 
or shown interesting reactions for industrial purposes are promising for more detailed 
investigation. In this context, this study concentrated on the exploration of the CYPome of 
the entomopathogenic fungus B. bassiana which has been sequenced in 2012[208] and was 
once one of the most frequently used whole cell biocatalysts.[219] A further area of focus 
was the analysis of 23 P450s from Rhodococcus jostii which had already been constructed 
as chimeric fusions by Ralph Hyde using the LICRED system. 
83 sequences that were annotated as cytochrome P450 enzymes were subjected to thorough 
bioinformatic investigation resulting in the selection of 7 genes that encode for putative 
CYPs with possible alkane hydroxylation function and 1 putative natural fusion enzyme 
(P450foxy homolog) for subsequent cloning, over-expression and activity screening. The 
fact that 2 of the selected cytochrome P450s shared 100% sequence identity with 
CYP52X1 and CYP5337A1, which have shown to be involved in insect hydrocarbon 
degradation,[203] allowed for the rather confident assumption that the selected P450s play a 
physiological role in B. bassiana and thus should yield active proteins in the event of 
successful expression. Although, heterologous expression of eukaryotic P450s using 
bacterial hosts such as E. coli can be very challenging due to the interference of the 
N terminal anchor, different codon bias as well as the need for an external NADPH-
cytochrome reductase, it was in the interest of this study to apply a system that can be 
easily handled and thus is more approachable from an industrial point of view. Hence, 
modifications of the selected genes have been realized on molecular level (codon 
optimization for E. coli and cleavage of N-terminal anchor) to ensure optimal expression in 
E. coli. Furthermore, encouraged by the remarkable success of the artificial fusion system 
designed by Sabbadin and co-workers, which proved not only to be efficacious when 
applied for prokaryotic P450 but also for eukaryotic P450 expression in E. coli[227, 266], and 
in order to bypass the need for a co-expressed reductase, a fusion library was constructed 
for the 7 selected B. bassiana P450s. Expression test which were performed using M9 
minimal medium with glucose as only carbon source resulted in rather low expression 
levels and proteins were only detectable in the insoluble fractions. Improvement of 
expression could be realized by altering the carbon source in the medium most likely due 
122 
to the avoidance of a phenomenon called catabolite repression that can lead to poor 
transcription when using a lac promoter.[250] Of the tested carbon sources glycerol seemed 
to have the biggest impact on expression performance. However, signals indicating soluble 
expression were still missing. The truncated version of the natural fusion (CYP505A1) as 
well as all chimeric fusions, except CYP584E2_LICRED, could finally solubly expressed 
using a chaperone co-expression system which confirmed previous reports stating similar 
findings.[252, 270] However, functional analysis using whole cells for biotransformation of 
substrates that are known to be hydroxylated by Beauveria bassiana or/and alkane 
hydroxylases failed to determine P450 identity. Failed activity assays that focused on 
lauric acid as substrate have been of particularly significance to confirm the shortage of 
active biocatalysts as CYP52G8 (identical to CYP52X1) has been reported to convert 
lauric acid to 12-hydroxylauric acid (Figure 7.1).[217] In addition, spectrophotometric 
characterization of whole cells and concentrated E. coli cell lysate confirmed activity assay 
results as characteristic Soret shift peaks couldn’t be identified either. Purification of 
soluble expressed chimeric fusions wasn’t possible due to the strong interaction with the 
co-expressed chaperones. 
 
Figure 7.1: Biotransformation of lauric acid using microsomes from yeast expressing CYP52X1  
In an attempt to preclude chaperone interference with protein activity and the impairment 
of the fused Rhf-reductase on solubility, 2 selected B. bassiana P450s have been cloned 
and expressed without the addition of chaperones and reductase. In the event of soluble 
expressed protein, strains co-expressing the natural B. bassiana reductase, which has been 
identified in this study (CYP505A2), could have been generated for detailed investigation 
of protein activities. However, soluble expression couldn’t be detected leading to the 
assumption that E. coli is not a suitable host for the production of active fungal P450s. 
Further changes of the genes on the molecular level are most likely necessary in order to 
enhance soluble expression of active proteins using E. coli as a host.  
As a result of the abortive heterologous protein expression in E. coli, S. cerevisiae has been 
employed for expression of Beauveria heme domains. There was good reason to believe 
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that this system would allow for expression of functional membrane associated B. bassiana 
P450s in microsomes since its functionality had been demonstrated in previous 
studies.[217, 274] In order to ensure functional expression it was considered important to 
recreate the parameters used in these studies. Hence, expression strain 
(S. cerevisiae WAT11), vector (pYeDP60) as well as conditions have not been varied. 
Each of the 7 selected B. bassiana heme domains were constructed with the addition of N-
terminal or C-terminal his-tag (18 bp histidine tag). In addition, constructs that have been 
generated containing no his-tag were thought to serve as comparison group to evaluate 
possible his-tag induced activity impairment. However, active fungal P450s could not be 
detected in S. cerevisiae microsomes most likely due to the codon bias in yeast as the gene 
sequences used for expression in this study derived from the E. coli codon optimised gene 
sequences while Zhang and co-workers employed fungal cDNA for PCR amplifications.  
One of the most challenging issues in this project was the management of a multitude of 
enzyme targets, particularly with regard to gene expression as investigation of individual 
requirements for functional protein production could not be realized. A more reasonable 
tactic to identify less P450s but P450s of particular interest might be a proteomic approach 
allowing for the identification of a protein in correspondence to a transformation reaction. 
First steps in this direction could be achieved at the end of this project. The original 
B. bassiana strain has been exposed to various hydroxylation substrates and the 
corresponding concentrated B. bassiana cell lysates were then employed for high-
resolution mass spectrometry in order to identify possible P450 targets responsible for 
these hydroxylation reactions (see Appendix C). P450 hits after LC-MS/MS analysis 
including the negative control are shown in Table C.1 (Appendix C). Although, only a total 
of 4 P450 enzymes could be identified, 2 of which were also observed in the negative 
control, it is noteworthy that CYP52T1 as well as the NADPH-cytochrome P450 reductase 
seem to be more strongly induced in Beauveria bassiana when 1-benzylpyrolidine (Table 
C.1, sample 2), lauric acid (Table C.1, sample 3) or 2-phenoxypropionic acid (Table C.1, 
sample 4) has been added to the growing fungus. This could therefore be a clue with regard 
to the physiological role of CYP52T1 in B. bassiana. It also needs to be mentioned that the 
acquired data are not quantitative as no replication took place. However, it could be 
demonstrated that this form of analysis could be useful for target selection in future studies 
especially with more refined sampling strategies. The only reason that this analysis 
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technology has not been used in the beginning of this project was the lack of available 
equipment and techniques. 
Eventhough the study of Beauveria bassiana P450s did not lead to the delivery of 
biocatalysts applicable to industry it was possible to investigate 23 chimeric fusions (P450 
heme domains cloned in LICRED vector) from Rhodococcus jostii in more detail. An 
extensive screen of expression conditions in respect of growth medium and expression 
temperature were conducted using E. coli Rosetta (DE3) as host. Soluble expressed 
proteins could be detected at 16 ˚C (Western blot) in 15 out of 23 cases using M9 minimal 
medium for growth. This result is not too surprising as it has been previously reported that 
recombinant protein expression at reduced growth temperatures can increase solubility of 
proteins that are prone to aggregation.[291] 7 of the P450 fusions have been further analysed 
using whole cells for biotransformation of substrates of industrial interest. Each of the 
strains expressing a chimeric fusion protein showed activity towards at least 1 or 2 of the 
tested substrates and substantiated the potential of the applied LICRED system as 
screening method for enzyme discovery. The fusion protein expressed in the E. coli strain 
with the most promising catalytic activity was further characterized in purified form and 
revealed interesting catalytic properties, such as the activity dependency on substrate and 
enzyme concentration as well as the correlation of physico-chemical parameters with 
conversion rates. The here presented results have recently been published in Bioorg. Med. 
Chem. (doi:10.1016/j.bmc.2015.07.025) and might have an impact of future screening 
assays in industry.  
In summary, it can be stated that although it wasn’t possible to deliver active biocatalysts 
from B. bassiana for industrial implementation, data of empirical value could be obtained 
that might impact future studies in regard to heterologous expression strategies for fungal 
P450s. Furthermore, industrial partners have been provided with a valuable screening 
platform (Rhodococcus P450 fusion library) allowing for identification of biocatalysts 
capable of producing drug metabolites. 
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Appendix A 
Table A. 1: Cytochromes P450 in B. bassiana ARSEF 2860 
CYP family Annotated CYP name Length (aa) NCBI Accession number CYP503 CYP503B1 526 EJP67620.1 
CYP504 
CYP504E5 296 EJP67926.1 CYP504A6 518 EJP66903.1 CYP504B10 533 EJP63215.1 CYP504E1 555 EJP67927.1 CYP504B10 576 EJP66859.1 
CYP505 CYP505A2 690 EJP66462.1 CYP505D4 1044 EJP67978.1 CYP505A1 1232 EJP64169.1 CYP5060 CYP5060A1 601 EJP70021.1 CYP5080 CYP5080B3 511 EJP68696.1 
CYP5099 CYP5099A1 466 EJP64478.1 CYP5099A1 522 EJP63211.1 
CYP51 CYP51F2 516 EJP64120.1 CYP51F1 525 EJP70591.1 
CYP52 
CYP52G6 528 EJP65762.1 CYP52G8 528 EJP68426.1 CYP52T1 534 EJP70096.1 CYP52T1 536 EJP68380.1 CYP52T1 536 EJP62931.1 CYP52T1 541 EJP62098.1 CYP5202 CYP5202A1 475 EJP69240.1 CYP526 CYP526H1 602 EJP63805.1 CYP5262 CYP5262A3 491 EJP62710.1 CYP528 CYP528A4 517 EJP65064.1 CYP5280 CYP5280A1P 526 EJP66155.1 CYP5282 CYP5282A1 528 EJP67855.1 
CYP5293 CYP5293A1 364 EJP64645.1 CYP5293A2 470 EJP61325.1 CYP5293A1 479 EJP66212.1 CYP53 CYP53A11 513 EJP61564.1 CYP534 CYP534C2 286 EJP68773.1 CYP537 CYP537A4 429 EJP62906.1 CYP539 CYP539B1 515 EJP65570.1 CYP540 CYP540B16 550 EJP67254.1 CYP541 CYP541A2 463 EJP70012.1 
CYP542 
CYP542B2 138 EJP61051.1 CYP542B1 199 EJP61998.1 CYP542B3 540 EJP61494.1 CYP542B3 540 EJP68382.1 CYP548 CYP548A5 530 EJP69550.1 CYP551 CYP551C1 523 EJP62242.1 CYP56 CYP56C1 493 EJP61452.1 
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    CYP family Annotated CYP name Length (aa) NCBI Accession number 
CYP561 CYP561D2P 512 EJP62441.1 CYP561D2P 525 EJP68106.1 
CYP570 CYP570E2 460 EJP69670.1 CYP570A1 490 EJP64736.1 CYP570H1 496 EJP64697.1 CYP578 CYP578A2 522 EJP63651.1 CYP58 CYP58A3 526 EJP62372.1 
CYP584 
CYP584D4 496 EJP65354.1 CYP584G1 510 EJP66430.1 CYP584E7 523 EJP66886.1 CYP584E2 528 EJP68333.1 CYP586 CYP586B1 546 EJP61887.1 CYP6001 CYP6001C8 1117 EJP67251.1 CYP6003 CYP6003A1 1121 EJP69120.1 CYP6004 CYP6004A2 1070 EJP66691.1 CYP61 CYP61A1 534 EJP64151.1 
CYP617 
CYP617A2 520 EJP68630.1 CYP617A1 547 EJP65976.1 CYP617A1 549 EJP67360.1 CYP617A1 566 EJP62088.1 
CYP620 CYP620C2 531 EJP70368.1 CYP620D1 537 EJP61298.1 CYP621 CYP621A2 519 EJP68308.1 CYP623 CYP623C1 490 EJP63692.1 
CYP625 CYP625A1 516 EJP64344.1 CYP625A1 522 EJP67065.1 CYP628 CYP628A2 537 EJP70675.1 CYP639 CYP639A3 520 EJP67629.1 CYP645 CYP645A1 550 EJP69853.1 
CYP65 CYP65T7 497 EJP62380.1 CYP65T7 497 EJP62380.1 CYP655 CYP655C1 529 EJP63691.1 CYP660 CYP660A2 535 EJP64784.1 CYP68 CYP68N1 508 EJP68182.1 
CYP682 CYP682H1 509 EJP67697.1 CYP682N1 530 EJP67851.1 CYP682H1 544 EJP67232.1 
CYP684 CYP684A2 483 EJP64479.1 CYP684A2 490 EJP63437.1 CYP684B2 509 EJP66339.1 
Table A.2: Cytochromes P450 in Rhodococcus jostii RHA1 
Number  ro number  Accession Number  Annotation  Ro01  02510  YP_702473.1  147B2  Ro02  02948  YP_702911.1  199A3  Ro03  04669  YP_704613.1  123A5  
127 
Number  ro number  Accession Number  Annotation  Ro04  02604  YP_702567.1  105Y1  Ro05  04667  YP_704611.1  125B1  Ro06  02651  YP_702614.1  125C1  Ro07  11069  YP_708874.1  257A1  Ro08  11320  YP_709125.1  116C2  Ro09  04588  YP_704532.1  142A4  Ro10  00423  YP_700417.1  254A1  Ro11  11277  YP_709082.1  258A1  Ro12  00377  YP_700371.1  254A3  Ro13  08608  YP_707273.1  116C1  Ro14  05719  YP_705651.1  130A4  Ro15  00393  YP_700387.1  254A2  Ro16  02355  YP_702318.1  125D1  Ro17  04679  YP_704623.1  125A14  Ro18  08984  YP_708186.1  256A1  Ro19  02382  YP_702345.1  255A2  Ro20  03876  YP_703834.1  255A1  Ro21  03826  YP_702614.1  124C1  Ro22  04671  YP_704615.1  51B  Ro23  04627  YP_704571.1  102B3  Absent  05210  YP_705149.1  136C1  Absent  03076  YP_703037.1  136C2      
Table A.3: Primer pairs used for PCR amplification of N-terminal anchor and truncated P450 heme domain from B. bassiana 
CYP number  Target area Forward Primer  (5’-3’)  Reverse Primer  (5’-3’)  
CYP52G6 
N-terminal anchor  CTAAATTACCGGATCCATGGCGCTCACTGCTATCC GCTTTCCAGAACACGTCGAAGCACAAAGGTGACGAC 
truncated heme domain  CGTGTTCTGGAAAGCCTGC  
GCGAATTCGAGCTCGGTACCTTACACTGCTTCATGCAGACG  
CYP52G8 
N-terminal anchor  CTAAATTACCGGATCCATGGCGGTACTATCCGTTA  GCTACGAAAACGAACGTACTCAATCACCTGGAGG  
truncated heme domain  GTTCGTTTTCGTAGCAAAGCAG 
GCGAATTCGAGCTCGGTACCTTATTCATCAAAGTGAACTTTCAGG 
CYP52T1 
N-terminal anchor  CTAAATTACCGGATCCATGGCTCTCCACGCTGCC ACGCTGAATGCTACG AGTCAGATAGACGGCCACC 
truncated heme domain  CGTAGCATTCAGCGTCGT 
GCGAATTCGAGCTCGGTACCTTAGCTGCTATTACCCAGG 
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CYP number  Target area Forward Primer  (5’-3’)  Reverse Primer  (5’-3’)  
CYP52T1_2 
N-terminal anchor  
CTAAATTACCGGATCCATGAACTTGTTGTCATCGTCTT 
ATAGCTAACCTGACGCCATACCACCTTGAGAATATAC 
truncated heme domain  CGTCAGGTTAGCTATCAGAGC 
GCGAATTCGAGCTCGGTACCTTAATTTGCCTGCTGCAGACG 
CYP52T1_3 
N-terminal anchor  
CTAAATTACCGGATCCATGACTCTCTCGCCTATTTCTAC 
TGCAAACAGCCAATGGTTTATCTCGATGCATACCCAC 
truncated heme domain  CATTGGCTGTTTGCACGTAAAC  
GCGAATTCGAGCTCGGTACCTTACAGCTGTGCTGCTTCACA 
CYP539B1 
N-terminal anchor  CTAAATTACCGGATCCATGCTTATCGAGGCTGTCA AACTTTATAGGCAACCGTGAGCCAGTTGACAATG 
truncated heme domain  GTTGCCTATAAAGTTGCAAAA GCGAATTCGAGCTCGGTACCTTAGGCCGTTTTTTCATCG 
 
Table A.4: Primer pairs used for PCR amplification of P450 targets from R. jostii  
Number  Gene Target  Forward Primer  (5’-3’)  Reverse Primer  (5’-3’)  Ro01  ro02510  CCAGGGACCAGCAATGTCGCGTGCGCAGCTGTTCCAGC  GAGGAGAAGGCGCGCCCACAGTCCACCAGCAGGTGC  Ro02  ro02948  CCAGGGACCAGCAATGTTCGCCCCCGCTCCCGCGTTGC  GAGGAGAAGGCGCGGGGCAGCCGCACCTTGACCG  Ro03  ro04669  CCAGGGACCAGCAATGACCGCAGCCTCGATGCCCG  GAGGAGAAGGCGCGGGCATCGCGGACCTGCACTTTCATGG  Ro04  ro02604  CCAGGGACCAGCAATGAGTAAAACGGTCGCCGTCCCGTACG  
GAGGAGAAGGCGCGCCGGGACGTTTCCGTCCAGGTGACC  Ro05  ro04667  CCAGGGACCAGCAATGACCGCATCTCGGATTGATCTGAAATGCC  
GAGGAGAAGGCGCGCACCGGACTGCGCGGATGAATCCG  Ro06  ro02651  CCAGGGACCAGCAATGACGTTATCGGCCCTGCACACCGACC  
GAGGAGAAGGCGCGTGACGTGGCCTTTCCGAGGTGAACG  Ro07  ro01169  CCAGGGACCAGCAATGACAGTCAGGACTGAACTGCAAGGGATTCCG  
GAGGAGAAGGCGCGGCCGACCGCCACGGTCACTGG  
Ro08  ro11320  CCAGGGACCAGCAATGACCGAAACCAGCGCGGAGCCTC  
GAGGAGAAGGCGCGGGGCCGGTCCTCAGGCACTGG  
Ro09  ro04588  CCAGGGACCAGCAATGCGGAGGAGTGCCTCGATGACGAACAGG  
GAGGAGAAGGCGCGGAGCTTCACCGGCATCTCCTCGAGC      
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Number  Gene Target  Forward Primer  (5’-3’)  Reverse Primer  (5’-3’)  Ro10  ro00423  CCAGGGACCAGCAATGACGACAACCCAACTACCCGACAGG  
GAGGAGAAGGCGCGGGACGCGGGTGTAAAGGTGATCGG  Ro11  ro11277  CCAGGGACCAGCAATGCTCGATCCGTTTGCGCCCGGCCTG  
GAGGAGAAGGCGCGGATCAGGTTTACTGGCATCTCAGTGGGGCC  Ro12  ro00377  CCAGGGACCAGCAATGGCTTTCGAAGGGTGTTCTGCCTTAACAACTC  
GAGGAGAAGGCGCGCAGTTCCGGAGTGAACGTGAGCGGTAGACG  Ro13  ro08068  CCAGGGACCAGCAATGACCGAAACCACTCCGGCACCG  GAGGAGAAGGCGCGCGGTCGGTCCTCGGGGAGC  Ro14  ro05719  CCAGGGACCAGCAATGGGCAATGTGTCTCACTATCGATACATGACC  
GAGGAGAAGGCGCGTGCTTCACGCACCCGGAACGGGACG  Ro15  ro00393  CCAGGGACCAGCAATGACCTCGACACAGCTCGATCTTCC  
GAGGAGAAGGCGCGGTGCGTCGGCGGCGTGAACG  
Ro16  ro02355  CCAGGGACCAGCAATGCAGCTCGCCGACGTCGATCTCTACAACC  
GAGGAGAAGGCGCGGAGGGACGAGGGCGTGAACGTCACC  Ro17  ro04679  CCAGGGACCAGCAATGGGCTCCTTTCCTTGTCCTCAGAAAATAGAACAGG  
GAGGAGAAGGCGCGGTGTCTGACCGGGCAACCGCCTGACG  Ro18  ro08984  CCAGGGACCAGCAATGACCACTGTCGACGAACCGGTACTCG  
GAGGAGAAGGCGCGCCAGGTCACGGGCAGCATAGTGATCGG  Ro19  ro02382  CCAGGGACCAGCAATGACCGCCACCCTGTCTTGGATCGACG  
GAGGAGAAGGCGCGCACCTCCCACGTGGCCCGGAG  
Ro20  ro03876  CCAGGGACCAGCAATGACCACCAGCACCACGTGGATCGAATCG  
GAGGAGAAGGCGCGGACCTCCCAGGTGACGTGCAGG  
Ro21  ro03826  CCAGGGACCAGCAATGACGGGTTCTGCGTCCGAAAAAATCATCTCGC  
GAGGAGAAGGCGCGCCGTCCGTCACGTGTCCGGGCCGGCAGTGC  Ro22  ro04671  CCAGGGACCAGCAATGAACCTGGCTACCCCGCAACGTGTGTCC  
GAGGAGAAGGCGCGCGTGCTTCGCTTCCGGTACCTCACG  Ro23  ro04627  CCAGGGACCAGCAATGCCAGTCACCGTACTGCTTGACACC  
GAGGAGAAGGCGCGACGCCGGCGGAGCTGCAGC  
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Appendix B 
E. coli codon optimized gene sequences of B. bassiana P450s  
Cytochrome P450 CYP505A1   ATGGATGTTGATCAGATTGCCTTTCGTTATCAGGATAGCGTTCGTGTTATTGATGCAATTCATAGCGCACTGGCAGATCATCAGACCATGAACATTCAGCATCAGGATCCGCAGGATCGTACCGCAAGCCAGAAACAGTGTGGTTTTAGCCCGTATGCAATGGTTGCCATGGTGGCTATGGTAGCCATGGTTGCAATGGAAGCAATGGTGAGCGAAGCACATCTGGCAACCGCACCGCAGGTTCTGACCGATGCAGCACAGGGTCGTCGTCAGGCACTGGAACCGCGTGAAATTGCAGTTCTGCGTGAAGCACGCGAAATTGCCGCACTGCGTAAAGCATTTGCAGAACAGGTTCCGACCCGTGCAGTTAAAGCAGATGGTATTCGTCATCAGGGTGATCTGCAGGCCGAAGCCGATGGCATTAAACGTGAAAATGAAAGCTGGAAAGGTGACCTGAAAACACCGGCAACCCCGAGCAGCCGTACCACCACCATTACCGCAGAAAGCATTCCGATTCCGGAACCGCCTGGTCTGCCGTTTATTGGTAATCTGGGTGAAATGCGTACCAGCCCGATTAATGATTTTAAACGTCTGGCAGATACCTACGGCGAAATTTATCGTATGCATCTGGGTGGTAGCGCATTTTGTGTTGTTAGCAGCCGTGAACTGGTTAATGATGCATGTGATGAACGTCGCTTCAAAAAAACCGTTGGTGGCACCCTGGGTAAAGTTCGTAATGCCATTCATGATGGTCTGTTTACCGCAGATAGCGAAACCGAACCGAATTGGGGTAAAGCACATCGTATTCTGGTTCCGGCATTTGGTCCGCTGAGCATTCGTAATATGTTTGATGAAATGCATGATATCGCCAGCCAGATGGCAATGAAATTTGCACGTCATAGCGGTGATCGTATTAATGCCAGTGATGATTTCACCCGTCTGGCCCTGGATACCGTTGCACTGTGTGCAATGGATTATCGCTTTAACAGCTATTATCGCGAAGAACTGCATCCGTTTGTTCGTGCAATGGGTGATTTTCTGACAGAAAGCGGTGCACGTAATCGTCGTCCGACCTTTGCACCGCAGTTTTTCTATCGTGCAGTGGATGAAAAATATGAGAAAGATATCAAAACCATGCGTGATGTTGCCGATGAAGTTGTTGCAAATCGTCGTGCAAATCCGAGCGAACGTAAAGATCTGCTGAGCGCAATGCTGGATGGTAAAGATCCTCAGGATGGTCAGCGTCTGACAGATGCAAGCATTACCGATCAACTGATTACCTTTCTGATTGCCGGTCATGAAACCACCTCAGGCACCCTGAGCTTTGCATTTTATCAGCTGCTGAAACATCCGGCAGAATATCGTAAAGTTCAAGAAGAAGTTGACGCAGTTGTTGGTCGTGATCGCATTACCGTTGAACATATTAGCAAACTGACCTATATTCAGGCCGTTCTGCGCGAAGTGCTGCGTGTTAATGCACCGATTCCAGCATTTAGCGTTGAAGCAAAAGAAGATACCCTGCTGGGAGGCAAATATTTCATTCCGAAAGAACATCGTCTGACCCTGCTGCTGGCAAAAAGCCATCTGGATCCGAGCGTTTATGGTGATAGCGCAAGCGATTTCAAACCGGAACGTATGCTGGACGAAAATTTTGCCCGTCTGAATAAAGAATTTCCGAGCGCATGGAAACCGTTTGGTAATGGCAAACGTGCATGTATTGGTCGTCCGTTTGCATGGCAAGAGGCAGTTCTGGCAATGGCAATTCTGTTTCAGAACTTTAATTTCACCCTGGACGATCCGAATTATACCCTGGAAATTCAAGAAACCCTGACCCTGAAACCGCACAACTTTTTTATGCGTGCAACCCTGCGTCATGGTATGAGCGCAACCGAACTGGAAGATCAGCTGAAAGGTGGCACCGTTCATAGCAAAAGCAGTGATGGTGCAGATACACCGGTTGCAGCAAGTGCCGGTGATGGTAAACCGCTGAGCGTTTTTTATGGTAGCAATAGCGGCACCTGTGAAGCACTGGCACAGCGTGCAGCAGCAGATGCCAGCGCACATGGTTTTAAAGTTACCGAAATCGGTCCGCTGGATAATGTTAATCAGAAACTGCCGACCGATCGTCCGGTTGTTATTGTTACCGCCAGCTATGAAGGTGAACCGCCTAGCAATGCAGCCCATTTTGTTGATTGGCTGAAAAGCCTGAAAGGCGACGAACTGAAAAATGTTAGCTATGCGGTTTTTGGTTGCGGTCATCATGATTGGGCACAGACCTTTCATAAAATTCCGAAACTGGTTGATGCGACCATGGCCGAACGTGGTGCCGATCGTATCATTCCGATGACCGGTACAGATGCAGCAGATCGTGATATGTTTAGCGATTTTGAAACCTGGGAAGATGAATGTCTGTGGCCTGCACTGAAAAAAAAATATGGTGCGGATGAAACCAAAGATGGTCAGGGTGCAAGCGCACTGACCGTTGAAATTACCCATCCGCGTAAAACCACCCTGCGCCAGGATGTTGAAGAAGCAGCAGTTATTGATACCAAAGTGCTGACCAAAGGCACCCAGAGCGTTAAAAAACATATTGAAATTCGTCTGCCGACGGGCATGACCTATAAAGCCGGTGATTATCTGGCAGTGCTGCCTTTTAATCCGGCAGCCACCATTGCCCGTGTTTTTCGTCGTTTTAGCATTAGCTGGGATGCAACCTTTACCATTACCTCAAATGGTCCGACAACCCTGCCGACAGGTGTTCCGATTAGCGCAACCAATGTTCTGGGTGCATATGTTGAACTGAGCCAGCCTGCAACCAAACGTAACATTCAGGCAATGATTGATAGCACCGAAGATGAAAAAACAGTGACCGCACTGAAAGGCCTGATTGGTGATAAATTCAGCGAAGAAGTTACCGCAAAACGTCTGAGTGCACTGGACCTGCTGGAAAAATTTCCGGCAGTGGGTCTGCTGTTTGAAAGTTTTCTGGCCATGCTGCCTCCGATGCGTGTTCGTCAGTATAGCATTAGTAGCAGTCCGCTGGTTGATCCTACCCGTGTTACCCTGACCTATTCACTGCTGGATGTTCCGGCACATAGCGGTCAGGGTCGCCATGTTGGTGTTGCCAGCCATTACCTGTTTAGCCTGCATGAAGGCGATAAAATTCATGTTGCAGTTCGTCCGAGTGCAGCCTTTCATCTGCCTGCCGATACCGAAAAAACCCCGATTATTTGT
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GTTGCAGCAGGCACCGGTCTGGCTCCGTTTCGTGGTTTTGCCGAAGAACGTGCAGCCATGATTGCAGCCGGTCGTAAACTGGCTCCGGCACTGCTGTTTTTTGGCTGTCGTGCACCGGGTGAAGATGATCTGTATGCCGAACAGTTTGCAGAGTGGCAGAAAATGGGTGTGATTGATGTTCGTCATGCATATAGCCGTGCAACCGATAAATCTCATGGTTGTAAATATGTGCAAGAACGCCTGAGCAATGATCGTGATGAAATCTATAAACTGTGGGATCAGGGTGCGCGTCTGTATCTGTGTGGTAGTCGTGCCGTGGGTAAAGGTATTGAAGATGCATGCGTTGAACTGGTGAAAGAAAATGCAGAACGCGAAAAAAGCAAAGAAGTGACCGACGAAGCAGCACGTGCATGGCTGGATAACCTGCGTAATGAACGTTTTATGGCCGATGTGTTTGACTAA  Cytochrome P450 CYP52G6  Transmembrane area was removed (nucleotides 4-54) for gene synthesis.     ATGCGTGTTCTGGAAAGCCTGCGTCATGCAAAAAATGCACGTGAACTGGGTTGTAAACCGCCTCCGCTGGCACCGATTAAAGATCCGCTGGGTATTCTGAGCCTGCTGGAAATGATTCAGGCAGATAAAGAAAAACGTGTTCCGGCACTGACCGAACAGCGTGTTAACAAAATGCGTGATGATAATGGTGGCAATTATGTTACCACCATGCGTCTGCGTACCGGTGCAGTTGAAAATATTCTGACCATTGATCCGAAAAACATTCAGGCAATTCTGGCCACCCAGTTTAAAGAATTTTGTGTTGGTGCACAGCGTGAAAGCTGTATGGGTCCGCTGCTGGGTGCAGGTATTTTTACCACCGATGGTCCGGCATGGTCACATAGCCGTGCAATGCTGCGTCCGCAGTTTACCCGTGATCAGATTAGCGATCTGAGTCTGGAAGAGGTTCATGTTCAGAATGCCTTTAAAGTTATGCCTCCGGTTAATAATCAGGGTTGGACCGAAGTTGATATTCAGACCGTTTTTTTTCGTCTGACCCTGGATAGCGCAACCGAACTGCTGTTTGGTGAAAGTTGTAAAAGCCAGCTGGTTGCACTGGATAATGCCAATAATGATAAAGAATTCAGCGCACGCGGTACAGATTTTGGTGCAAATTTTGATCGTGGTCAGTGGTATCTGAGCCAGCGTGTTCGTACCCCGTTTCTGAAATTTCTGTATAACGGTGACGAGTTTAAAAACTGCTGCAAAGAAGTGCACCGTTTTGTTGATCAGTGTGTTGAACGTGCCCTGCGTGAAACCAGCAAAAAAAAACTGGATGCAGATGGTAAACCGCTGGAAGGTGGTGAACATTATGTTTTTCTGCATGCAATGGCAGCCGAAACCCAGGATCCGATTGAACTGCGTGCACAGCTGCTGAATGTTCTGCTGGCAGGTCGTGATACCACCGCAAGCCTGCTGAGCTGGACCGTTATGCTGCTGGCACGTCATCCGGATAAATTTCAGCGCCTGCGTCGTGATATCATTGAAACCTTTGGTGGTTATGAAAATCCGCGTAATCTGACCTTTGCAAATCTGAAAGCATGTACCTATCTGCAGCGTGTGATGACCGAAGTGCTGCGTCTGTTTCCGCCTCTGCCGATGAATGCACGTTATGCAACCTGTGATACCAGCCTGCCTCGTGGTGGTGGTCCGGATGCAGAAAGTCCGGTTTATGTTAAAAAAGGTCAGGCCGTGCTGTATAATGCACATATTCTGCATCGTCGTACCGATATTTGGGGTCCTGATGCCGGTGAATTTAACCCGGATCGTTGGGAAGGTCGTAAAGGTGGTTGGGAATATCTGCCGTTTAATGGCGGTCCGCGTATTTGTATTGGTCAGCAGTTTGCCCTGACCGAAGCAGGTTATGTTCTGGCACGCCTGCTGCAGCGTTTTGATGGCCTGGAAGAACTGAATCCGAGCAGCAAAGTTAGCTGGGGTCTGACACTGGTTAGCCAGCCTGGTGAAAGCGTTAAAGTTCGTCTGCATGAAGCAGTGTAA  Cytochrome P450 CYP52G8  Transmembrane area was removed (nucleotides 4-84) for gene synthesis.  ATGGTTCGTTTTCGTAGCAAAGCAGCACGTCTGGGTTGTAAAAGCGCACCGAGCGGTATTAGCAGCGATTGGAGTGGTATTAGCCTGATGCGTAAAGGTCTGAAAGCACAGCGTGAAAAAAATGTTCCGAATTGGATGCGTCATGAATTTGCACGTCTGAGCGCACGTGAAGGTCGTCCGGTTGGCACCTTTGAAATGAGCGCACCGCTGTTTCGTCGTGTTCTGTTTACCAGCGAACCGGAAAACATTAAAACCATTCTGGCAACCAGCTTCAAAGATTTTAGCCTGGGTGATAATCGTCGCGGTAACTTTAAACCGCTGCTGGGTGAAGGTATTTTTGCAAGTGATGGTAAAAAATGGGAACATAGCCGTGCAATGCTGCGTCCGCAGTTTGTTCGTAGCCAGGTTAGCGATATTAGTCTGGAAGAAACCCATGTTCAGAATCTGATGACCGTTCTGGATAGCCATCTGGATAAAACCACCGGTTGGAGCGGTGCAGTTGATCTGCAGCCGCTGTTTTTTCGTCTGACCCTGGATAGCGCAACCGAATTTCTGTTTGGTGAAAGCGTTAATAGCCAGCTGCGTCGTGAAGGTGATGCAGATAATGATGCACATGCATTTGCGACCAGCTTTGATGCAAGCCAGAATCAGCTGGCAGTTGCAGGTCGTTATGGTAGCAATTATTGGATTGGTCATACCAAAGCCTTTCGTGAAGATGTTCGTATCTGCCACGAATTCATCGATTACTTTGTTCAGAAAGCACTGAATGGTCAGCGTGATACCAGTGAAAAAGCAGATGCCGATAAAGAAGAACGCTACGTTTTTCTGGAAGCAATTGCACGTGAAACCAGCGATCCGGTTGAACTGCGTAGTCAGCTGATTAACATTCTGCTGGCAGGTCGCGATACCACCGCAAGCACCCTGGGTTGGTTTTTTCATATTATGGGTCAGGCACGTAACGCCCATATCTATAAACGTCTGCGTCAGGCAATTCTGGATGAATTTGGCACCTATCGTAATCCGAAACCGATTACCTTTGAAGGCCTGAAAAATCTGACCTATCTGCAGTGGTGTATTAATGAAACCCTGCGTCTGTATCCGATTGTTCCGATGAATGGTCGTGCAGCAGTTAAAGATACCGTTCTGCCGCTGGGTGGTGGTCCGGATGGTCGTAGCCCGATTCTGGTTAAAAAAGGTCAGGATATTGGTTATAGCGTGCATGTTATGCATCATCGTACCGATCTGTGGGGTGCAGATGCAGATGATTTTCGTCCGGAACGTTGGGAAAAACGCAAACCGGGTTGGGATTATCTGCCGTTTAATGGCGGTCCGCGTATTTGTATTGGTCAGCAGTTTGCACTGACCGAAATTGCATATGTTGTTGCACGTATGCTGCAGCGTTTTGATGAACTGGATGGTAGCACCCTGAGCGCAGAAAGCCATGGTCTGGGTCTGACCAATTGTCCGGGTGAAGGCGTTACCCTGAAAGTTCACTTTGATGAATAA  
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Cytochrome P450 CYP52T1  Transmembrane area was removed (nucleotides 4-60) for gene synthesis.  ATGCGTAGCATTCAGCGTCGTAATGCACGTGATCGTCTGGCACGTCAGCATGGTTGTGAACCGCTGACCCTGGCATATAACAAACTGCCGTTTGGTCTGGATCGTAAATGGCAGATTGTTACCCATCGTGGTAATATTCTGGATGATCTGATTACCACCCGTTTTGCAGAACTGGGTAGCTATATCTATACCGATAATCAGTGGGGTAGCCCTCCGATTATTTGTGCAGAACCGGCAGCAATTAAAGCAGTTCTGAGCACCAAATTTCGTGATTGGGATATGGATAGCAATCGTTATCCGGCACTGGGTCCGTGGCTGGGTCGTGGTGTTCTGGTTAGCAGCCATCAGGGTAAAGGTAGCCTGTGGCTGACCGCACGTACCCTGCTGCGTCCGATGTTTGCAAGCGTTGCAACCTATAATCATGCCCTGATGGAAAAAAGCGTTCAGGATTTTCTGAGTACCATGAGCCGTGTTAATGAAGATAGCGCAACCCGTAGCGATCTGCTGCCGCTGATTCGTCGTCTGAATATTGATATTATCACCGCCATTTTTTGCGGTGGTAGCATTGGTGCACAGAAAAAAGGTCTGGAAGCAGGTCCGCGTGCAGCAGCAGCTGCAGCAGCCGCAAGTCCGGGTAAAAAACCGACCCTGGAAGAGGCATTTGATGCAATTGAACCGATTGCAGGTCTGCGCCTGCAGACCGGTAGTCTGTATTGGCTGTTTACCAGCAAACCGTTTCGTGATGCATGTGATACCTTTAGCGAACTGGCAAATGGTTGGATTAATCAGGCACTGCGTAAAACCCATGAAAAAAGCAGTCCGCAGGGTGGTGGCCTGGATGGTGTTGCAGAAGCAGCACAGAGCTTTACCGAAGAACTGGTGAGCAGCACCGAAGATCGTGAACTGCTGCGTGATATTCTGGTTCAGCTGCTGTTTGCAGGTATTGATACCAGCACCAGTATGCTGAGCTTTGCACTGCTGGAACTGGGTCGTCATCCGGGTAGCTGGACCCGTCTGCGTGCGGAACTGGCAGAACATAGCCTGCTGAGCGCAGGTCCGGAAACCATTACCGCAGGTCAGCTGAAAGATTGTGTTTTCCTGCAGAATGTTGTGAAAGAAACCCTGCGTCTGTATCCGCCTGTTCCGATTAATAGCCGTGAAGCAATTCGTGATACCGTTCTGCCGACCGGTGGTGGTGCAGATGGTAGCAAACCGGTGTTTGTTCCGAAAGGCACCAGCCTGAAATATAGCCCGTATGTTATGCATCGTCGTAGTGATCTGTATGGTCCGGATGCAATGGAATGGAAACCGGATCGTTGGCTGGGACGTAGCCATGGTTGGGATTATCTGCCGTTTAATGGTGGTCCGCGTATTTGTATTGGTCAGAAATTTGCACTGACCGCAGGCGCATATGTTCTGACACGTCTGGCCCAGCAGTTTGATACCTGTGAAGCAGCAAGCAGCAATAAAGGTCCGCTGGAAAGCAAACTGGGTGCCGTTCTGATTCCGGCAGCCGGTGTTCCGGTGAGCCTGGGTAATAGCAGCTAA  Cytochrome P450 CYP52T1_2  Transmembrane area was removed (nucleotides 4-78) for gene synthesis.  ATGCGTCAGGTTAGCTATCAGAGCCTGGCACGTCGTGCAGGTTGTAAACCGCCTCCGGCACGTCCGTATCGTCTGCCGTTTGCAATTGATAATATTGTTCGTACCATGCGTGCCATTCTGGATCATACCCTGCAGAATGATGAAGTTGCAGTGTATGAAGAAATGGGTTGTCCGGCAACCTGGCGTCAGAACATTCTGGGTGTTTGGTATCATGCAACCGCAGATCCGGAAAACATTAAAGCACTGCTGGCAACCCAGTTTAACGATTTTGAACTGGGTAGCATTCGTCTGGATCACATGGGTCCGCTGATTGGTCATGGTATTTTTACCAGTGATGGTAAAGAATGGCAGCAGCAGCGTAGCATGCTGCGTCCGCAGTTTACCCGTGCACAGATTAGCAATCTGACCCTGCTGGAAGCACATGTTCAGAACCTGTTTCAGCATTTTGATAGTCCGCATGCAGGTAGCTGGACCGCAGAAGTTGATCTGGCACCGCTGTTTTTTAACCTGACCCTGGATGCAGCAACCGAATTTCTGTTTGGTCAGAGCGTTGAAAGCCAGATTCATCATGGCAAAAAAAGCCATGGTGGTAGCGATAGCGGTAAAAAAAGTGGTCAGGATGGTCTGATTAGTGGTAAAGATTGGAGTAGCTTTGGTCGTGCATTTGATCGTGCAAATGCAACCATTGCACTGCGTGGTATGCTGATGGATTTCTATTATCTGTATCGTCCGAGCAGCCTGGCCCAGGATTGTCGTGAAGTTCATAAATTTGCCGATCATTTTGTTCAGCGTGCACTGAATACCGAAGTTCAGGATACCGAAGGTGATAGCGAAACCGAAGCATATGTTTTTCTGCGTGAACTGGTTAAAACCACCCGTGATCCGTATGTTCTGCGTAGCCAGCTGCTGAATATTCTGCTGGCAGGTCGTGATACCACCGCAGGTCTGCTGGGTTGGACCTTTTACCTGCTGGCACGCCATCCGGATTATTACAGCAAACTGCATCGTATTGTTGTGGAAACCTTTGGTCCGAGCTGTAGCGCAGATAGCGCAAGCATTATTACCTTTGAAAGCCTGAAAGCATGTCATCCGGTTCAGCATCTGCTGAGCGAAGCACTGCGTCTGCATCCGGTTGTTCCGGAAAATGGTCGTCGTGCCGTTCGCGATACCACCCTGCCTCGTGGTGGCGGTCCGGATGGTCAGAGTCCGGTTTTTATTCGTAAAGGCCAGGATGTTCTGTATAGCGTTAATGTTATGCATCGTCGTAAAGATCTGTGGGGTGATGATGCACATGAATTTCGTCCGGAACGTTGGGCAGATCGTAAACATGGTTGGGAATATCTGCCTTTTAATGGTGGTCCGCGTATTTGTCTGGGTCAGCAGTTTGCACTGACCGAAGCAGCCTATGTTGTTGTTCGTATGCTGCAGAAATATGGTCGCATTGAAAATCTGGATCCGGATACCGTTACCCGTCATCGTTATACCCTGACCACCGCACCGGTTAAAGTTGCCGTTCGTCTGCAGCAGGCAAATTAA          
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Cytochrome P450 CYP52T1_3  Transmembrane area was removed (nucleotides 4-81) for gene synthesis.  ATGCATTGGCTGTTTGCACGTAAACTGGGTTGTAAACCGGCACATGTTCGTCGTAGCAAACTGCCGCTGGGTCTGGATAATGTTCTGCGTATGGCAAAAGCAGCCAAAAATCAAGAACTGCAGAATGATGATCAGCTGGTGCATCAAGAAATGGGTTGTCCGAGCACCTGGGTTCAGAATTTTCTGGGTTTTTGGTGTCATACCACCGTTGATCCGGAAAACATTAAAGCAATTCTGGCCACGCAGTTCAAAGATTTTGAAATGGGTCCGTTTCGTACCGATACCCTGAGTCCGCTGCTGGGTCATGGTATTTTTACCAGCAATGGTAAAGAATGGTACATCGTGAATTTCGATCCGCTGAAACGTGATGTTCTGCTGACCTTTATGTTTACCCGTAATCAGATTAGCAGCCTGGAACTGGAAGAAGTTCATATTCAGCACCTGTTTGGTCGTTTTCATCATGGTGCAGATGGTAGCTGGACCAGCCCGATTGATCTGGGTCCGCTGTTTTTTAACCTGACCCTGGATAGCGCAACCGAATTTCTGTTTGGCCAGAGCGTTGATAGCCAGCTGCTGGATAGCCCGAATGCAGCAAAAGCAACCAGCAGCGAACATGAAACCAAAGCAAATCGTGATAGCAAAGATTGGAGCAGCTTTGGTCGTGCATTTGATCGTGCAAATACCACCATTAGCTTTAAAGGTATGCTGATGGATTTCCACTTTCTGTATAGTCCGAAAAGCTTTACCGATGATTGCAATACCGTTCATCGTTTCGCCGATTATTTTGTTCAGCAGGCACTGAATGAAGAACAAGAAGTTAGCGGTAGTCCGGATAGTAAAGGTGAAACCGAAGCATTTGTTTTTCTGCGTGAACTGGTTAAAAGCACCAAAGATCCGAAAGCACTGCGTGGTCAGCTGCTGAATATTCTGCTGGCAGGTCGTGATACCACCGCAGGTCTGCTGGGTTGGACCTTTTACCTGCTGGCACGTCATCCGGATTATTATAGCAAATTTCACCGCATTATCGTGGAAACCTTTGGTCCGTATAGTGAACATGCAAGCAGCCTGACCTTTGAAAGCCTGAAAGCATGTAGCCATCTGCAGAATCTGCTGAGCGAAGTTCTGCGTCTGCATCCGGTTGTGCCGGAAAATTCACGTCGTGCAACCCGTAATACCATGCTGCCTCGTGGTGGTGGTGTTGATGGTAATGCACCGGTTTATATTCGCAAAGGTGAAGAGGTGATTTACAACGTGAATGTTATGCATCGTCGCAAAGATATTTGGGGTGATGATGCAGATGAATTTCGTCCTCAGCGTTGGATTGGTAGCAAACATGGTTGGGAATATCTGCCGTTTAATGGCGGTCCGCGTATTTGTCTGGGTCAGCAGTTTGCACTGACCGAAGCAGGTTTTGTTGTTGTTCGTCTGCTGCAGCGTTATTCCAAAATTGAAAATCTGGATACCGAAACCGTGACCAAACATCAGTATACCCTGACCACCGCACCGGTTAAAGTTCTGGTTCGTTTTTGTGAAGCAGCACAGCTGTAA  Cytochrome P450 CYP539B1 Transmembrane area was removed (nucleotides 4-87) for gene synthesis.  ATGGTTGCCTATAAAGTTGCAAAAAGCAGCGGTGTTCGTGCACCGAGCATTGGTGATAATCCGATTAGCGCAATTCGTGTTAGCCTGACCGCAGTTAAATATCAGAATCAGAATCGCCTGTACGATTTCTTTAAAAGCATTTTCGATGCAGGTACACCGGAATGTCCGAATGCAGTTGAAGCACTGTTTTTTGGTCGTCGCATTATCTTTACCCAAGAACCGGAACATATCAAAACCGTTCTGACCGCAAAATTTGCCGATTATGGTAAAGGTCCGAAATTTCATGAAGTTTGGGCACCGTTTCTGGGCGATAGCATTTTTACCACCGATGGTGCACAGTGGCATGATAGCCGTACCCTGATTCGTCCGATGTTTGTTAAAGATCGTGTTCGCGATATGGGCATTTTTGAACGTTGGAGCGATAAACTGATTAGCAAACTGCCTGCAAGCGGTGAAACCGTTGATATGTGTGACCTGTTTTATCGTATGACCCTGGATCTGACCACCGATTTTCTGCTGGGTAGCGGTGTTGGTAGCCTGGATAACCCGAATAGCGAATTTAGCAATGCATTTACCGTTGTTCAGCGTCTGCAGATGATTCTGACCATTATGCTGCCGTTTCGTCGTTTTATTCCGCAGCAGCAGTATCGTGATGGTATTAAAACCCTGGAAAAATTCATGACCCCGTATATTCAGCAGACCCTGAGCCTGACACCGGAAGAACTGGAAAAACTGAGCAAATCCGATAAACAGTTTACCTTTCTGCATAACATTGCCCTGTTTAGCCGTGATCCGAAAGTTATTCGTGATCAGATTATGGCAGTTCTGCTGGCAGGTCGTGATACCACCGCAGCCACCCTGAGCTGGACCATTTATGAACTGGCAAATTATCCGGATGTTTGGACCAAACTGCGTCAGACCGTTCTGGAAAAAGTTGGTCCGGATAGCAATCCGACCTATGAAGATATTAAAGGCATTACCTATCTGACCCATGCAATTAGCGAAACCCTGCGTCTGTATCCGGCAGTTCCGTATAACATTCGTAGCTGTCTGCAGGATAGCACCCTGACAGGTGCACCGGGTCAGCCGGATATTGCATGTTTTAAAGGTAACCATGTGATCTATAGCACCTATGCAATGCAGCGTCGTCGTGATCTGTATCCTCCGGTGAGCGAAACCTTTGCAGATCCGGATATCTATTCACCGGATCGTTGGGATCATTGGACACCGCGTCCGTGGCAGTATGTTCCGTTTAATGGTGGTCCGCGTATTTGTATTGGCCAGAATTTTGCCATTACCGAAATTGGTTATGTGCTGGTTAAACTGCTGCAGAAATATGAACGTCTGGAATATCGTGACGATTGGAATGCACAGTTTCATAAAGCAGAAATTGTTGGTTGTCCGGGTCGTGGTGTTCCGGTGGCCTTTTTTGAACCGGAAAAAACCGATGAAAAAACGGCCTAA           
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Cytochrome P450 CYP584E2  ATGGCACTGGGTCAGCTGGCACCGACCGTTGCAGTTCTGAGCGATCATCCGGTTCGTGATCTGATTCTGCTGA
GCCTGATTGCCGTTCTGGGTTATCCGATTTTTCGCCATCTGATTGCATGGCGTGCCCTGGGTCGTGCATATGC
CCTGCATGATTGTGAACGTCCGGCAGCATATCCGCATAAAGATCCGCTGTTTGGTTTTGATGCAATTCTGGCA
AATATTGCAGCAGCACGTAATCATCGTTTTACCGCAAGCGAACTGCAGCGTTTTCAGGATATTGGTGCAGATA
CCTATTACACCTGGATTCAGGGTCGTCAGATTGTTGTTACCCGTGATCCGGATAATGTTCGTTGTATTCTGGG
CACCAATTGCAAAGATTATAGCATTGGTGGTCGTCGTGCACTGTTTGGTCGTTTTCTGGGTAATGGTATTTTT
GTGAGCGAAGGTGAAGAATGGGTTCGTAGCCGTGCACGTCTGCGTCGTAATTTTAGCCGTGAACAGGTTGCAG
ATCTGGCAATGCTGGAACGTCATGTTGCAAAACTGTTTCAGGTTCTGCCTGGTGATGATCAGCCGAATGCAGT
TGTTGATCTGCAGGATTGTTTTCTGCGTTTTACCACCGATAGCAGCAGCGAATTTCTGTTTGGCCATAGCACC
GATACCCTGGTTCGTCCGAGCGCACGTGATGTTGCATTTGGTGAAGCATTTACCCTGAGCCTGGATATTATCA
CACAGAAAATGCGTCGTGGTCCGCTGAATCGTTTTTATCCGAAAGATCCTCGTGAAGATAGCGCATTTCAGAT
TGTGCGTGATTATGTTCGTGCCTTTGTTGATGAAGCAGCAGCCCTGCGTGAGAAAAAAACCGCAGATGGTGAA
CTGCTGGAAGGCCATGAAGATGCAGGTCCGGAACATCGTTATCTGATCCTGCGTGAACTGGTTCGCGATTTTG
ATGATAAAGAACGCATTTGCGACGAACTGATTAGCCTGATTACCGCAGGTCGTGATACCACCGCAAGCCTGCT
GAGCAGCGCCTTTCATGTTCTGAGCCGTCGTCCGAATATTTGGCGTACCCTGCGTAATGAAATTCAGCATCTG
AATGGTCATCCGCCTAGCTATGAACAGCTGCGCAACCTGAAATTTGTGAAATACATTATCAATGAAACCCTGC
GTCTGTATCCGCCTGTTTTTCGTAATGCACGTAAAGCAGTTCGCGATACCATTCTGCCGACCGGTGGTGGTCC
GAATGGCACCAGTCCGGTTTTTGTTCCTAAAGATACCGGTGTTGTTTATAGCGCATGGGCAATGCATCGTCGT
ACCGATCTGTATGGTCCGGATGCAACCGAATTTAATCCGGAACGTTGGGCAACCCAGCGTCATGGTTGGGATT
ATCTGCCGTTTGGTGGCGGTCCGCGTATTTGTCTGGGCCAGCAGTATGCACTGACCGAAGCACTGTATGTTCT
GGTTCGTATGGCACAGCAATATGTTGCAGTTGAAACAGCAGATGATACCCCGTGGACCGAACATATTTGCCTG
ACCCTGGCAATTAAAGATGGTGTTAATTGTAAACTGACCCGTGCCAAAAACTAA 
 Sequences of the truncated transmembrane areas of B. bassiana P450s  Cytochrome P450 CYP52G6   ATGGCGCTCACTGCTATCCTCATCGGCCTCGTCGTCGTCACCTTTGTGCTTCGA  Cytochrome P450 CYP52G8   ATGGCGGTACTATCCGTTATTTCGCTTCCGGCGCTGCTGGTCTCTTTGACCGTTGCCTTTATCCTCCTCCAGGTGATTGAGTAC  Cytochrome P450 CYP52T1   ATGGCTCTCCACGCTGCCTACCTATTTATTGCAGCGACGCTGGTGGCCGTCTATCTGACT  Cytochrome P450 CYP52T1_2   ATGAACTTGTTGTCATCGTCTTTTGCTGCAGTTCTTCTATCGGCTGTCATTGCCGCGTATATTCTCAAGGTGGTATGG  Cytochrome P450 CYP52T1_3   ATGACTCTCTCGCCTATTTCTACTTTTCTCGCCGGTGCTGCTATCCTTTACCTTGCTAGGTGGGTATGCATCGAGATAAAC  Cytochrome P450 CYP539B1  ATGCTTATCGAGGCTGTCAATACAACGACGGTGGCTCTGGCCATTCCTGTCTGTCTGCTTTTGTTTGTCATTGTCAACTGGCTCACG  
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Appendix C: LC-MS/MS analysis of Beauveria bassiana proteome  
C.1 Introduction 
As a consequence of the unsuccessful heterologous expression of P450s selected from 
B. bassiana in E. coli and S. cerevisiae and thus the absence of active biocatalysts that 
could be tested against drugs of industrial significance or that could be investigated for 
interesting reactions, it was considered important to provide at least information that might 
be useful for future projects. It was therefore decided to investigate the applicability of the 
LC-MS/MS Protein Identification technology as a tool for possible identification of 
specific P450s from B. bassiana. This approach would allow the identification of an 
enzyme in correspondence to a transformation reaction and offers immediate data 
regarding the nature of the enzyme. Therefore, we designed an experimental setup that 
exposed the fungus to selected drugs (known to be hydroxylated by B. bassiana) in the 
hope to initiate expression of particular cytochrome P450s. A negative control (B. bassiana 
grown in liquid medium without addition of substrate) was thought to act as reference for 
the analysis. The only reason that this technology has not been used and refined in the 
beginning of this project was the lack of available equipment and techniques. 
C.2 Materials and methods 
The Beauveria bassiana strain used for proteomic analysis was ordered at CBS culture 
collection (CBS number: 209.27) and resuscitated on solid Oatmeal Agar (SigmarAldrich, 
72.5 g per liter). The plates were incubated at 25 °C until an appreciable level of biomass 
was grown (7-10 days) and then stored at 4 °C for further use. 
A loopful of the white fungal biomass from the oatmeal agar plate was transferred into 
50 ml sterile liquid corn-steep medium (7.5 g/l corn steep solids, 10 g/l glucose, pH 4.8) 
using a nichrome loop. The fungus was then grown in an orbital shaker at 28 °C and 
150 r.p.m. After 72 h of growth, substrate (see Figure C.1) dissolved in small amount of 
ethanol (0.5 ml) was added to the liquid medium (final concentration of 0.1 mg/ml) to 
initiate biotransformation.  
GC samples were taken after 0 h, 4 h, 24 h and 48 h as described in 4.1.3.3 in order to 
confirm metabolization of the added substrate. On the basis of the GC analysis, cell harvest 
of freshly grown 50 ml liquid cultures that served as the actual sample for proteome 
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analysis took place 24 h after substrate addition. At that time, biotransformation was 
already in progress and still ongoing and should therefore account for a steady expression 
level of the protein(s) involved in the biotransformation of the substrate.  
 Figure C.1: substrates added for biotransformation in B. bassiana  
Cells were harvested by centrifugation at 4500 r.p.m. for 20 min. Supernatant was 
discarded and the cell pellet resuspended in 40 ml of buffer A (50 mM Tris/HCl pH 7.5, 
300 mM NaCl). Cells were disrupted at high pressure (35000 psi) using a French Press and 
cell debris were then pelleted by centrifugation at 13000 r.p.m. (30 min, 4 °C). The cell 
pellet was discarded and the obtained cell lysate was 10 x concentrated. Concentrated 
proteins were prepared for SDS-PAGE as described in 2.7.3. The electrophoresis was 
stopped after approximately 8 min. The gel was stained in order to visualize the protein 
band which was then excised from the gel using a scalpel and send to the Technology 
Facility (University of York) for protein identification by LC-MS/MS. Analysis of 
prepared protein samples were performed as follows: 
In-gel Digestion 
In-gel tryptic digestion was performed after reduction with DTE and 
S-carbamidomethylation with iodoacetamide. Gel pieces were washed two times with 50 % 
(v:v) aqueous acetonitrile containing 25 mM ammonium bicarbonate, then once with 
acetonitrile and dried in a vacuum concentrator for 20 min. Sequencing-grade, modified 
porcine trypsin (Promega) was dissolved in 50 mM acetic acid, then diluted 5-fold with 25 
mM ammonium bicarbonate to give a final trypsin concentration of 0.02 g/L. Gel pieces 
were rehydrated by adding 25 L of trypsin solution, and after 10 min enough 25 mM 
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ammonium bicarbonate solution was added to cover the gel pieces. Digests were incubated 
overnight at 37 oC. Peptides were extracted by washing three times with 50 % (v:v) 
aqueous acetonitrile containing 0.1 % trifluoroacetic acid (v:v), before being dried down in 
a vacuum concentrator and reconstituting in aqueous 0.1 % trifluoroacetic acid (v:v). 
LC-MS/MS 
Samples were loaded onto a nanoAcquity UPLC system (Waters) equipped with a 
nanoAcquity Symmetry C18, 5 µm trap (180 µm x 20 mm Waters) and a nanoAcquity HSS 
T3 1.8 µm C18 capillary column (75 m x 250 mm, Waters). The trap wash solvent was 
0.1 % (v/v) aqueous formic acid and the trapping flow rate was 10 µl/min. The trap was 
washed for 5 min before switching flow to the capillary column. Separation used a gradient 
elution of two solvents (solvent A: aqueous 0.1 % (v/v) formic acid; solvent B: acetonitrile 
containing 0.1 % (v/v) formic acid). The capillary column flow rate was 300 nl/min and 
the column temperature was 60 °C. The gradient profile was linear 2-30 % B over 125 min 
then linear 30-50 % B over 5 mins. All runs then proceeded to wash with 95 % solvent B 
for 2.5 min. The column was returned to initial conditions and re-equilibrated for 25 min 
before subsequent injections.  
The nanoLC system was interfaced with a maXis HD LC-MS/MS system (Bruker 
Daltonics) with CaptiveSpray ionisation source (Bruker Daltonics). Positive ESI-MS and 
MS/MS spectra were acquired using AutoMSMS mode. Instrument control, data 
acquisition and processing were performed using Compass 1.7 software (microTOF 
control, Hystar and DataAnalysis, Bruker Daltonics). Instrument settings were: ion spray 
voltage: 1,450 V, dry gas: 3 l/min, dry gas temperature: 150 °C, ion acquisition range: m/z 
150-2,000, MS spectra rate: 5 Hz, MS/MS spectra rate: 5 Hz at 2,500 cts to 20 Hz at 
250,000 cts, cycle time: 1 s, quadrupole low mass: 300 m/z, collision RF: 1,400 Vpp, 
transfer time 120 ms. The collision energy and isolation width settings were automatically 
calculated using the AutoMSMS fragmentation table, absolute threshold 200 counts, 
preferred charge states: 2 – 4, singly charged ions excluded. A single MS/MS spectrum 
was acquired for each precursor and former target ions were excluded for 0.8 min unless 
the precursor intensity increased fourfold. 
Database Searching 
Tandem mass spectra were searched against the Beauveria bassiana subset of the UniProt 
database (22,786 sequences; 11,343,437 residues) using a locally-running copy of the 
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Mascot program (Matrix Science Ltd., version 2.5.1), through the Bruker ProteinScape 
interface (version 2.1). Results were passed through Mascot percolator to achieve a false 
discovery rate of <1% and further filtered to accept only peptides with an expect score of 
0.05 or lower. 
C.3 Results and discussion 
At first glace, the outcome of this experiment was rather disappointing as it was only 
possible to verify four P450 enzymes (i.e., 2 x CYP52T1, CYP539B5 and CYP52A12) and 
the NADPH-cytochrome P450 reductase (see Table C.1). Moreover, two of the identified 
cytochromes P450 were also observed in the negative control, indicating a possible 
housekeeping function of these enzymes in the organism and thus were most likely not 
expressed as a direct response to the addition of the substrate. On the other hand, it was 
noticed that CYP52T1 as well as the NADPH-cytochrome P450 reductase seem to be more 
strongly induced in samples 2, 3 and 4 (Table C.1) which in turn leaves room to actually 
speculate about its physiological role regarding the metabolization of corresponding 
substrates in B. bassiana. It is important to emphasize the fact that this experiment was 
performed at the end of this project to explore the possibilities of proteome analysis for 
P450s in B. bassiana. Experimental setups as well as preparation of the protein samples 
need to be improved in order to aquire quantitative data that could lead to the identification 
of specific enzymes. Nonetheless, it could be demonstrated that it is possible to identify 
P450s in the cell lysate of B. bassiana and thus confirmed the potential use of high-
resolution mass spectrometry for target selection in future studies.  
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Table C.1: P450 hits on exposure to hydroxylation substrates in Beauveria bassiana using LC-MS analysis sample 1: no substrate (negative control); sample 2: 1-benzylpyrolidine; sample 3: lauric acid; sample 4: 2-phenoxypropionic acid; sample 5: 1-benzoylpiperidine 
Sample Family Accession Score Mass No. Spectra No. Sequences emPAI Molar % Description 
1 443 J4UN70 60 76854 4 3 0.13 0.03 NADPH--cytochrome P450 reductase OS=Beauveria bassiana (strain ARSEF 2860)  
1 501 J4WEG4 47 60824 3 2 0.1 0.02 Cytochrome P450 CYP52T1 OS=Beauveria bassiana (strain ARSEF 2860)  
1 603 E2EAF9 35 59082 2 1 0.05 0.01 Cytochrome P450 monooxygenase CYP539B5  OS=Beauveria bassiana  
2 240 A0A0A2V9Y1 102 76849 8 4 0.17 0.06 NADPH--cytochrome P450 reductase  OS=Beauveria bassiana D1-5  
2 249 J4WEG4 96 60824 4 3 0.16 0.06 Cytochrome P450 CYP52T1  OS=Beauveria bassiana (strain ARSEF 2860)  
3 325 J4WEG4 83 60824 3 3 0.16 0.05 Cytochrome P450 CYP52T1  OS=Beauveria bassiana (strain ARSEF 2860)  
3 533 J4UN70 43 76854 3 3 0.13 0.04 NADPH--cytochrome P450 reductase  OS=Beauveria bassiana (strain ARSEF 2860)  
4 223 A0A0A2V9Y1 102 76849 10 5 0.22 0.07 NADPH--cytochrome P450 reductase  OS=Beauveria bassiana D1-5  
4 396 J4WEG4 47 60824 4 2 0.1 0.03 Cytochrome P450 CYP52T1 OS=Beauveria bassiana (strain ARSEF 2860)  
4 757 J5JHI3 16 60064 1 1 0.05 0.01 Cytochrome P450 CYP52T1  OS=Beauveria bassiana (strain ARSEF 2860)  
5 370 A0A0A2V9Y1 60 76849 4 3 0.13 0.04 NADPH--cytochrome P450 reductase  OS=Beauveria bassiana D1-5  
5 615 E2EAF9 26 59082 1 1 0.05 0.01 Cytochrome P450 monooxygenase CYP539B5  OS=Beauveria bassiana  
5 742 A0A0A2WAI9 18 60755 1 1 0.05 0.01 Cytochrome P450 52A12  OS=Beauveria bassiana D1-5  
Crudely Lower = more Higher  = more Higher  = more Higher  = more Higher  = more 
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Appendix D 
Table D.1: List of the 65 substrates used in activity assays of Rhodococcus jostii. 
No. Substrate Structure MW 
1 Acetominophen 
 
151.20 
2 Aminopyrine 
 
231.30 
3 Amlodipine 
 
408.90 
4 Amodiaquine 
 
355.90 
5 Atorvastatin 
 
558.60 
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6 Benzbromarone 
 
424.10 
7 Caffeine 
 
194.20 
8 Carbamazepine 
 
236.30 
9 Celecoxib 
 
381.40 
10 Chloroxazone 
 
169.60 
11 Clopridogrel 
 
321.80 
12 Clozapine 
 
326.80 
142 
No. Substrate Structure MW 
13 Dextromethorphan 
 
271.40 
14 Dichlofenac 
 
296.20 
15 Diltiazem 
O
O
S
NO
N
O  
414.50 
16 Donepezil 
 
379.50 
17 Erythromycin 
 
733.90 
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18 Ethinylestradiol 
 
296.40 
19 Fluoxetine 
 
309.30 
20 Flutamide 
 
276.20 
21 Furosemide 
 
330.70 
22 Imipramine 
 
280.40 
23 Indomethacin 
 
357.80 
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24 Levofloxacin 
 
361.40 
25 Metoprolol 
 
267.40 
26 Nevirapine 
 
266.30 
27 Nifedipine 
 
346.30 
28 Olanzapine 
 
312.40 
29 Olmesartan 
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30 Omeprazole 
 
345.40 
31 Phenytoin 
O NH
OHN
 
252.30 
32 Pioglitazone 
N
O
OHN
O S
 
356.40 
33 Pravastatin 
 
424.50 
34 Procainamide 
 
235.30 
35 Propranolol 
 
259.30 
146 
No. Substrate Structure MW 
36 Ritonavir 
N
S
NO
NHO
NH
NH
O O
NS
HO
 
 
37 Rosiglitazone 
 
357.40 
38 Sulfamethoxazole 
 
253.30 
39 Tacrine 
 
198.30 
40 Tamoxifen 
 
371.50 
41 Ticlodipine 
 
263.80 
147 
No. Substrate Structure MW 
42 Tienilic acid 
 
331.20 
43 Valproic acid 
 
144.20 
44 Valsartan 
 
435.50 
45 Verapamil 
 
454.60 
46 Warfarin 
 
308.30 
47 Zafirlukast 
S
O
O
HN
O
O
N
HN
OO
 
575.70 
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No. Substrate Structure MW 
48 Zomepirac 
 
291.70 
49 Cortisone 
 
346.46 
50 Estrone 
 
270.37 
51 Testosterone 
 
288.43 
52 17-a-hydroxy- pregnenolone 
 
332.48 
53 17-a-progesterone 
 
330.47 
54 Ethisterone 
 
312.45 
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No. Substrate Structure MW 
55 Deoxycortico-sterone 
 
330.47 
56 Andrenosterone 
 
300.40 
57 Pregnenolone 
 
316.48 
58 Progesterone 
 
314.47 
59 Cholesterol 
 
386.66 
60 b-estradiol 
 
272.39 
61 Corticosterone 
 
360.45 
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62 (+-)-Dihydro-thebainon 
 
301.38 
63 
(8a'S)-5',6'-dimethoxy-1'-methyl-
2',3',8',8a'-tetrahydro-1'H-
spiro[cyclohex[2]ene-1,7'-
cyclopenta[ij]isoquinolin]-4-one  
313.40 
64 
(5a,14a)-7-(2-hydroxypropan-2-
yl)-17-methyl-4,5-
epoxymorphinan-3-ol 
  
329.43 
65 
(5a,6a)-3-methoxy-17-methyl-
7,8-didehydro-4,5-
epoxymorphinan-6-ol 
  
299.36 
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Abbreviations 
4CL 4-coumarate CoA ligase 
A alanine or adenine 
aa amino acids 
Abs optical absorbance 
ADE 2d selection marker for adenine auxotrphy 
ADR adrenoxodin reductase 
ADS amorphadiene synthase 
ADX adrenodoxin 
Ala alanine 
ALA δ-aminolevulinic acid 
AMP adenosine monophosphate 
ampR ampicillin resistence gene 
ANS anthocyanidin synthase 
araB gene encoding for AraB 
Arg arginine  
Asp aspartic acid  
ATR1 Arabidopsis thaliana cytochrome P450 reductase 1 
BCAs biological control agents 
BLAST Basic Local Alignment Search Tool 
bp base pairs 
BSA bovine serum albumine 
BSTFA N,O-bis(trimethylsilyl)trifluoroacetamide 
C cysteine or cytosine 
C4H cinnamic acid 4-hydroxylase 
cAMP cyclic adenosine monophosphate 
camR chloramphenicol resistence gene 
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canR resistance to canavanine sulphate 
CAP cyclic AMP receptor protein 
CBS Centraalbureau voor Schimmelcultures 
cDNA complementary DNA 
CHI chalcone isomerase 
CHS chalcone synthase 
CO carbon monoxide 
CPA cyclophosphamide 
CPR cytochrome P450 reductase 
CYP cytochrome P450 
cyr+ encodes adenylate cyclase: required for cAMP production and cAMP-dependent protein kinase signaling 
Cys cysteine  
D aspartic acid 
Da dalton 
dATP deoxyadenosine triphosphate 
DCDD dichlorinated dibenzo-p-dioxins 
dcm cytosine methylation at second C of CCWGG sites  
DE3 Lysogen that encodes T7 RNA polymerase 
DFR dihydroflavonol 4-reductase 
DMAPP dimethyl allyl pyrophosphate 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP dinucleotide triphosphate 
dTTP deoxythymidine triphosphate 
E glutamic acid 
e.g. exempli gratia 
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EDTA ethylenediaminetetraacetic acid 
endA1 gene encoding DNA-specific endonuclease I 
ER endoplasmic reticulum 
et al. et alii 
etc. et cetera 
F’ F plasmid: a self-transmissible, low-copy plasmid used for the generation of single-stranded DNA when infected with M13 phage; may contain  a resistance marker to allow maintenance and will often carry the lacI and lacZ∆M15 genotypes 
F- host strain does not carry the F plasmid 
f1 ori f1 phage origin of replication 
F3'5'H flavonoid 3’,5‘-hydroxylase 
F3H flavanone 3-hydroxylase 
F3'H flavonoid 3‘-hydroxylase 
FAD flavin adenine dinucleotide 
FdR ferredoxin reductase 
Fdx ferredoxin 
Fe iron, ferrum 
FMN flavin mononucleotide 
FPP farnesyl pyrophosphate 
G glycine or guanine 
g gram 
Ga gigaannum: 109 (1,000,000,000) years 
Gal4p novel yeast gene required for glucose repression  
GAL10-CYC1 hybrid yeast promoter 
GDEPT gene directed enzyme pro-drug therapy 
Glu glutamic acid 
Gly glycine 
154 
GPP geranyl pyrophosphate 
gyrA96 DNA gyrase mutant: produces resistance to nalidixic acid  
i.e. id est 
h hour(s) 
his 6x histidines residues 
HiTEL High Throughput Expression Laboratory 
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A 
HRV human rhinovirus 
HSD human 3β-hydroxysteroid dehydrogenase/isomerase 
HsdR17 endonuclease R, host restriction of foreign DNA 
hsdSB specificity determinant for HsdM and HsdR (both restriction and methylation of certain sequences is deleted from the strain) 
IPP isopentenyl pyrophosphate 
IPTG isopropyl β-D-1-thiogalactopyranoside 
kb kilo base pairs 
kDa kilodaltons 
kJ kilojoules 
L leucine 
l litre 
LacI repressor gene for IPTG induction  
lacIqZΔM15 Allows α-complementation for blue/white selection of recombinant colonies in lacZ mutant hosts 
LacZ ß-galactosidase 
LB Lysogeny Broth 
Leu leucine 
LIC Ligation independent cloning 
LICRED Ligation Independent Cloning plasmid with P450Rhf reductase domain 
M molar 
155 
Ma megaannus: 106 (1,000,000) years 
MATa mating type locus in yeats: MATa haploids express the genes a1 and a2 from the MAT locus 
min minutes 
MTBE methyl tert-butyl ether 
MW molecular weight 
NAD+ nicotinamide adenine dinucleotide, oxidised form 
NADH nicotinamide adenine dinucleotide, reduced form 
NADP+ nicotinamide adenine dinucleotide phosphate, oxidised form 
NADPH nicotinamide adenine dinucleotide phosphate, reduced form 
NCBI National Center for Biotechnology Information 
nm nanometers 
OD600 optical density at 600 nm 
OFOR 2-oxoacid:ferredoxin oxidoreductase 
oLac Lac operator 
ompT mutation in the protease VII protein in outer membrane: reduces degradation of heterologous expressed proteins 
ORF open reading frame 
ori origin of replication 
P proline 
PAGE polyacrylamide gel electrophoresis 
PAH polycyclic aromatic hydrocarbons 
PAL phenylalanine ammonia lyase 
pBR322 ori origin of replication of the plasmid pBR322 
PCBs polychlorinated biphenyls 
PCDD polychlorinated dibenzo-p-dioxins 
PCR polymerase chain reaction 
PEG poly-ethylene glycol 
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pGAL galactose promoter 
PGH2 prostaglandin H2  
Phe phenylalanine 
pRARE2 plasmid which carries seven rare-codon tRNA genes 
Pro proline 
proA+B+ mutations in proline biosynthesis; strain requires proline for growth in minimal medium  
pT7 T7 promotor 
R arginine 
RBS ribosome binding site 
RDX hexahydro -1,3,5-trinitro -1,3,5-triazine 
recA1 mutation in a gene responsible for general recombination of DNA 
relA1 locus regulates the coupling between transcription and translation; relaxed phenotype: permits RNA synthesis in absence of protein synthesis 
RNA ribose nucleic acid 
r.p.m. revolutions per minute 
S serine or sulphur 
SDS sodium dodecyl sulfate 
s second(s) 
Ser serine 
SGI synthetic media for yeast 
SOC Super Optimal Broth 
SRP signal recognition particle 
SRS substrate recognition site 
STY space–time yield 
subE44 tRNA glutamine suppressor of amber  
T threonine or thymine 
157 
TAE Tris-acetate-EDTA 
TBST mixture of Tris-buffered saline and Tween 20 
TEG Tris buffer, EDTA and Glucose 
TEK Tris buffer, EDTA and KCl 
TEMED N, N, N’, N’-Tetramethylethylendiamine 
TES Tris buffer, EDTA and sorbitol 
tetR tetracycline resistance gene 
thi-1 requires thiamine for growth on minimal media 
Thr threonine 
Tn10 transposon carrying tetracycline resistance 
tPGK phosphoglycerate kinase terminator 
TriCDD trichlorinated dibenzo-p-dioxins 
Tris 2-amino-2-hydroxymethyl-1,3-propanediol 
tT7 T7 terminator 
TXA2 tromboxane A2 
UAS upstream activation sequence 
URA3 selection marker for uracil auxotrophy 
UV ultra violet (light) 
v/v volume to volume ratio 
w/v weight to volume ratio 
YPGA yeast medium containing yeast extract, bactopeptone, glucose and adenine 
YPGE yeast medium containing yeast extract, bactopeptone, glucose and
 ethanol 
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